,ID,Event,Item,Dictionary,Verbatim Term,Preferred Term,RXCUI,Drug Name,Normalized RxNorm Id,Approximate RxNorm Id,Best RxNorm Id,Requires Review,VA_has_VAClass_extended,VA_has_VAClass,STRUCT_isa_structure,DISPOS_isa_disposition,ATC1-4,MESHPA,DISEASE_may_treat,DISEASE_ci_with,DISEASE_may_prevent,CHEM_has_ingredient,PK_has_pk,MOA_has_moa,PE_has_pe,EPC_has_epc,SCHEDULE_has_schedule,CHEM_ci_chemclass,CHEM_has_chemical_structure,THERAP_isa_therapeutic,TC_has_tc,MOA_ci_moa,DISEASE_induces,PE_ci_pe,DISEASE_may_diagnose,PK_site_of_metabolism
0,1,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram 20 MG,353383.0,Escitalopram 20 MG,321988.0,321988.0,321988,False,"ANTIDEPRESSANTS,OTHER;VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS","ANTIDEPRESSANTS,OTHER;VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS",Medicinal product categorized by structure;Benzofuran-containing product,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,ANTIDEPRESSANTS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;PSYCHOANALEPTICS;Selective serotonin reuptake inhibitors,Molecular Mechanisms of Pharmacological Action;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Selective Serotonin Reuptake Inhibitors;Serotonin Agents;Neurotransmitter Agents;Physiological Effects of Drugs,"Depressive Disorder, Major;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Depressive Disorder;Mood Disorders;Disease;Mental Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Organic Chemicals;Propylamines;Heterocyclic Compounds, 2-Ring;Escitalopram;Benzofurans;Substances;Substances and Cells (CHEM);Nitriles;Amines;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Receptor Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Neurotransmitter Transporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions,Increased Immunologically Active Molecule Activity;Generalized Systemic Effects;Physiologic Effect (PE);Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Increased Immunologic Activity;Increased Serotonin Activity;Serotonin Activity Alteration;Immunologic Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Increased Central Nervous System Serotonin Activity;Nervous System Activity Alteration,Nervous System Agent;Serotonin Reuptake Inhibitor;Established Pharmacologic Class (EPC),,"Pimozide;Substances;Benzimidazoles;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Medicinal product categorized by therapeutic role;Antidepressant agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
1,30,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram,321988.0,Escitalopram,321988.0,321988.0,321988,False,"ANTIDEPRESSANTS,OTHER;VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS","ANTIDEPRESSANTS,OTHER;VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS",Medicinal product categorized by structure;Benzofuran-containing product,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,ANTIDEPRESSANTS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;PSYCHOANALEPTICS;Selective serotonin reuptake inhibitors,Molecular Mechanisms of Pharmacological Action;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Selective Serotonin Reuptake Inhibitors;Serotonin Agents;Neurotransmitter Agents;Physiological Effects of Drugs,"Depressive Disorder, Major;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Depressive Disorder;Mood Disorders;Disease;Mental Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Organic Chemicals;Propylamines;Heterocyclic Compounds, 2-Ring;Escitalopram;Benzofurans;Substances;Substances and Cells (CHEM);Nitriles;Amines;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Receptor Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Neurotransmitter Transporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions,Increased Immunologically Active Molecule Activity;Generalized Systemic Effects;Physiologic Effect (PE);Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Increased Immunologic Activity;Increased Serotonin Activity;Serotonin Activity Alteration;Immunologic Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Increased Central Nervous System Serotonin Activity;Nervous System Activity Alteration,Nervous System Agent;Serotonin Reuptake Inhibitor;Established Pharmacologic Class (EPC),,"Pimozide;Substances;Benzimidazoles;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Medicinal product categorized by therapeutic role;Antidepressant agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
2,1,Concomitant Medications,Generic Name,RxNorm,mirena,Mirena,152061.0,Mirena,152061.0,152061.0,152061,False,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Steroid-containing product,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Progestogens;Emergency contraceptives,"Therapeutic Uses;Contraceptives, Oral, Synthetic;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Contraceptive Agents, Hormonal;Contraceptive Agents, Female;Contraceptives, Oral;Reproductive Control Agents;Physiological Effects of Drugs",,"Digestive System Neoplasms;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Neoplasms;Drug Hypersensitivity;Liver Diseases;Skin and Connective Tissue Diseases;Hypertension;Myocardial Ischemia;Endocrine System Diseases;Heart Diseases;Thrombosis;Vasculitis;Diabetes Mellitus;Hemorrhage;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Neoplasms by Site;Adenoma;Venous Thrombosis;Reproduction;Peripheral Vascular Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Thromboembolism;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Cerebrovascular Disorders;Hyperbilirubinemia;Phlebitis;Metabolic Diseases;Liver Neoplasms;Neoplasms by Histologic Type;Breast Diseases;Neoplasms, Glandular and Epithelial;Mental Disorders;Female Urogenital Diseases;Coronary Disease;Jaundice;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Uterine Neoplasms;Headache Disorders;Substance-Related Disorders;Pathologic Processes;Breast Neoplasms;Skin Manifestations;Skin Diseases;Endometrial Neoplasms;Kidney Diseases;Urogenital Neoplasms;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Uterine Diseases;Genital Diseases, Female;Central Nervous System Diseases;Chemically-Induced Disorders;Uterine Hemorrhage;Signs and Symptoms;Adenoma, Liver Cell;Heart Valve Diseases;Tobacco Use Disorder;Genital Neoplasms, Female;Pathological Conditions, Signs and Symptoms;Embolism and Thrombosis;Thrombophlebitis;Nervous System Diseases;Disease;Male Urogenital Diseases;Brain Diseases","Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction",Substances and Cells (CHEM);Levonorgestrel;Steroids;Norsteroids;Norgestrel;Norpregnanes;Substances;Norpregnenes;Fused-Ring Compounds;Polycyclic Compounds,,Sex Hormone Receptor Agonists;Receptor Interactions;Progestational Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Physiologic Effect (PE);Endocrine Activity Alteration;Organ System Specific Effects;Decreased Embryonic Implantation;Inhibit Ovulation;Inhibit Ovum Fertilization;Embryonic Implantation Alteration;Reproductive System Activity Alteration;Female Reproductive System Activity Alteration;Embryonic & Fetal Alteration;Ovarian Function Alteration;Hypothalamic Endocrine Activity Alteration;Ovum Fertilization Alteration;Ovulation Alteration,Established Pharmacologic Class (EPC);Hormone;Progestin-containing Intrauterine Device;Chemical Structure;Progestin,,,"Gonadal Steroid Hormones;Gonadal Hormones;Progesterone Congeners;Hormones;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",Medicinal product categorized by therapeutic role;Contraceptive agent,,,"Pregnancy Complications;Pregnancy;Reproductive Physiological Phenomena;Reproduction;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Outcome;Abortion, Spontaneous;Urogenital Diseases;Disease",Physiologic Effect (PE);Blood Pressure Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure,,
3,16,Concomitant Medications,Generic Name,RxNorm,Mirena,Mirena Drug Implant Product,1181044.0,Mirena Drug Implant Product,152061.0,152061.0,152061,False,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Steroid-containing product,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Progestogens;Emergency contraceptives,"Therapeutic Uses;Contraceptives, Oral, Synthetic;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Contraceptive Agents, Hormonal;Contraceptive Agents, Female;Contraceptives, Oral;Reproductive Control Agents;Physiological Effects of Drugs",,"Digestive System Neoplasms;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Neoplasms;Drug Hypersensitivity;Liver Diseases;Skin and Connective Tissue Diseases;Hypertension;Myocardial Ischemia;Endocrine System Diseases;Heart Diseases;Thrombosis;Vasculitis;Diabetes Mellitus;Hemorrhage;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Neoplasms by Site;Adenoma;Venous Thrombosis;Reproduction;Peripheral Vascular Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Thromboembolism;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Cerebrovascular Disorders;Hyperbilirubinemia;Phlebitis;Metabolic Diseases;Liver Neoplasms;Neoplasms by Histologic Type;Breast Diseases;Neoplasms, Glandular and Epithelial;Mental Disorders;Female Urogenital Diseases;Coronary Disease;Jaundice;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Uterine Neoplasms;Headache Disorders;Substance-Related Disorders;Pathologic Processes;Breast Neoplasms;Skin Manifestations;Skin Diseases;Endometrial Neoplasms;Kidney Diseases;Urogenital Neoplasms;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Uterine Diseases;Genital Diseases, Female;Central Nervous System Diseases;Chemically-Induced Disorders;Uterine Hemorrhage;Signs and Symptoms;Adenoma, Liver Cell;Heart Valve Diseases;Tobacco Use Disorder;Genital Neoplasms, Female;Pathological Conditions, Signs and Symptoms;Embolism and Thrombosis;Thrombophlebitis;Nervous System Diseases;Disease;Male Urogenital Diseases;Brain Diseases","Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction",Substances and Cells (CHEM);Levonorgestrel;Steroids;Norsteroids;Norgestrel;Norpregnanes;Substances;Norpregnenes;Fused-Ring Compounds;Polycyclic Compounds,,Sex Hormone Receptor Agonists;Receptor Interactions;Progestational Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Physiologic Effect (PE);Endocrine Activity Alteration;Organ System Specific Effects;Decreased Embryonic Implantation;Inhibit Ovulation;Inhibit Ovum Fertilization;Embryonic Implantation Alteration;Reproductive System Activity Alteration;Female Reproductive System Activity Alteration;Embryonic & Fetal Alteration;Ovarian Function Alteration;Hypothalamic Endocrine Activity Alteration;Ovum Fertilization Alteration;Ovulation Alteration,Established Pharmacologic Class (EPC);Hormone;Progestin-containing Intrauterine Device;Chemical Structure;Progestin,,,"Gonadal Steroid Hormones;Gonadal Hormones;Progesterone Congeners;Hormones;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",Medicinal product categorized by therapeutic role;Contraceptive agent,,,"Pregnancy Complications;Pregnancy;Reproductive Physiological Phenomena;Reproduction;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Outcome;Abortion, Spontaneous;Urogenital Diseases;Disease",Physiologic Effect (PE);Blood Pressure Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure,,
4,2,Concomitant Medications,Generic Name,RxNorm,norethindrone,,,,7514.0,7514.0,7514,False,"CONTRACEPTIVES,SYSTEMIC;VA CLASSES;HORMONES/SYNTHETICS/MODIFIERS;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;ANTINEOPLASTIC HORMONES;ANTINEOPLASTICS","CONTRACEPTIVES,SYSTEMIC;VA CLASSES;HORMONES/SYNTHETICS/MODIFIERS;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;ANTINEOPLASTIC HORMONES;ANTINEOPLASTICS",Medicinal product categorized by structure;Steroid-containing product,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROGESTOGENS;Estren derivatives;Progestogens;Progestogens and estrogens, sequential preparations;Progestogens and estrogens, fixed combinations","Reproductive Control Agents;Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptives, Oral, Combined;Contraceptives, Oral, Sequential;Contraceptives, Oral, Hormonal;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Contraceptive Agents, Female;Contraceptives, Oral;Contraceptive Agents, Hormonal;Physiological Effects of Drugs","Endocrine System Diseases;Gonadal Disorders;Hemorrhage;Menorrhagia;Urogenital Diseases;Sebaceous Gland Diseases;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Female Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endometriosis;Hypogonadism;Endometrial Hyperplasia;Skin Diseases;Acne Vulgaris;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Acneiform Eruptions;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Cardiovascular Diseases;Drug Hypersensitivity;Neoplasms;Liver Diseases;Thrombosis;Vasculitis;Hemorrhage;Urogenital Diseases;Digestive System Diseases;Neoplasms by Site;Venous Thrombosis;Lung Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Thromboembolism;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Phlebitis;Breast Diseases;Female Urogenital Diseases;Vascular Diseases;Disease;Embolism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Breast Neoplasms;Skin Diseases;Drug-Related Side Effects and Adverse Reactions;Pulmonary Embolism;Pregnancy;Reproductive Physiological Phenomena;Uterine Diseases;Genital Diseases, Female;Uterine Hemorrhage;Chemically-Induced Disorders;Respiratory Tract Diseases;Pathological Conditions, Signs and Symptoms;Embolism and Thrombosis;Thrombophlebitis;Pathologic Processes;Peripheral Vascular Diseases;Skin and Connective Tissue Diseases","Osteoporosis;Disease;Pregnancy;Nutritional and Metabolic Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Musculoskeletal Diseases;Metabolic Diseases;Bone Diseases;Bone Diseases, Metabolic",Substances and Cells (CHEM);Norethindrone Acetate;Steroids;Norsteroids;Norpregnanes;Substances;Fused-Ring Compounds;Norpregnenes;Polycyclic Compounds;Norethindrone,,Sex Hormone Receptor Agonists;Receptor Interactions;Progestational Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Physiologic Effect (PE);Endocrine Activity Alteration;Gonadotropin Releasing Hormone Alteration;Organ System Specific Effects;Decreased Embryonic Implantation;Inhibit Ovulation;Embryonic Implantation Alteration;Decreased Luteinizing Hormone Secretion;Reproductive System Activity Alteration;Pituitary Gland Activity Alteration;Female Reproductive System Activity Alteration;Embryonic & Fetal Alteration;Ovarian Function Alteration;Hypothalamic Endocrine Activity Alteration;Ovulation Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Progestin;Hormone,,,"Gonadal Steroid Hormones;Gonadal Hormones;Progesterone Congeners;Hormones;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",Medicinal product categorized by therapeutic role;Contraceptive agent,,,,,,
5,33,Concomitant Medications,Generic Name,RxNorm,norethi,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],748977.0,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],,7514.0,7514,True,"CONTRACEPTIVES,SYSTEMIC;VA CLASSES;HORMONES/SYNTHETICS/MODIFIERS;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;ANTINEOPLASTIC HORMONES;ANTINEOPLASTICS","CONTRACEPTIVES,SYSTEMIC;VA CLASSES;HORMONES/SYNTHETICS/MODIFIERS;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;ANTINEOPLASTIC HORMONES;ANTINEOPLASTICS",Medicinal product categorized by structure;Steroid-containing product,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROGESTOGENS;Estren derivatives;Progestogens;Progestogens and estrogens, sequential preparations;Progestogens and estrogens, fixed combinations","Reproductive Control Agents;Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptives, Oral, Combined;Contraceptives, Oral, Sequential;Contraceptives, Oral, Hormonal;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Contraceptive Agents, Female;Contraceptives, Oral;Contraceptive Agents, Hormonal;Physiological Effects of Drugs","Endocrine System Diseases;Gonadal Disorders;Hemorrhage;Menorrhagia;Urogenital Diseases;Sebaceous Gland Diseases;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Female Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endometriosis;Hypogonadism;Endometrial Hyperplasia;Skin Diseases;Acne Vulgaris;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Acneiform Eruptions;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Cardiovascular Diseases;Drug Hypersensitivity;Neoplasms;Liver Diseases;Thrombosis;Vasculitis;Hemorrhage;Urogenital Diseases;Digestive System Diseases;Neoplasms by Site;Venous Thrombosis;Lung Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Thromboembolism;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Phlebitis;Breast Diseases;Female Urogenital Diseases;Vascular Diseases;Disease;Embolism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Breast Neoplasms;Skin Diseases;Drug-Related Side Effects and Adverse Reactions;Pulmonary Embolism;Pregnancy;Reproductive Physiological Phenomena;Uterine Diseases;Genital Diseases, Female;Uterine Hemorrhage;Chemically-Induced Disorders;Respiratory Tract Diseases;Pathological Conditions, Signs and Symptoms;Embolism and Thrombosis;Thrombophlebitis;Pathologic Processes;Peripheral Vascular Diseases;Skin and Connective Tissue Diseases","Osteoporosis;Disease;Pregnancy;Nutritional and Metabolic Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Musculoskeletal Diseases;Metabolic Diseases;Bone Diseases;Bone Diseases, Metabolic",Substances and Cells (CHEM);Norethindrone Acetate;Steroids;Norsteroids;Norpregnanes;Substances;Fused-Ring Compounds;Norpregnenes;Polycyclic Compounds;Norethindrone,,Sex Hormone Receptor Agonists;Receptor Interactions;Progestational Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Physiologic Effect (PE);Endocrine Activity Alteration;Gonadotropin Releasing Hormone Alteration;Organ System Specific Effects;Decreased Embryonic Implantation;Inhibit Ovulation;Embryonic Implantation Alteration;Decreased Luteinizing Hormone Secretion;Reproductive System Activity Alteration;Pituitary Gland Activity Alteration;Female Reproductive System Activity Alteration;Embryonic & Fetal Alteration;Ovarian Function Alteration;Hypothalamic Endocrine Activity Alteration;Ovulation Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Progestin;Hormone,,,"Gonadal Steroid Hormones;Gonadal Hormones;Progesterone Congeners;Hormones;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",Medicinal product categorized by therapeutic role;Contraceptive agent,,,,,,
6,3,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Biguanide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Nutritional and Metabolic Diseases;Urologic Diseases;Drug Hypersensitivity;Liver Diseases;Endocrine System Diseases;Acidosis;Acid-Base Imbalance;Diabetes Mellitus;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ketosis;Kidney Diseases;Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Chemically-Induced Disorders;Disease;Male Urogenital Diseases;Renal Insufficiency",,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM);Metformin,Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Polysaccharide Metabolism Alteration;Cell Glucose Transport Alteration;Decreased Gluconeogenesis;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration;Decreased Glycogenesis,Biguanide;Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator,,,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM),,,,,,,
7,5,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Biguanide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Nutritional and Metabolic Diseases;Urologic Diseases;Drug Hypersensitivity;Liver Diseases;Endocrine System Diseases;Acidosis;Acid-Base Imbalance;Diabetes Mellitus;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ketosis;Kidney Diseases;Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Chemically-Induced Disorders;Disease;Male Urogenital Diseases;Renal Insufficiency",,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM);Metformin,Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Polysaccharide Metabolism Alteration;Cell Glucose Transport Alteration;Decreased Gluconeogenesis;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration;Decreased Glycogenesis,Biguanide;Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator,,,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM),,,,,,,
8,8,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Biguanide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Nutritional and Metabolic Diseases;Urologic Diseases;Drug Hypersensitivity;Liver Diseases;Endocrine System Diseases;Acidosis;Acid-Base Imbalance;Diabetes Mellitus;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ketosis;Kidney Diseases;Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Chemically-Induced Disorders;Disease;Male Urogenital Diseases;Renal Insufficiency",,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM);Metformin,Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Polysaccharide Metabolism Alteration;Cell Glucose Transport Alteration;Decreased Gluconeogenesis;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration;Decreased Glycogenesis,Biguanide;Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator,,,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM),,,,,,,
9,24,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Biguanide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Nutritional and Metabolic Diseases;Urologic Diseases;Drug Hypersensitivity;Liver Diseases;Endocrine System Diseases;Acidosis;Acid-Base Imbalance;Diabetes Mellitus;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ketosis;Kidney Diseases;Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Chemically-Induced Disorders;Disease;Male Urogenital Diseases;Renal Insufficiency",,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM);Metformin,Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Polysaccharide Metabolism Alteration;Cell Glucose Transport Alteration;Decreased Gluconeogenesis;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration;Decreased Glycogenesis,Biguanide;Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator,,,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM),,,,,,,
10,28,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Biguanide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Nutritional and Metabolic Diseases;Urologic Diseases;Drug Hypersensitivity;Liver Diseases;Endocrine System Diseases;Acidosis;Acid-Base Imbalance;Diabetes Mellitus;Urogenital Diseases;Digestive System Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ketosis;Kidney Diseases;Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Chemically-Induced Disorders;Disease;Male Urogenital Diseases;Renal Insufficiency",,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM);Metformin,Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Polysaccharide Metabolism Alteration;Cell Glucose Transport Alteration;Decreased Gluconeogenesis;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration;Decreased Glycogenesis,Biguanide;Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator,,,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM),,,,,,,
11,3,Concomitant Medications,Generic Name,RxNorm,Epesin,,,,,,,True,,,,,,,,,,,,,,,,,,,,,,,,
12,4,Concomitant Medications,Generic Name,RxNorm,tylenol,,,,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
13,10,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
14,17,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
15,18,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
16,20,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
17,21,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
18,22,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
19,26,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
20,28,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
21,41,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
22,43,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
23,45,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product,,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Anilides,"Central Nervous System Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,,,,,,,,,,
24,5,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Peptide-containing product,Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Enzyme inhibitor-containing product,"CARDIOVASCULAR SYSTEM;ACE INHIBITORS, PLAIN;ACE inhibitors, plain;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",Protease Inhibitors;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents,"Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Hypertension;Endocrine System Diseases;Myocardial Ischemia;Heart Diseases;Diabetes Mellitus;Urogenital Diseases;Glucose Metabolism Disorders;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction;Kidney Diseases;Ischemia;Infarction;Diabetes Complications;Heart Failure;Necrosis;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Pathologic Processes;Disease;Male Urogenital Diseases","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Immune System Diseases;Hyperaldosteronism;Urticaria;Adrenal Gland Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Adrenocortical Hyperfunction;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypotension;Skin Diseases, Vascular;Hypersensitivity, Immediate;Skin Diseases;Angioedema;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Chemically-Induced Disorders;Hypersensitivity;Disease;Skin and Connective Tissue Diseases","Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Endocrine System Diseases;Heart Diseases;Diabetes Mellitus;Cardiomegaly;Hypertrophy, Left Ventricular;Urogenital Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertrophy;Ventricular Dysfunction;Kidney Diseases;Diabetes Complications;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Disease;Male Urogenital Diseases","Lisinopril;Amino Acids, Peptides, and Proteins;Peptides;Oligopeptides;Dipeptides;Substances;Substances and Cells (CHEM)",,Protease Inhibitors;Enzyme Inhibitors;Angiotensin-converting Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA),Decreased Mineralocorticoid Secretion;Endocrine Activity Alteration;Renal Arterial Vasodilation;Organ System Specific Effects;Cardiovascular Activity Alteration;Arterial Vasodilation;Decreased Kinin Degradation;Increased Renal Ion Excretion;Decreased Intravascular Volume;Physiologic Effect (PE);Decreased Blood Pressure;Generalized Systemic Effects;Vascular Alterations;Vasodilation;Renal/Urological Activity Alteration;Blood Pressure Alteration;Increased Renal Na+ Excretion;Hematologic Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Intravascular Volume Alteration;Vascular Tone Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Immunologically Active Molecule Degradation;Decreased Renal K+ Excretion;Adrenal Cortical Activity Alteration;Immunologic Activity Alteration;Immunologically Active Molecule Degradation Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity;Decreased Bradykinin Degradation,Cardiovascular Agent;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Antimicrobial;Anti-infective,,,,,,,,,,
25,8,Concomitant Medications,Generic Name,RxNorm,lisinopril,,,,29046.0,29046.0,29046,False,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Peptide-containing product,Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Enzyme inhibitor-containing product,"CARDIOVASCULAR SYSTEM;ACE INHIBITORS, PLAIN;ACE inhibitors, plain;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",Protease Inhibitors;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents,"Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Hypertension;Endocrine System Diseases;Myocardial Ischemia;Heart Diseases;Diabetes Mellitus;Urogenital Diseases;Glucose Metabolism Disorders;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction;Kidney Diseases;Ischemia;Infarction;Diabetes Complications;Heart Failure;Necrosis;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Pathologic Processes;Disease;Male Urogenital Diseases","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Immune System Diseases;Hyperaldosteronism;Urticaria;Adrenal Gland Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Adrenocortical Hyperfunction;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypotension;Skin Diseases, Vascular;Hypersensitivity, Immediate;Skin Diseases;Angioedema;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Chemically-Induced Disorders;Hypersensitivity;Disease;Skin and Connective Tissue Diseases","Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Endocrine System Diseases;Heart Diseases;Diabetes Mellitus;Cardiomegaly;Hypertrophy, Left Ventricular;Urogenital Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertrophy;Ventricular Dysfunction;Kidney Diseases;Diabetes Complications;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Disease;Male Urogenital Diseases","Lisinopril;Amino Acids, Peptides, and Proteins;Peptides;Oligopeptides;Dipeptides;Substances;Substances and Cells (CHEM)",,Protease Inhibitors;Enzyme Inhibitors;Angiotensin-converting Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA),Decreased Mineralocorticoid Secretion;Endocrine Activity Alteration;Renal Arterial Vasodilation;Organ System Specific Effects;Cardiovascular Activity Alteration;Arterial Vasodilation;Decreased Kinin Degradation;Increased Renal Ion Excretion;Decreased Intravascular Volume;Physiologic Effect (PE);Decreased Blood Pressure;Generalized Systemic Effects;Vascular Alterations;Vasodilation;Renal/Urological Activity Alteration;Blood Pressure Alteration;Increased Renal Na+ Excretion;Hematologic Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Intravascular Volume Alteration;Vascular Tone Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Immunologically Active Molecule Degradation;Decreased Renal K+ Excretion;Adrenal Cortical Activity Alteration;Immunologic Activity Alteration;Immunologically Active Molecule Degradation Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity;Decreased Bradykinin Degradation,Cardiovascular Agent;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Antimicrobial;Anti-infective,,,,,,,,,,
26,9,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Peptide-containing product,Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Enzyme inhibitor-containing product,"CARDIOVASCULAR SYSTEM;ACE INHIBITORS, PLAIN;ACE inhibitors, plain;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",Protease Inhibitors;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents,"Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Hypertension;Endocrine System Diseases;Myocardial Ischemia;Heart Diseases;Diabetes Mellitus;Urogenital Diseases;Glucose Metabolism Disorders;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction;Kidney Diseases;Ischemia;Infarction;Diabetes Complications;Heart Failure;Necrosis;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Pathologic Processes;Disease;Male Urogenital Diseases","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Immune System Diseases;Hyperaldosteronism;Urticaria;Adrenal Gland Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Adrenocortical Hyperfunction;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypotension;Skin Diseases, Vascular;Hypersensitivity, Immediate;Skin Diseases;Angioedema;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Chemically-Induced Disorders;Hypersensitivity;Disease;Skin and Connective Tissue Diseases","Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Endocrine System Diseases;Heart Diseases;Diabetes Mellitus;Cardiomegaly;Hypertrophy, Left Ventricular;Urogenital Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertrophy;Ventricular Dysfunction;Kidney Diseases;Diabetes Complications;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Disease;Male Urogenital Diseases","Lisinopril;Amino Acids, Peptides, and Proteins;Peptides;Oligopeptides;Dipeptides;Substances;Substances and Cells (CHEM)",,Protease Inhibitors;Enzyme Inhibitors;Angiotensin-converting Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA),Decreased Mineralocorticoid Secretion;Endocrine Activity Alteration;Renal Arterial Vasodilation;Organ System Specific Effects;Cardiovascular Activity Alteration;Arterial Vasodilation;Decreased Kinin Degradation;Increased Renal Ion Excretion;Decreased Intravascular Volume;Physiologic Effect (PE);Decreased Blood Pressure;Generalized Systemic Effects;Vascular Alterations;Vasodilation;Renal/Urological Activity Alteration;Blood Pressure Alteration;Increased Renal Na+ Excretion;Hematologic Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Intravascular Volume Alteration;Vascular Tone Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Immunologically Active Molecule Degradation;Decreased Renal K+ Excretion;Adrenal Cortical Activity Alteration;Immunologic Activity Alteration;Immunologically Active Molecule Degradation Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity;Decreased Bradykinin Degradation,Cardiovascular Agent;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Antimicrobial;Anti-infective,,,,,,,,,,
27,5,Concomitant Medications,Generic Name,RxNorm,Atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;VA CLASSES,CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product,HMG-CoA reductase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, PLAIN;Anatomical Therapeutic Chemical (ATC1-4);HMG CoA reductase inhibitors;Lipid modifying agents in combination with other drugs;LIPID MODIFYING AGENTS, COMBINATIONS;Combinations of various lipid modifying agents",Physiological Effects of Drugs;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Anticholesteremic Agents;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Hypolipidemic Agents;Lipid Regulating Agents;Calcium Channel Blockers;Cardiovascular Agents;Antihypertensive Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Antimetabolites;Calcium-Regulating Hormones and Agents,"Vascular Diseases;Cardiovascular Diseases;Disease;Arterial Occlusive Diseases;Nutritional and Metabolic Diseases;Lipid Metabolism Disorders;Hyperlipoproteinemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Myocardial Ischemia;Hypercholesterolemia;Heart Diseases;Dyslipidemias;Arteriosclerosis;Hyperlipidemias;Metabolic Diseases;Coronary Artery Disease;Coronary Disease","Hepatic Insufficiency;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Postpartum Period;Drug Hypersensitivity;Liver Diseases;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Liver Failure;Lactation;Digestive System Diseases;Disease","Vascular Diseases;Cardiovascular Diseases;Disease;Arterial Occlusive Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Myocardial Ischemia;Heart Diseases;Arteriosclerosis;Coronary Artery Disease;Coronary Disease","Fatty Acids;Heptanoic Acids;Azoles;Lipids;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Heterocyclic Compounds;Atorvastatin",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism,Enzyme Inhibitors;Sterol Synthesis Inhibitors;Cholesterol Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Hydroxymethylglutaryl-CoA Reductase Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Cholesterol Metabolism Alteration;Decreased Cholesterol Synthesis;Sterol Metabolism Alteration;Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Lipid Metabolism Alteration,Cardiovascular Agent;Established Pharmacologic Class (EPC);HMG-CoA Reductase Inhibitor;Enzyme Inhibitor;Enzyme Interaction,,,,,,,,,,
28,8,Concomitant Medications,Generic Name,RxNorm,atorvastatin,,,,83367.0,83367.0,83367,False,CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;VA CLASSES,CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product,HMG-CoA reductase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, PLAIN;Anatomical Therapeutic Chemical (ATC1-4);HMG CoA reductase inhibitors;Lipid modifying agents in combination with other drugs;LIPID MODIFYING AGENTS, COMBINATIONS;Combinations of various lipid modifying agents",Physiological Effects of Drugs;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Anticholesteremic Agents;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Hypolipidemic Agents;Lipid Regulating Agents;Calcium Channel Blockers;Cardiovascular Agents;Antihypertensive Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Antimetabolites;Calcium-Regulating Hormones and Agents,"Vascular Diseases;Cardiovascular Diseases;Disease;Arterial Occlusive Diseases;Nutritional and Metabolic Diseases;Lipid Metabolism Disorders;Hyperlipoproteinemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Myocardial Ischemia;Hypercholesterolemia;Heart Diseases;Dyslipidemias;Arteriosclerosis;Hyperlipidemias;Metabolic Diseases;Coronary Artery Disease;Coronary Disease","Hepatic Insufficiency;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Postpartum Period;Drug Hypersensitivity;Liver Diseases;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Liver Failure;Lactation;Digestive System Diseases;Disease","Vascular Diseases;Cardiovascular Diseases;Disease;Arterial Occlusive Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Myocardial Ischemia;Heart Diseases;Arteriosclerosis;Coronary Artery Disease;Coronary Disease","Fatty Acids;Heptanoic Acids;Azoles;Lipids;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Heterocyclic Compounds;Atorvastatin",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism,Enzyme Inhibitors;Sterol Synthesis Inhibitors;Cholesterol Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Hydroxymethylglutaryl-CoA Reductase Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Cholesterol Metabolism Alteration;Decreased Cholesterol Synthesis;Sterol Metabolism Alteration;Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Lipid Metabolism Alteration,Cardiovascular Agent;Established Pharmacologic Class (EPC);HMG-CoA Reductase Inhibitor;Enzyme Inhibitor;Enzyme Interaction,,,,,,,,,,
29,24,Concomitant Medications,Generic Name,RxNorm,atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;VA CLASSES,CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product,HMG-CoA reductase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, PLAIN;Anatomical Therapeutic Chemical (ATC1-4);HMG CoA reductase inhibitors;Lipid modifying agents in combination with other drugs;LIPID MODIFYING AGENTS, COMBINATIONS;Combinations of various lipid modifying agents",Physiological Effects of Drugs;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Anticholesteremic Agents;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Hypolipidemic Agents;Lipid Regulating Agents;Calcium Channel Blockers;Cardiovascular Agents;Antihypertensive Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Antimetabolites;Calcium-Regulating Hormones and Agents,"Vascular Diseases;Cardiovascular Diseases;Disease;Arterial Occlusive Diseases;Nutritional and Metabolic Diseases;Lipid Metabolism Disorders;Hyperlipoproteinemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Myocardial Ischemia;Hypercholesterolemia;Heart Diseases;Dyslipidemias;Arteriosclerosis;Hyperlipidemias;Metabolic Diseases;Coronary Artery Disease;Coronary Disease","Hepatic Insufficiency;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Postpartum Period;Drug Hypersensitivity;Liver Diseases;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Liver Failure;Lactation;Digestive System Diseases;Disease","Vascular Diseases;Cardiovascular Diseases;Disease;Arterial Occlusive Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Myocardial Ischemia;Heart Diseases;Arteriosclerosis;Coronary Artery Disease;Coronary Disease","Fatty Acids;Heptanoic Acids;Azoles;Lipids;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Heterocyclic Compounds;Atorvastatin",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism,Enzyme Inhibitors;Sterol Synthesis Inhibitors;Cholesterol Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Hydroxymethylglutaryl-CoA Reductase Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Cholesterol Metabolism Alteration;Decreased Cholesterol Synthesis;Sterol Metabolism Alteration;Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Lipid Metabolism Alteration,Cardiovascular Agent;Established Pharmacologic Class (EPC);HMG-CoA Reductase Inhibitor;Enzyme Inhibitor;Enzyme Interaction,,,,,,,,,,
30,5,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Other cough suppressants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Butylamines;Alkanes;Organic Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Acyclic;Amines;Butanes",,Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions;Antiporter Interactions,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Tracheobronchial Stretch Receptor Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Non-narcotic Antitussive,,,,Medicinal product categorized by therapeutic role;Antitussive agent,Respiratory System Agent;Therapeutic Categories;Antitussive Agent,,,,,
31,21,Concomitant Medications,Generic Name,RxNorm,Benzonatate,benzonatate,18993.0,benzonatate,18993.0,18993.0,18993,False,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Other cough suppressants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Butylamines;Alkanes;Organic Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Acyclic;Amines;Butanes",,Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions;Antiporter Interactions,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Tracheobronchial Stretch Receptor Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Non-narcotic Antitussive,,,,Medicinal product categorized by therapeutic role;Antitussive agent,Respiratory System Agent;Therapeutic Categories;Antitussive Agent,,,,,
32,41,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Other cough suppressants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Butylamines;Alkanes;Organic Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Acyclic;Amines;Butanes",,Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions;Antiporter Interactions,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Tracheobronchial Stretch Receptor Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Non-narcotic Antitussive,,,,Medicinal product categorized by therapeutic role;Antitussive agent,Respiratory System Agent;Therapeutic Categories;Antitussive Agent,,,,,
33,5,Concomitant Medications,Generic Name,RxNorm,beclomethasone dipropionate,Beclomethasone Dipropionate,1348.0,Beclomethasone Dipropionate,1348.0,1348.0,1348,False,"VA CLASSES;NASAL AND THROAT AGENTS,TOPICAL;ANTI-INFLAMMATORIES,NASAL;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION","VA CLASSES;NASAL AND THROAT AGENTS,TOPICAL;ANTI-INFLAMMATORIES,NASAL;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION",Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product;Steroid-containing product;Glucocorticoid-containing product,,"NASAL PREPARATIONS;Glucocorticoids;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;RESPIRATORY SYSTEM;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);DERMATOLOGICALS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;CORTICOSTEROIDS, PLAIN;Corticosteroids;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES","Glucocorticoids;Respiratory System Agents;Therapeutic Uses;Anti-Asthmatic Agents;Hormones;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Inflammation;Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Infections;Nose Diseases;Pathologic Processes;Disease;Rhinitis;Rhinitis, Allergic","Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Respiratory Hypersensitivity;Disease;Respiratory Tract Diseases;Drug Hypersensitivity;Bronchial Diseases;Status Asthmaticus;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Chemically-Induced Disorders;Immune System Diseases;Hypersensitivity, Immediate;Asthma","Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Polyps;Nasal Polyps;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Bronchial Diseases;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Nose Diseases;Pathological Conditions, Signs and Symptoms;Disease","Substances and Cells (CHEM);Steroids, Chlorinated;Pregnadienes;Pregnanes;Steroids;Substances;Pregnadienetriols;Fused-Ring Compounds;Polycyclic Compounds;Beclomethasone",Fecal Excretion;Pharmacokinetics (PK);Elimination;Renal Excretion;Route of Excretion,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Cellular Synthetic Activity Alteration;Organ System Specific Effects;Translation Alteration;Cellular Cycle Alteration;Cardiovascular Activity Alteration;Cellular Motion Alteration;Vasoconstriction;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Vascular Alterations;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Vascular Tone Alteration;Decreased Cellular Migration;Adrenal Cortical Activity Alteration;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
34,6,Concomitant Medications,Generic Name,RxNorm,Augmentin,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],618037.0,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],151392.0,151392.0,151392,False,"PENICILLINS,AMINO DERIVATIVES;ANTIMICROBIALS;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES","PENICILLINS,AMINO DERIVATIVES;ANTIMICROBIALS;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES",Medicinal product categorized by structure;Beta-lactam antibacterial agent;Nitrogen and/or nitrogen compound-containing product;Broad spectrum penicillin antibacterial agent;Penicillin antibacterial agent;Beta-lactam-containing product;Aminopenicillin antibacterial agent;Penicillin-containing product,Aminopenicillin antibacterial agent;Broad spectrum penicillin antibacterial agent;Medicinal product categorized by disposition,"ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);BETA-LACTAM ANTIBACTERIALS, PENICILLINS;Penicillins with extended spectrum;ANTIBACTERIALS FOR SYSTEMIC USE",Therapeutic Uses;beta-Lactamase Inhibitors;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents;Anti-Bacterial Agents,"Listeriosis;Helicobacter Infections;Pasteurellaceae Infections;Actinomycosis;Urologic Diseases;Sexually Transmitted Diseases, Bacterial;Skin and Connective Tissue Diseases;Sexually Transmitted Diseases;Spirochaetales Infections;Paranasal Sinus Diseases;Wounds and Injuries;Urogenital Diseases;Digestive System Diseases;Bites and Stings;Actinomycetales Infections;Gastrointestinal Diseases;Haemophilus Infections;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Disease Attributes;Intestinal Diseases;Streptococcal Infections;Otitis Media;Duodenal Diseases;Infections;Bites, Human;Female Urogenital Diseases;Chlamydiaceae Infections;Peptic Ulcer;Soft Tissue Infections;Respiratory Tract Infections;Otitis;Poisoning;Tick-Borne Diseases;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Urinary Tract Infections;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Staphylococcal Infections;Skin Diseases;Bacterial Infections;Ear Diseases;Bacterial Infections and Mycoses;Duodenal Ulcer;Gram-Positive Bacterial Infections;Respiratory Tract Diseases;Chlamydia Infections;Chemically-Induced Disorders;Stomach Diseases;Borrelia Infections;Skin Diseases, Infectious;Skin Diseases, Bacterial;Pathological Conditions, Signs and Symptoms;Nose Diseases;Lyme Disease;Pathologic Processes;Disease;Male Urogenital Diseases;Communicable Diseases;Vector Borne Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Liver Diseases;Chemically-Induced Disorders;Cholestasis, Extrahepatic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cholestasis;Bile Duct Diseases;Digestive System Diseases;Disease;Biliary Tract Diseases","Bacterial Infections;Bacterial Infections and Mycoses;Cardiovascular Diseases;Endocarditis, Bacterial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Heart Diseases;Endocarditis;Cardiovascular Infections;Infections;Disease","Penicillin G;Lactams;Clavulanic Acid;Organic Chemicals;Clavulanic Acids;Ampicillin;Amides;Amoxicillin;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;beta-Lactams;Penicillins;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Transpeptidase Inhibitors;beta Lactamase Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Decreased Cell Wall Synthesis & Repair;Cellular Structure Alteration;Cell Wall Alteration,,,"Sulfides;Acids, Noncarboxylic;Carboxylic Acids;Ditiocarb;Gases;beta-Lactams;Disulfiram;Substances and Cells (CHEM);Electrolytes;Lactams;Amides;Sulfur Compounds;Substances;Acids;Acids, Acyclic;Carbamates;Ions;Inorganic Chemicals;Heterocyclic Compounds;Penicillins;Heterocyclic Compounds, Fused-Ring;Hydrogen Sulfide;Anions;Organic Chemicals;Thiocarbamates;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 2-Ring;Disulfides",,Antiinfective agent;Beta-lactam antibacterial agent;Antibacterial agent;Broad spectrum penicillin antibacterial agent;Medicinal product categorized by therapeutic role;Penicillin antibacterial agent;Aminopenicillin antibacterial agent,Antibacterial Agent;Anti-infective Agent;Therapeutic Categories,,,,,
35,6,Concomitant Medications,Generic Name,RxNorm,Doxycycline,Doxycycline,3640.0,Doxycycline,3640.0,3640.0,3640,False,ANTIMICROBIALS;TETRACYCLINES;VA CLASSES,ANTIMICROBIALS;TETRACYCLINES;VA CLASSES,Medicinal product categorized by structure;Tetracycline structure-containing product;Tetracycline antibacterial agent,,ANTIINFECTIVES FOR SYSTEMIC USE;ALIMENTARY TRACT AND METABOLISM;STOMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Tetracyclines;Antiinfectives and antiseptics for local oral treatment;TETRACYCLINES;ANTIBACTERIALS FOR SYSTEMIC USE,Antimalarials;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antiprotozoal Agents;Anti-Infective Agents;Anti-Bacterial Agents;Antiparasitic Agents,"Conjunctivitis, Bacterial;Sexually Transmitted Diseases, Bacterial;Sexually Transmitted Diseases;Spirochaetales Infections;Pneumonia, Bacterial;Cholera;Conjunctival Diseases;Plague;Urogenital Diseases;Spotted Fever Group Rickettsiosis;Pneumonia;Relapsing Fever;Lung Diseases;Mycoplasma Infections;Eye Infections;Genital Diseases;Disease Attributes;Trachoma;Chlamydophila Infections;Infections;Eye Diseases;Chlamydiaceae Infections;Rocky Mountain Spotted Fever;Mycoplasmatales Infections;Tick-Borne Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rickettsiaceae Infections;Gram-Negative Bacterial Infections;Treponemal Infections;Skin Diseases;Campylobacter Infections;Pleural Diseases;Rickettsia Infections;Bacterial Infections;Vibrio Infections;Bacterial Infections and Mycoses;Skin Diseases, Infectious;Respiratory Tract Diseases;Enterobacteriaceae Infections;Granuloma Inguinale;Borrelia Infections;Pleural Effusion;Gram-Positive Bacterial Infections;Chlamydia Infections;Conjunctivitis;Corneal Diseases;Bacillaceae Infections;Skin Diseases, Bacterial;Anthrax;Syphilis;Yersinia Infections;Pathological Conditions, Signs and Symptoms;Eye Infections, Bacterial;Psittacosis;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Communicable Diseases;Vector Borne Diseases","Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Child;Drug Hypersensitivity;Chemically-Induced Disorders;Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Age Groups;Child, Preschool;Digestive System Diseases;Disease","Parasitic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Infections;Malaria;Protozoan Infections;Disease;Vector Borne Diseases","Hydrocarbons;Naphthacenes;Tetracyclines;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Polycyclic Aromatic Hydrocarbons;Doxycycline;Substances;Substances and Cells (CHEM);Polycyclic Compounds",,Enzyme Interactions;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cellular Synthetic Activity Alteration;Organ System Specific Effects;Cell Membrane Alteration;Musculoskeletal Activity Alteration;Cellular Division Phase Alteration;Cellular Cycle Alteration;Translation Alteration;Cellular Structure Alteration;Striated Muscle Anabolism Alteration;Decreased Mitosis;Striated Muscle Metabolic Alteration;Mitosis Alteration;Decreased Protein Synthesis,Tetracycline-class Drug;Established Pharmacologic Class (EPC);Chemical Structure,,"Hydrocarbons;Naphthacenes;Tetracyclines;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Polycyclic Compounds;Tetracycline","Hydrocarbons;Naphthacenes;Tetracyclines;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Polycyclic Compounds",Antiinfective agent;Antibacterial agent;Antimalarial agent;Medicinal product categorized by therapeutic role;Antiprotozoal agent;Antiparasitic-containing product;Tetracycline antibacterial agent,,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Pathological Conditions, Signs and Symptoms;Sclerosis;Disease",,,
36,6,Concomitant Medications,Generic Name,RxNorm,Advair,,,,301543.0,301543.0,301543,False,"ANTIASTHMA,OTHER;ANTIASTHMA/BRONCHODILATORS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS","ANTIASTHMA,OTHER;ANTIASTHMA/BRONCHODILATORS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Androstane-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product;Glucocorticoid-containing product;Phenol structure-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"NASAL PREPARATIONS;Glucocorticoids;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);RESPIRATORY SYSTEM;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;DERMATOLOGICALS;CORTICOSTEROIDS, PLAIN;Corticosteroids;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES","Autonomic Agents;Bronchodilator Agents;Adrenergic beta-Agonists;Anti-Asthmatic Agents;Anti-Allergic Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Sympathomimetics;Physiological Effects of Drugs;Therapeutic Uses;Hormones;Glucocorticoids;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Dermatologic Agents;Neurotransmitter Agents;Adrenergic Agonists","Lung Diseases, Obstructive;Immune System Diseases;Rhinitis, Allergic;Lung Diseases;Infections;Asthma;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Lung Diseases;Disease Attributes;Acute Disease;Infections;Asthma;Status Asthmaticus;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Milk Hypersensitivity;Hypersensitivity, Immediate;Skin Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Skin Diseases, Infectious;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Food Hypersensitivity;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases","Lung Diseases, Obstructive;Immune System Diseases;Lung Diseases;Asthma, Exercise-Induced;Polyps;Asthma;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Exercise-Induced Allergies;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Nasal Polyps;Hypersensitivity;Bronchial Spasm;Pathological Conditions, Anatomical;Nose Diseases;Pathological Conditions, Signs and Symptoms;Disease",Phenethylamines;Salmeterol Xinafoate;Polycyclic Compounds;Steroids;Ethanol;Androstenes;Androstanes;Fluticasone;Substances and Cells (CHEM);Ethanolamines;Alcohols;Amino Alcohols;Substances;Fused-Ring Compounds;Ethylamines;Organic Chemicals;Albuterol;Amines;Androstadienes,,Adrenergic beta-Agonists;Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Hormone Receptor Interactions;Adrenergic Agonists;Hormone Receptor Agonists;Adrenergic beta2-Agonists,Cellular Activity Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Cellular Synthetic Activity Alteration;Translation Alteration;Cardiovascular Activity Alteration;Cellular Cycle Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Respiratory/Pulmonary Activity Alteration;Cellular Motion Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Vascular Permeability Alteration;Vascular Alterations;Decreased Polymorphonuclear Leukocyte Migration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Decreased Cellular Migration;Respiratory Smooth Muscle Tone Alteration;Decreased Vascular Permeability;Bronchial Smooth Muscle Tone Alteration;Adrenal Cortical Activity Alteration;Decreased Fibroblast Migration;Bronchodilation;Nervous System Activity Alteration;Autonomic Nervous System Activity Alteration;Decreased Capillary Permeability;Decreased Protein Synthesis,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Chemical Structure;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist;Corticosteroid,,,,,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
37,6,Concomitant Medications,Generic Name,RxNorm,Prednisone,Prednisone 10 MG,317663.0,Prednisone 10 MG,8640.0,8640.0,8640,False,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product;Steroid-containing product;Glucocorticoid-containing product,Medicinal product categorized by disposition;Immunomodulator-containing product,"Glucocorticoids;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;CORTICOSTEROIDS FOR SYSTEMIC USE;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN","Glucocorticoids;Antineoplastic Agents;Therapeutic Uses;Antineoplastic Agents, Hormonal;Hormones;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Purpura;Nutritional and Metabolic Diseases;Lymphoma;Drug Hypersensitivity;Anemia, Hemolytic;Conjunctivitis, Allergic;Neoplasms;Collagen Diseases;Dermatitis, Seborrheic;Skin Diseases, Genetic;Hypersensitivity, Delayed;Rhinitis, Allergic;Spondylarthritis;Iritis;Psoriasis;Autoimmune Diseases of the Nervous System;Neoplasms by Histologic Type;Autoimmune Diseases;Thrombocytopenia;Erythema Multiforme;Dermatitis;Colitis, Ulcerative;Respiratory Tract Infections;Spinal Diseases;Skin Diseases, Vesiculobullous;Arthritis, Psoriatic;Skin Manifestations;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Leukoencephalopathies;Drug-Related Side Effects and Adverse Reactions;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Lung Injury;Male Urogenital Diseases;Thyroiditis;Immune System Diseases;Hemorrhage;Thoracic Injuries;Arthritis;Multiple Sclerosis;Actinomycetales Infections;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Calcium Metabolism Disorders;Blood Coagulation Disorders;Water-Electrolyte Imbalance;Mycobacterium Infections;Nephrotic Syndrome;Pemphigus;Lung Diseases, Interstitial;Dermatitis, Contact;Synovitis;Skin Diseases;Bursitis;Lymphoproliferative Disorders;Skin Diseases, Papulosquamous;Dermatitis Herpetiformis;Bacterial Infections and Mycoses;Lymphatic Diseases;Respiratory Tract Diseases;Anemia;Gram-Positive Bacterial Infections;Uveal Diseases;Hypersensitivity;Rheumatic Diseases;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Hemorrhagic Disorders;Uveitis;Berylliosis;Urologic Diseases;Endocrine System Diseases;Purpura, Thrombocytopenic, Idiopathic;Sebaceous Gland Diseases;Digestive System Diseases;Anemia, Hemolytic, Autoimmune;Lung Diseases;Inflammatory Bowel Diseases;Leukemia;Rhinitis;Purpura, Thrombocytopenic;Erythema;Intestinal Diseases;Ankylosis;Connective Tissue Diseases;Uveitis, Anterior;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Graft vs Host Disease;Kidney Diseases;Spondylarthropathies;Bacterial Infections;Respiratory Hypersensitivity;Dermatitis, Atopic;Bronchial Diseases;Thrombotic Microangiopathies;Hemic and Lymphatic Diseases;Gastroenteritis;Sarcoidosis;Hematologic Diseases;Lupus Erythematosus, Systemic;Lung Diseases, Obstructive;Musculoskeletal Diseases;Wounds and Injuries;Conjunctival Diseases;Drug Eruptions;Panuveitis;Urogenital Diseases;Bone Diseases, Infectious;Adrenal Gland Diseases;Colitis;Gastrointestinal Diseases;Occupational Diseases;Nephrosis;Tuberculosis, Pulmonary;Immunoproliferative Disorders;Pneumoconiosis;Infections;Asthma;Serum Sickness;Eye Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Inflammation;Demyelinating Autoimmune Diseases, CNS;Spondylitis, Ankylosing;Demyelinating Diseases;Blood Platelet Disorders;Tuberculosis;Colonic Diseases;Hypercalcemia;Thyroid Diseases;Conjunctivitis;Skin Diseases, Eczematous;Central Nervous System Diseases;Spondylitis;Genetic Diseases, Inborn;Chemically-Induced Disorders;Nose Diseases;Iris Diseases;Adrenal Insufficiency;Brain Diseases","DNA Virus Infections;Drug-Related Side Effects and Adverse Reactions;Bacterial Infections and Mycoses;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycoses;Herpesviridae Infections;Varicella Zoster Virus Infection;Chickenpox;Infections;Disease;Virus Diseases","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Polymyositis;Musculoskeletal Diseases;Neuralgia;Immune System Diseases;Pain;Arthritis;Crystal Arthropathies;Joint Diseases;Myositis;Metabolic Diseases;Autoimmune Diseases;Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arthritis, Gouty;Skin Diseases;Dermatomyositis;Neurologic Manifestations;Arthritis, Rheumatoid;Signs and Symptoms;Rheumatic Diseases;Genetic Diseases, Inborn;Peripheral Nervous System Diseases;Gout;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Disease;Skin and Connective Tissue Diseases;Muscular Diseases",Pregnadienediols;Pregnadienes;Pregnanes;Steroids;Prednisone;Substances;Fused-Ring Compounds;Substances and Cells (CHEM);Polycyclic Compounds,,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Enzyme Inhibitors;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Lipoxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Carbohydrate Metabolism Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Cellular Synthetic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Activity;Cardiovascular Activity Alteration;Cellular Cycle Alteration;Translation Alteration;Cellular Motion Alteration;Lipid Metabolism Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Leukotriene Activity;Decreased Thromboxane Activity;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Decreased Eicosanoid Activity;Vascular Permeability Alteration;Vascular Alterations;Decreased Polymorphonuclear Leukocyte Migration;Immunologically Active Molecule Activity Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Decreased Cellular Migration;Metabolic Activity Alteration;Decreased Prostaglandin Activity;Decreased Vascular Permeability;Adrenal Cortical Activity Alteration;Decreased Fibroblast Migration;Immunologic Activity Alteration;Decreased Immunologic Activity;Decreased Capillary Permeability;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
38,7,Concomitant Medications,Generic Name,RxNorm,truvada,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],1744006.0,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],495430.0,495430.0,495430,False,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,Medicinal product categorized by structure;Pyrimidine-containing product;Nitrogen and/or nitrogen compound-containing product,Reverse transcriptase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition;Transferase inhibitor-containing product,"ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIVIRALS FOR SYSTEMIC USE;DIRECT ACTING ANTIVIRALS;Antivirals for treatment of HIV infections, combinations",Antiviral Agents;Anti-HIV Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Nucleic Acid Synthesis Inhibitors;Reverse Transcriptase Inhibitors;Anti-Retroviral Agents;Anti-Infective Agents,"Liver Diseases;Hepatitis B, Chronic;Sexually Transmitted Diseases;Acquired Immunodeficiency Syndrome;Immune System Diseases;Immunologic Deficiency Syndromes;Urogenital Diseases;Digestive System Diseases;Blood-Borne Infections;Retroviridae Infections;Slow Virus Diseases;Genital Diseases;Hepatitis B;Disease Attributes;RNA Virus Infections;Chronic Disease;Infections;DNA Virus Infections;Hepatitis, Viral, Human;Hepadnaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hepatitis;Sexually Transmitted Diseases, Viral;Virus Diseases;Lentivirus Infections;Pathological Conditions, Signs and Symptoms;Hepatitis, Chronic;HIV Infections;Pathologic Processes;Disease;Communicable Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ribonucleosides;Tenofovir;Nucleosides;Emtricitabine;Purines;Substances and Cells (CHEM);Deoxyribonucleosides;Deoxycytidine;Organophosphonates;Substances;Pyrimidine Nucleosides;Organophosphorus Compounds;Cytidine;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Nucleic Acids, Nucleotides, and Nucleosides;Glycosides;Adenine;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Pyrimidines;Heterocyclic Compounds, 2-Ring;Carbohydrates",,Enzyme Inhibitors;Nucleic Acid Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Reverse Transcription to DNA Alteration;Immunologically Active Molecule Activity Alteration;Increased Immunologically Active Molecule Activity;Cellular Synthetic Activity Alteration;Increased Immunologic Activity;Cellular Cycle Alteration;Immunologic Activity Alteration;Nucleic Acid Transcription Alteration;Decreased Reverse Transcription to DNA,Established Pharmacologic Class (EPC);Nucleic Acid Synthesis Inhibitor;Nucleoside Analog Antiviral;Enzyme Inhibitor;Enzyme Interaction;Nucleic Acid Related Agent;Antimicrobial;Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor;Anti-infective,,,"Nucleic Acids, Nucleotides, and Nucleosides;Glycosides;Nucleosides;Substances;Substances and Cells (CHEM);Carbohydrates",Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,,,,
39,23,Concomitant Medications,Generic Name,RxNorm,truvada,Truvada Pill,1185615.0,Truvada Pill,495430.0,495430.0,495430,False,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,Medicinal product categorized by structure;Pyrimidine-containing product;Nitrogen and/or nitrogen compound-containing product,Reverse transcriptase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition;Transferase inhibitor-containing product,"ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIVIRALS FOR SYSTEMIC USE;DIRECT ACTING ANTIVIRALS;Antivirals for treatment of HIV infections, combinations",Antiviral Agents;Anti-HIV Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Nucleic Acid Synthesis Inhibitors;Reverse Transcriptase Inhibitors;Anti-Retroviral Agents;Anti-Infective Agents,"Liver Diseases;Hepatitis B, Chronic;Sexually Transmitted Diseases;Acquired Immunodeficiency Syndrome;Immune System Diseases;Immunologic Deficiency Syndromes;Urogenital Diseases;Digestive System Diseases;Blood-Borne Infections;Retroviridae Infections;Slow Virus Diseases;Genital Diseases;Hepatitis B;Disease Attributes;RNA Virus Infections;Chronic Disease;Infections;DNA Virus Infections;Hepatitis, Viral, Human;Hepadnaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hepatitis;Sexually Transmitted Diseases, Viral;Virus Diseases;Lentivirus Infections;Pathological Conditions, Signs and Symptoms;Hepatitis, Chronic;HIV Infections;Pathologic Processes;Disease;Communicable Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ribonucleosides;Tenofovir;Nucleosides;Emtricitabine;Purines;Substances and Cells (CHEM);Deoxyribonucleosides;Deoxycytidine;Organophosphonates;Substances;Pyrimidine Nucleosides;Organophosphorus Compounds;Cytidine;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Nucleic Acids, Nucleotides, and Nucleosides;Glycosides;Adenine;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Pyrimidines;Heterocyclic Compounds, 2-Ring;Carbohydrates",,Enzyme Inhibitors;Nucleic Acid Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Reverse Transcription to DNA Alteration;Immunologically Active Molecule Activity Alteration;Increased Immunologically Active Molecule Activity;Cellular Synthetic Activity Alteration;Increased Immunologic Activity;Cellular Cycle Alteration;Immunologic Activity Alteration;Nucleic Acid Transcription Alteration;Decreased Reverse Transcription to DNA,Established Pharmacologic Class (EPC);Nucleic Acid Synthesis Inhibitor;Nucleoside Analog Antiviral;Enzyme Inhibitor;Enzyme Interaction;Nucleic Acid Related Agent;Antimicrobial;Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor;Anti-infective,,,"Nucleic Acids, Nucleotides, and Nucleosides;Glycosides;Nucleosides;Substances;Substances and Cells (CHEM);Carbohydrates",Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,,,,
40,8,Concomitant Medications,Generic Name,RxNorm,glipizide,,,,4821.0,4821.0,4821,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Sulfonylurea-containing product;Nitrogen and/or nitrogen compound-containing product;Urea and/or urea derivative-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Sulfonylureas;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Acid-Base Imbalance;Acidosis;Diabetes Mellitus;Immune System Diseases;Metabolic Diseases;Ketosis;Autoimmune Diseases;Diabetes Mellitus, Type 1;Glucose Metabolism Disorders;Disease",,Sulfonylurea Compounds;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Glipizide;Urea;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Endocrine Activity Alteration;Pancreatic Islet Activity Alteration;Organ System Specific Effects;Cell Glucose Transport Alteration;Decreased Glycolysis;Increased Insulin Secretion;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration,Blood Glucose Regulator;Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea,,,Sulfonylurea Compounds;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Urea;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,,,,,,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism
41,24,Concomitant Medications,Generic Name,RxNorm,glipizide,glipiZIDE,4821.0,glipiZIDE,4821.0,4821.0,4821,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Sulfonylurea-containing product;Nitrogen and/or nitrogen compound-containing product;Urea and/or urea derivative-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Sulfonylureas;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Acid-Base Imbalance;Acidosis;Diabetes Mellitus;Immune System Diseases;Metabolic Diseases;Ketosis;Autoimmune Diseases;Diabetes Mellitus, Type 1;Glucose Metabolism Disorders;Disease",,Sulfonylurea Compounds;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Glipizide;Urea;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Endocrine Activity Alteration;Pancreatic Islet Activity Alteration;Organ System Specific Effects;Cell Glucose Transport Alteration;Decreased Glycolysis;Increased Insulin Secretion;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration,Blood Glucose Regulator;Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea,,,Sulfonylurea Compounds;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Urea;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,,,,,,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism
42,28,Concomitant Medications,Generic Name,RxNorm,Glipizide,Glipizide 10 MG,317379.0,Glipizide 10 MG,4821.0,4821.0,4821,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Sulfonylurea-containing product;Nitrogen and/or nitrogen compound-containing product;Urea and/or urea derivative-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product,,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Sulfonylureas;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Acid-Base Imbalance;Acidosis;Diabetes Mellitus;Immune System Diseases;Metabolic Diseases;Ketosis;Autoimmune Diseases;Diabetes Mellitus, Type 1;Glucose Metabolism Disorders;Disease",,Sulfonylurea Compounds;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Glipizide;Urea;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,Insulin Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Carbohydrate Metabolism Alteration;Endocrine Activity Alteration;Pancreatic Islet Activity Alteration;Organ System Specific Effects;Cell Glucose Transport Alteration;Decreased Glycolysis;Increased Insulin Secretion;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration,Blood Glucose Regulator;Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea,,,Sulfonylurea Compounds;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Urea;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,,,,,,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism
43,8,Concomitant Medications,Generic Name,RxNorm,gabapentin,,,,25480.0,25480.0,25480,False,"ANTICONVULSANTS;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTICONVULSANTS;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Amino acid-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,Calcium channel blocker-containing product;Medicinal product categorized by disposition,OTHER ANALGESICS AND ANTIPYRETICS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Gabapentinoids,Central Nervous System Agents;Antimanic Agents;Therapeutic Uses;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;Anticonvulsants;Tranquilizing Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics;Peripheral Nervous System Agents;Central Nervous System Depressants;Excitatory Amino Acid Antagonists;Psychotropic Drugs;Sensory System Agents;Neurotransmitter Agents;Physiological Effects of Drugs;Anti-Anxiety Agents,"Neuralgia;Pain;Phobic Disorders;Bipolar and Related Disorders;Anxiety Disorders;Mental Disorders;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Epilepsy;Neuralgia, Postherpetic;Bipolar Disorder;Signs and Symptoms;Central Nervous System Diseases;Peripheral Nervous System Diseases;Epilepsies, Partial;Pathological Conditions, Signs and Symptoms;Mood Disorders;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Carboxylic Acids;Hydrocarbons, Cyclic;Polycyclic Compounds;Amino Acids;Substances and Cells (CHEM);gamma-Aminobutyric Acid;Cyclohexanes;Substances;Cyclohexanecarboxylic Acids;Fatty Acids, Volatile;Gabapentin;Fatty Acids;Macrocyclic Compounds;Acids, Acyclic;Lipids;Carbamates;Hydrocarbons, Alicyclic;Hydrocarbons;Amino Acids, Peptides, and Proteins;Organic Chemicals;Acids, Carbocyclic;Cycloparaffins;Butyrates;Aminobutyrates;Amines",,Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA),Physiologic Effect (PE);Decreased Central Nervous System Disorganized Electrical Activity;Organ System Specific Effects;Decreased Organized Electrical Activity;Decreased Disorganized Electrical Activity;Disorganized Electrical Activity Alteration;Organized Electrical Activity Alteration;Electrical Activity Alteration;Nervous System Activity Alteration,Nervous System Agent;Established Pharmacologic Class (EPC);Anti-epileptic Agent,,,,Medicinal product categorized by therapeutic role;Anticonvulsant agent,Central Nervous System Agent;Anti-epileptic Agent;Therapeutic Categories,,,,,
44,9,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;CARDIOVASCULAR SYSTEM;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;RESPIRATORY SYSTEM;Other throat preparations;Propionic acid derivatives;OTHER CARDIAC PREPARATIONS;MUSCULO-SKELETAL SYSTEM;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;OTHER GYNECOLOGICALS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Carboxylic Acids;Organic Chemicals;Acids, Carbocyclic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,,,,,,,,,,
45,13,Concomitant Medications,Generic Name,RxNorm,Advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;CARDIOVASCULAR SYSTEM;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;RESPIRATORY SYSTEM;Other throat preparations;Propionic acid derivatives;OTHER CARDIAC PREPARATIONS;MUSCULO-SKELETAL SYSTEM;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;OTHER GYNECOLOGICALS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Carboxylic Acids;Organic Chemicals;Acids, Carbocyclic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,,,,,,,,,,
46,31,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;CARDIOVASCULAR SYSTEM;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;RESPIRATORY SYSTEM;Other throat preparations;Propionic acid derivatives;OTHER CARDIAC PREPARATIONS;MUSCULO-SKELETAL SYSTEM;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;OTHER GYNECOLOGICALS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Carboxylic Acids;Organic Chemicals;Acids, Carbocyclic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,,,,,,,,,,
47,9,Concomitant Medications,Generic Name,RxNorm,Naproxen,Naproxen,7258.0,Naproxen,7258.0,7258.0,7258,False,"ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;ANTIRHEUMATICS","ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS",Medicinal product categorized by structure;Naphthalene-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;OTHER GYNECOLOGICALS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS","Gout Suppressants;Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Common Cold;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Toothache;Pain;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Facial Pain;Joint Diseases;Metabolic Diseases;Autoimmune Diseases;Ankylosis;RNA Virus Infections;Headache;Infections;Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Tooth Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Respiratory Tract Infections;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Back Pain;Fever;Pathologic Processes;Bursitis;Spondylarthropathies;Body Temperature Changes;Virus Diseases;Neurologic Manifestations;Arthritis, Rheumatoid;Stomatognathic Diseases;Respiratory Tract Diseases;Picornaviridae Infections;Signs and Symptoms;Rheumatic Diseases;Genetic Diseases, Inborn;Spondylitis;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Nervous System Diseases;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug-Related Side Effects and Adverse Reactions;Disease;Reproductive Physiological Phenomena;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy Trimesters;Pregnancy Trimester, Third","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Naphthaleneacetic Acids;Naphthalenes;Naproxen;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Polycyclic Compounds",Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,,,,,,,,,,
48,22,Concomitant Medications,Generic Name,RxNorm,Naproxen,Aleve,215101.0,Aleve,7258.0,7258.0,7258,False,"ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;ANTIRHEUMATICS","ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS",Medicinal product categorized by structure;Naphthalene-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;OTHER GYNECOLOGICALS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS","Gout Suppressants;Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Common Cold;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Toothache;Pain;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Facial Pain;Joint Diseases;Metabolic Diseases;Autoimmune Diseases;Ankylosis;RNA Virus Infections;Headache;Infections;Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Tooth Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Respiratory Tract Infections;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Back Pain;Fever;Pathologic Processes;Bursitis;Spondylarthropathies;Body Temperature Changes;Virus Diseases;Neurologic Manifestations;Arthritis, Rheumatoid;Stomatognathic Diseases;Respiratory Tract Diseases;Picornaviridae Infections;Signs and Symptoms;Rheumatic Diseases;Genetic Diseases, Inborn;Spondylitis;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Nervous System Diseases;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug-Related Side Effects and Adverse Reactions;Disease;Reproductive Physiological Phenomena;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy Trimesters;Pregnancy Trimester, Third","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Naphthaleneacetic Acids;Naphthalenes;Naproxen;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Polycyclic Compounds",Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,,,,,,,,,,
49,9,Concomitant Medications,Generic Name,RxNorm,Dayquil,DayQuil Cough,1114038.0,DayQuil Cough,,1114038.0,1114038,True,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Ether structure-containing product,Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Antitussive Agents;Neurotransmitter Agents;Physiological Effects of Drugs,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Alkaloids;Heterocyclic Compounds, 4 or More Rings;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Phenanthrenes;Polycyclic Aromatic Hydrocarbons;Dextromethorphan;Substances;Substances and Cells (CHEM);Opiate Alkaloids;Polycyclic Compounds;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Morphinans;Heterocyclic Compounds, Bridged-Ring",,Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Sigma-1 Receptor Interactions;Serotonin Transporter Interactions;Sigma Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ligand-Gated Ion Channel Interactions;Membrane Transporter Interactions;Symporter Interactions;NMDA Receptor Antagonists,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Medullary Respiratory Center Activity Alteration;Decreased Medullary Respiratory Drive,Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
50,16,Concomitant Medications,Generic Name,RxNorm,Dayquil,,,,,1114038.0,1114038,True,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Ether structure-containing product,Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Antitussive Agents;Neurotransmitter Agents;Physiological Effects of Drugs,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Alkaloids;Heterocyclic Compounds, 4 or More Rings;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Phenanthrenes;Polycyclic Aromatic Hydrocarbons;Dextromethorphan;Substances;Substances and Cells (CHEM);Opiate Alkaloids;Polycyclic Compounds;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Morphinans;Heterocyclic Compounds, Bridged-Ring",,Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Sigma-1 Receptor Interactions;Serotonin Transporter Interactions;Sigma Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ligand-Gated Ion Channel Interactions;Membrane Transporter Interactions;Symporter Interactions;NMDA Receptor Antagonists,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Medullary Respiratory Center Activity Alteration;Decreased Medullary Respiratory Drive,Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
51,9,Concomitant Medications,Generic Name,RxNorm,nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,,"COLD REMEDIES,COMBINATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product,NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;ANTIHISTAMINES FOR SYSTEMIC USE",Respiratory System Agents;Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Histamine Antagonists;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;Histamine H1 Antagonists;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Histamine Agents;Antitussive Agents;Antiemetics;Neurotransmitter Agents;Physiological Effects of Drugs;Gastrointestinal Agents,"Signs and Symptoms, Respiratory;Immune System Diseases;Pain;Respiration Disorders;Rhinitis, Allergic;Sleep Disorders, Intrinsic;Infections;Headache;Mental Disorders;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Sleep Initiation and Maintenance Disorders;Neurologic Manifestations;Respiratory Hypersensitivity;Respiratory Tract Diseases;Signs and Symptoms;Hypersensitivity;Dyssomnias;Pathological Conditions, Signs and Symptoms;Nose Diseases;Sleep Wake Disorders;Cough;Nervous System Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Alkaloids;Hydrocarbons, Cyclic;Doxylamine;Substances and Cells (CHEM);Opiate Alkaloids;Morphinans;Heterocyclic Compounds, Bridged-Ring;Pyridines;Hydrocarbons, Aromatic;Substances;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Heterocyclic Compounds, 1-Ring;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Dextromethorphan",,Receptor Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Interactions;Symporter Interactions;Ion Channel Interactions;Sigma Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists;Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Neurotransmitter Transporter Interactions;Histamine Receptor Antagonists;Ion Transporter Interactions;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Respiratory/Pulmonary Activity Alteration;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Medullary Respiratory Center Activity Alteration;Decreased Medullary Respiratory Drive;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Antihistamine;Ion Channel or Pump Agent;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Respiratory Agent;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
52,16,Concomitant Medications,Generic Name,RxNorm,Nyquil,,,,,1234386.0,1234386,True,,"COLD REMEDIES,COMBINATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product,NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;ANTIHISTAMINES FOR SYSTEMIC USE",Respiratory System Agents;Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Histamine Antagonists;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;Histamine H1 Antagonists;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Histamine Agents;Antitussive Agents;Antiemetics;Neurotransmitter Agents;Physiological Effects of Drugs;Gastrointestinal Agents,"Signs and Symptoms, Respiratory;Immune System Diseases;Pain;Respiration Disorders;Rhinitis, Allergic;Sleep Disorders, Intrinsic;Infections;Headache;Mental Disorders;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Sleep Initiation and Maintenance Disorders;Neurologic Manifestations;Respiratory Hypersensitivity;Respiratory Tract Diseases;Signs and Symptoms;Hypersensitivity;Dyssomnias;Pathological Conditions, Signs and Symptoms;Nose Diseases;Sleep Wake Disorders;Cough;Nervous System Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Alkaloids;Hydrocarbons, Cyclic;Doxylamine;Substances and Cells (CHEM);Opiate Alkaloids;Morphinans;Heterocyclic Compounds, Bridged-Ring;Pyridines;Hydrocarbons, Aromatic;Substances;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Heterocyclic Compounds, 1-Ring;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Dextromethorphan",,Receptor Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Interactions;Symporter Interactions;Ion Channel Interactions;Sigma Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists;Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Neurotransmitter Transporter Interactions;Histamine Receptor Antagonists;Ion Transporter Interactions;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Respiratory/Pulmonary Activity Alteration;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Medullary Respiratory Center Activity Alteration;Decreased Medullary Respiratory Drive;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Antihistamine;Ion Channel or Pump Agent;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Respiratory Agent;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
53,21,Concomitant Medications,Generic Name,RxNorm,Nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,,"COLD REMEDIES,COMBINATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product,NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;ANTIHISTAMINES FOR SYSTEMIC USE",Respiratory System Agents;Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Histamine Antagonists;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;Histamine H1 Antagonists;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Histamine Agents;Antitussive Agents;Antiemetics;Neurotransmitter Agents;Physiological Effects of Drugs;Gastrointestinal Agents,"Signs and Symptoms, Respiratory;Immune System Diseases;Pain;Respiration Disorders;Rhinitis, Allergic;Sleep Disorders, Intrinsic;Infections;Headache;Mental Disorders;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Sleep Initiation and Maintenance Disorders;Neurologic Manifestations;Respiratory Hypersensitivity;Respiratory Tract Diseases;Signs and Symptoms;Hypersensitivity;Dyssomnias;Pathological Conditions, Signs and Symptoms;Nose Diseases;Sleep Wake Disorders;Cough;Nervous System Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Alkaloids;Hydrocarbons, Cyclic;Doxylamine;Substances and Cells (CHEM);Opiate Alkaloids;Morphinans;Heterocyclic Compounds, Bridged-Ring;Pyridines;Hydrocarbons, Aromatic;Substances;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Heterocyclic Compounds, 1-Ring;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Dextromethorphan",,Receptor Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Interactions;Symporter Interactions;Ion Channel Interactions;Sigma Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists;Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Neurotransmitter Transporter Interactions;Histamine Receptor Antagonists;Ion Transporter Interactions;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Respiratory/Pulmonary Activity Alteration;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Medullary Respiratory Center Activity Alteration;Decreased Medullary Respiratory Drive;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Antihistamine;Ion Channel or Pump Agent;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Respiratory Agent;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
54,32,Concomitant Medications,Generic Name,RxNorm,NyQuil,,,,,1234386.0,1234386,True,,"COLD REMEDIES,COMBINATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product,NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;ANTIHISTAMINES FOR SYSTEMIC USE",Respiratory System Agents;Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Histamine Antagonists;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;Histamine H1 Antagonists;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Histamine Agents;Antitussive Agents;Antiemetics;Neurotransmitter Agents;Physiological Effects of Drugs;Gastrointestinal Agents,"Signs and Symptoms, Respiratory;Immune System Diseases;Pain;Respiration Disorders;Rhinitis, Allergic;Sleep Disorders, Intrinsic;Infections;Headache;Mental Disorders;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Sleep Initiation and Maintenance Disorders;Neurologic Manifestations;Respiratory Hypersensitivity;Respiratory Tract Diseases;Signs and Symptoms;Hypersensitivity;Dyssomnias;Pathological Conditions, Signs and Symptoms;Nose Diseases;Sleep Wake Disorders;Cough;Nervous System Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Alkaloids;Hydrocarbons, Cyclic;Doxylamine;Substances and Cells (CHEM);Opiate Alkaloids;Morphinans;Heterocyclic Compounds, Bridged-Ring;Pyridines;Hydrocarbons, Aromatic;Substances;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Heterocyclic Compounds, 1-Ring;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Dextromethorphan",,Receptor Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Interactions;Symporter Interactions;Ion Channel Interactions;Sigma Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists;Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Neurotransmitter Transporter Interactions;Histamine Receptor Antagonists;Ion Transporter Interactions;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Respiratory/Pulmonary Activity Alteration;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Medullary Respiratory Center Activity Alteration;Decreased Medullary Respiratory Drive;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Antihistamine;Ion Channel or Pump Agent;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Respiratory Agent;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
55,10,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
56,12,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
57,19,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
58,20,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
59,21,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
60,32,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
61,42,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS",Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Propionic acid and/or propionic acid derivative-containing product,COX-2 inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;MUSCULO-SKELETAL SYSTEM;Antiinflammatory preparations, non-steroids for topical use;OTHER CARDIAC PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Anatomical Therapeutic Chemical (ATC1-4);CARDIAC THERAPY;RESPIRATORY SYSTEM;Other cardiac preparations;CARDIOVASCULAR SYSTEM;Other throat preparations;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;OPIOIDS;Antiinflammatory products for vaginal administration;ANALGESICS;NERVOUS SYSTEM;Propionic acid derivatives","Central Nervous System Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Cyclooxygenase Inhibitors;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Arthritis, Juvenile;Immune System Diseases;Pain;Premenstrual Syndrome;Hemorrhage;Menorrhagia;Urogenital Diseases;Bone Diseases, Infectious;Arthritis;Spondylarthritis;Crystal Arthropathies;Postoperative Complications;Joint Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Genital Diseases;Autoimmune Diseases;Ankylosis;Infections;Pain, Postoperative;Female Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Spondylitis, Ankylosing;Spinal Diseases;Dysmenorrhea;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Bursitis;Spondylarthropathies;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Uterine Hemorrhage;Uterine Diseases;Genital Diseases, Female;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Spondylitis;Nervous System Diseases;Pelvic Pain;Gout;Pathological Conditions, Signs and Symptoms;Bone Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Menstruation Disturbances","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Urogenital Diseases;Pregnancy Trimester, Third;Pregnancy Complications;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Trimesters;Infections;Asthma;Bronchial Hyperreactivity;Pregnancy, Ectopic;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Ibuprofen;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Lysine;Carboxylic Acids;Amino Acids, Diamino;Acids, Carbocyclic;Organic Chemicals;Amino Acids;Amino Acids, Basic;Substances;Substances and Cells (CHEM);Phenylpropionates",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Physiologic Effect (PE);Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Enzyme Inhibitor,CSA SCHEDULE;SCHEDULE II,,,,,,,,,
62,10,Concomitant Medications,Generic Name,RxNorm,tessalon perles,Tessalon Perles,220224.0,Tessalon Perles,220224.0,220224.0,220224,False,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Other cough suppressants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Butylamines;Alkanes;Organic Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Acyclic;Amines;Butanes",,Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions;Antiporter Interactions,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Tracheobronchial Stretch Receptor Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Non-narcotic Antitussive,,,,Medicinal product categorized by therapeutic role;Antitussive agent,Respiratory System Agent;Therapeutic Categories;Antitussive Agent,,,,,
63,11,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,Medicinal product categorized by structure;Recombinant deoxyribonucleic acid-containing product,,,,,,,Substances and Cells (CHEM);Biological Products;COVID-19 Vaccines;Vaccines;Substances;Ad26COVS1;Viral Vaccines;Complex Mixtures,,,,,,,,,,,,,,
64,21,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,Medicinal product categorized by structure;Recombinant deoxyribonucleic acid-containing product,,,,,,,Substances and Cells (CHEM);Biological Products;COVID-19 Vaccines;Vaccines;Substances;Ad26COVS1;Viral Vaccines;Complex Mixtures,,,,,,,,,,,,,,
65,14,Concomitant Medications,Generic Name,RxNorm,sudafed,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],1052767.0,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],203302.0,203302.0,203302,False,"DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS","DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product,Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Alpha adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product,NASAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics,Respiratory System Agents;Autonomic Agents;Vasoconstrictor Agents;Therapeutic Uses;Anti-Asthmatic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Nasal Decongestants;Cardiovascular Agents;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Lung Diseases;RNA Virus Infections;Infections;Asthma;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Virus Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Picornaviridae Infections;Bronchial Diseases;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Phenethylamines;Substances and Cells (CHEM);Amino Alcohols;Alcohols;Pseudoephedrine;Organic Chemicals;Propanolamines;Substances;Ethylamines;Propanols;Amines,,Adrenergic beta-Agonists;Adrenergic alpha-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Cardiovascular Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Vascular Tone Alteration;Vascular Alterations;Vasoconstriction;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;Receptor Interaction;Sympathomimetic Agent;Nervous System Agent;alpha-Adrenergic Agonist,,,,,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
66,16,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,"DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS","DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product,Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Alpha adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product,NASAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics,Respiratory System Agents;Autonomic Agents;Vasoconstrictor Agents;Therapeutic Uses;Anti-Asthmatic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Nasal Decongestants;Cardiovascular Agents;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Lung Diseases;RNA Virus Infections;Infections;Asthma;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Virus Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Picornaviridae Infections;Bronchial Diseases;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Phenethylamines;Substances and Cells (CHEM);Amino Alcohols;Alcohols;Pseudoephedrine;Organic Chemicals;Propanolamines;Substances;Ethylamines;Propanols;Amines,,Adrenergic beta-Agonists;Adrenergic alpha-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Cardiovascular Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Vascular Tone Alteration;Vascular Alterations;Vasoconstriction;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;Receptor Interaction;Sympathomimetic Agent;Nervous System Agent;alpha-Adrenergic Agonist,,,,,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
67,26,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,"DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS","DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product,Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Alpha adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product,NASAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics,Respiratory System Agents;Autonomic Agents;Vasoconstrictor Agents;Therapeutic Uses;Anti-Asthmatic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Nasal Decongestants;Cardiovascular Agents;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Lung Diseases;RNA Virus Infections;Infections;Asthma;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Virus Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Picornaviridae Infections;Bronchial Diseases;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Phenethylamines;Substances and Cells (CHEM);Amino Alcohols;Alcohols;Pseudoephedrine;Organic Chemicals;Propanolamines;Substances;Ethylamines;Propanols;Amines,,Adrenergic beta-Agonists;Adrenergic alpha-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Cardiovascular Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Vascular Tone Alteration;Vascular Alterations;Vasoconstriction;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;Receptor Interaction;Sympathomimetic Agent;Nervous System Agent;alpha-Adrenergic Agonist,,,,,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
68,36,Concomitant Medications,Generic Name,RxNorm,sudafed,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],1049668.0,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],203302.0,203302.0,203302,False,"DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS","DECONGESTANTS,SYSTEMIC;VA CLASSES;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product,Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Alpha adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product,NASAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics,Respiratory System Agents;Autonomic Agents;Vasoconstrictor Agents;Therapeutic Uses;Anti-Asthmatic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Nasal Decongestants;Cardiovascular Agents;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Lung Diseases;RNA Virus Infections;Infections;Asthma;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Virus Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Picornaviridae Infections;Bronchial Diseases;Hypersensitivity;Nose Diseases;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Phenethylamines;Substances and Cells (CHEM);Amino Alcohols;Alcohols;Pseudoephedrine;Organic Chemicals;Propanolamines;Substances;Ethylamines;Propanols;Amines,,Adrenergic beta-Agonists;Adrenergic alpha-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Cardiovascular Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Vascular Tone Alteration;Vascular Alterations;Vasoconstriction;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;Receptor Interaction;Sympathomimetic Agent;Nervous System Agent;alpha-Adrenergic Agonist,,,,,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
69,14,Concomitant Medications,Generic Name,RxNorm,Excedrine Migraine,,,,,209468.0,209468,True,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Salicylate-containing product;Alkaloid-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Methyl xanthine-containing product;Organic acid and/or organic acid derivative-containing product;Purine and/or purine derivative-containing product;Phenol structure-containing product,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Phosphodiesterase inhibitor-containing product;Enzyme inhibitor-containing product,"OTHER ANALGESICS AND ANTIPYRETICS;Salicylic acid and derivatives;BLOOD AND BLOOD FORMING ORGANS;Xanthine derivatives;ANTITHROMBOTIC AGENTS;ALIMENTARY TRACT AND METABOLISM;STOMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;Platelet aggregation inhibitors excl. heparin;NERVOUS SYSTEM;DERMATOLOGICALS;PSYCHOANALEPTICS;PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS;Other dermatologicals;OTHER DERMATOLOGICAL PREPARATIONS;Anilides;Other agents for local oral treatment","Analgesics;Antipyretics;Fibrinolytic Agents;Central Nervous System Agents;Purinergic Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Cyclooxygenase Inhibitors;Purinergic P1 Receptor Antagonists;Anti-Inflammatory Agents;Platelet Aggregation Inhibitors;Sensory System Agents;Central Nervous System Stimulants;Physiological Effects of Drugs;Therapeutic Uses;Phosphodiesterase Inhibitors;Purinergic Antagonists;Fibrin Modulating Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Hematologic Agents;Analgesics, Non-Narcotic;Cardiovascular Agents;Antirheumatic Agents;Neurotransmitter Agents","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Signs and Symptoms, Respiratory;Osteoarthritis;Musculoskeletal Diseases;Immune System Diseases;Pain;Arthritis;Respiration Disorders;Crystal Arthropathies;Joint Diseases;Apnea;Metabolic Diseases;Autoimmune Diseases;Streptococcal Infections;Infections;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Fatigue;Rheumatic Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Bacterial Infections;Bacterial Infections and Mycoses;Respiratory Tract Diseases;Gram-Positive Bacterial Infections;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Nervous System Diseases;Gout;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Child, Preschool;Hemorrhage;Digestive System Diseases;Pregnancy Trimester, Third;Gastrointestinal Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Polyps;Life Phases, Behavior Mechanisms and Physiologic States;Gastrointestinal Hemorrhage;Metabolic Diseases;Pregnancy Trimesters;Herpesviridae Infections;Infections;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;DNA Virus Infections;Metabolism, Inborn Errors;Blood Coagulation Disorders;Blood Platelet Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Age Groups;Infant;Vomiting;Otorhinolaryngologic Diseases;Signs and Symptoms, Digestive;Melena;Virus Diseases;Drug-Related Side Effects and Adverse Reactions;Hematemesis;Child;Respiratory Tract Diseases;Anemia;Genetic Diseases, Inborn;Signs and Symptoms;Nasal Polyps;Chemically-Induced Disorders;Reproductive Physiological Phenomena;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Nose Diseases;Varicella Zoster Virus Infection;Chickenpox;Pathologic Processes;Disease;Hemorrhagic Disorders","Cardiovascular Diseases;Brain Ischemia;Stroke;Hypertension;Hypertension, Pregnancy-Induced;Myocardial Ischemia;Heart Diseases;Pain;Urogenital Diseases;Cerebral Infarction;Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Cerebrovascular Disorders;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pre-Eclampsia;Fever;Pathologic Processes;Ischemic Attack, Transient;Ischemia;Infarction;Body Temperature Changes;Neurologic Manifestations;Central Nervous System Diseases;Signs and Symptoms;Necrosis;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Brain Infarction;Brain Diseases","Phenols;Alkaloids;Carboxylic Acids;Hydrocarbons, Cyclic;Caffeine;Purines;Substances and Cells (CHEM);Amines;Purinones;Aniline Compounds;Hydrocarbons, Aromatic;Xanthines;Amides;Acetaminophen;Substances;Acetanilides;Anilides;Benzene Derivatives;Hydroxy Acids;Salicylates;Heterocyclic Compounds;Aspirin;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Hydroxybenzoates;Benzoates;Organic Chemicals;Acids, Carbocyclic;Heterocyclic Compounds, 2-Ring",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);Enzyme Interactions;G-Protein-linked Receptor Interactions,Platelet Aggregation Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Coagulation Activity Alteration;Peripheral Nervous System Activity Alteration;Cardiovascular Activity Alteration;Decreased Collecting Duct Water Permeability;Respiratory/Pulmonary Activity Alteration;Smooth Muscle Tone Alteration;Collecting Duct Water Permeability Alteration;Increased Central Nervous System Organized Electrical Activity;Decreased Coagulation Activity;Physiologic Effect (PE);Generalized Systemic Effects;Hemostasis Alteration;Organized Electrical Activity Alteration;Decreased Eicosanoid Production;Central Nervous System Stimulation;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Decreased Immunologically Active Molecule Production;Renal/Urological Activity Alteration;Decreased Platelet Aggregation;Musculoskeletal Activity Alteration;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Hematologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Central Nervous System Activity Alteration;Bronchodilation;Immunologic Activity Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity;Autonomic Nervous System Activity Alteration;Increased Organized Electrical Activity;Electrical Activity Alteration;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Central Nervous System Stimulant;Platelet Aggregation Inhibitor;Enzyme Inhibitor;Chemical Structure;Hematology Agent;Nervous System Agent;Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Methylxanthine,,,"Purinones;Alkaloids;Xanthines;Purines;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,,,,,,
70,15,Concomitant Medications,Generic Name,RxNorm,Fosinopril,Fosinopril Oral Tablet [Monopril],367691.0,Fosinopril Oral Tablet [Monopril],50166.0,50166.0,50166,False,CARDIOVASCULAR MEDICATIONS;VA CLASSES;ACE INHIBITORS,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;ACE INHIBITORS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Amino acid derivative-containing product,Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Enzyme inhibitor-containing product,"CARDIOVASCULAR SYSTEM;ACE INHIBITORS, PLAIN;ACE inhibitors, plain;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",Protease Inhibitors;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents,"Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Hypertension;Endocrine System Diseases;Heart Diseases;Diabetes Mellitus;Urogenital Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction;Kidney Diseases;Diabetes Complications;Heart Failure;Diabetic Nephropathies;Disease;Male Urogenital Diseases","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Immune System Diseases;Hyperaldosteronism;Urticaria;Adrenal Gland Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Adrenocortical Hyperfunction;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypotension;Skin Diseases, Vascular;Hypersensitivity, Immediate;Skin Diseases;Angioedema;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Chemically-Induced Disorders;Hypersensitivity;Disease;Skin and Connective Tissue Diseases","Cardiovascular Diseases;Nutritional and Metabolic Diseases;Urologic Diseases;Endocrine System Diseases;Heart Diseases;Diabetes Mellitus;Cardiomegaly;Hypertrophy, Left Ventricular;Urogenital Diseases;Glucose Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Ventricular Dysfunction, Left;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertrophy;Ventricular Dysfunction;Kidney Diseases;Diabetes Complications;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Diabetic Nephropathies;Disease;Male Urogenital Diseases","Acids, Noncarboxylic;Carboxylic Acids;Amino Acids;Amino Acids, Cyclic;Substances and Cells (CHEM);Phosphinic Acids;Substances;Proline;Imines;Organophosphorus Compounds;Acids;Phosphorus Acids;Acids, Acyclic;Fosinopril;Phosphorus Compounds;Imino Acids;Inorganic Chemicals;Amino Acids, Peptides, and Proteins;Organic Chemicals",,Protease Inhibitors;Enzyme Inhibitors;Angiotensin-converting Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA),Decreased Mineralocorticoid Secretion;Endocrine Activity Alteration;Renal Arterial Vasodilation;Organ System Specific Effects;Cardiovascular Activity Alteration;Arterial Vasodilation;Decreased Kinin Degradation;Increased Renal Ion Excretion;Decreased Intravascular Volume;Physiologic Effect (PE);Decreased Blood Pressure;Generalized Systemic Effects;Vascular Alterations;Vasodilation;Renal/Urological Activity Alteration;Blood Pressure Alteration;Increased Renal Na+ Excretion;Hematologic Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Intravascular Volume Alteration;Vascular Tone Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Immunologically Active Molecule Degradation;Decreased Renal K+ Excretion;Adrenal Cortical Activity Alteration;Immunologic Activity Alteration;Immunologically Active Molecule Degradation Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity;Decreased Bradykinin Degradation,Cardiovascular Agent;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Antimicrobial;Anti-infective,,,,,,Protease Inhibitors;Enzyme Inhibitors;Angiotensin-converting Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA),,,,
71,15,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine (Pfizer),,,,,2468230.0,2468230,True,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,"Substances and Cells (CHEM);Recombinant Proteins;Amino Acids, Peptides, and Proteins;mRNA Vaccines;Biological Products;Vaccines, Synthetic;COVID-19 Vaccines;Proteins;Vaccines;Antigens;Biological Factors;Substances;Viral Vaccines;Complex Mixtures;Nucleic Acid-Based Vaccines;BNT162 Vaccine",,,,,,,,,,,,,,
72,18,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine (Pfizer),,,,,2468230.0,2468230,True,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,"Substances and Cells (CHEM);Recombinant Proteins;Amino Acids, Peptides, and Proteins;mRNA Vaccines;Biological Products;Vaccines, Synthetic;COVID-19 Vaccines;Proteins;Vaccines;Antigens;Biological Factors;Substances;Viral Vaccines;Complex Mixtures;Nucleic Acid-Based Vaccines;BNT162 Vaccine",,,,,,,,,,,,,,
73,16,Concomitant Medications,Generic Name,RxNorm,Zyrtec,ZyrTEC,58930.0,ZyrTEC,58930.0,58930.0,58930,False,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",Medicinal product categorized by structure;Piperazine and/or piperazine derivative-containing product,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,SENSORY ORGANS;Other antiallergics;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Piperazine derivatives;OPHTHALMOLOGICALS;DECONGESTANTS AND ANTIALLERGICS;ANTIHISTAMINES FOR SYSTEMIC USE,"Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Anti-Allergic Agents;Histamine H1 Antagonists;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Histamine Agents;Neurotransmitter Agents;Physiological Effects of Drugs","Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Rhinitis, Allergic;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases, Vascular;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Nose Diseases;Skin Diseases;Infections;Disease;Skin and Connective Tissue Diseases;Rhinitis;Urticaria","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Heterocyclic Compounds, 1-Ring;Cetirizine;Piperazines;Substances;Hydroxyzine;Substances and Cells (CHEM);Heterocyclic Compounds",,Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Histamine-1 Receptor Antagonist;Receptor Interaction;Established Pharmacologic Class (EPC);Receptor Antagonist,,,,,,,,,,
74,23,Concomitant Medications,Generic Name,RxNorm,zyrtec,Zyrtec,58930.0,Zyrtec,58930.0,58930.0,58930,False,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",Medicinal product categorized by structure;Piperazine and/or piperazine derivative-containing product,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,SENSORY ORGANS;Other antiallergics;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Piperazine derivatives;OPHTHALMOLOGICALS;DECONGESTANTS AND ANTIALLERGICS;ANTIHISTAMINES FOR SYSTEMIC USE,"Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Anti-Allergic Agents;Histamine H1 Antagonists;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Histamine Agents;Neurotransmitter Agents;Physiological Effects of Drugs","Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Rhinitis, Allergic;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases, Vascular;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Nose Diseases;Skin Diseases;Infections;Disease;Skin and Connective Tissue Diseases;Rhinitis;Urticaria","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Heterocyclic Compounds, 1-Ring;Cetirizine;Piperazines;Substances;Hydroxyzine;Substances and Cells (CHEM);Heterocyclic Compounds",,Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Histamine-1 Receptor Antagonist;Receptor Interaction;Established Pharmacologic Class (EPC);Receptor Antagonist,,,,,,,,,,
75,38,Concomitant Medications,Generic Name,RxNorm,Zyrtec,,,,58930.0,58930.0,58930,False,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",Medicinal product categorized by structure;Piperazine and/or piperazine derivative-containing product,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,SENSORY ORGANS;Other antiallergics;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Piperazine derivatives;OPHTHALMOLOGICALS;DECONGESTANTS AND ANTIALLERGICS;ANTIHISTAMINES FOR SYSTEMIC USE,"Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Anti-Allergic Agents;Histamine H1 Antagonists;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Histamine Agents;Neurotransmitter Agents;Physiological Effects of Drugs","Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Rhinitis, Allergic;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases, Vascular;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Nose Diseases;Skin Diseases;Infections;Disease;Skin and Connective Tissue Diseases;Rhinitis;Urticaria","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Heterocyclic Compounds, 1-Ring;Cetirizine;Piperazines;Substances;Hydroxyzine;Substances and Cells (CHEM);Heterocyclic Compounds",,Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Histamine-1 Receptor Antagonist;Receptor Interaction;Established Pharmacologic Class (EPC);Receptor Antagonist,,,,,,,,,,
76,16,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,,,Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Alcohol-containing product;Azole-containing product;Vitamin D and/or vitamin D derivative-containing product;Metal and/or metallic compound-containing product;Retinoid-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Thiazole-containing product;Medicinal product categorized by structure;Vitamin A and/or vitamin A derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Steroid-containing product,Hormone-containing product;Medicinal product categorized by disposition;Calcium regulating hormone-containing product,"VITAMINS;LIPID MODIFYING AGENTS, PLAIN;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);Other nasal preparations;Vitamin A, plain;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Organic acids;Vitamin B1, plain;GENITO URINARY SYSTEM AND SEX HORMONES;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;LIPID MODIFYING AGENTS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;ANTIANEMIC PREPARATIONS;Vitamin D and analogues;OPHTHALMOLOGICALS;Other plain vitamin preparations;Ascorbic acid (vitamin C), plain;CARDIOVASCULAR SYSTEM;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;STOMATOLOGICAL PREPARATIONS;Caries prophylactic agents;Retinoids for topical use in acne;OTHER PLAIN VITAMIN PREPARATIONS;PERIPHERAL VASODILATORS;Nicotinic acid and derivatives;NASAL PREPARATIONS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;BLOOD AND BLOOD FORMING ORGANS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;DERMATOLOGICALS;Fluoride;MINERAL SUPPLEMENTS",Antimetabolites;Micronutrients;Radiation-Sensitizing Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Vasodilator Agents;Therapeutic Uses;Bone Density Conservation Agents;Lipid Regulating Agents;Vitamins;Protective Agents;Antioxidants;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Cariostatic Agents;Cardiovascular Agents;Photosensitizing Agents;Vitamin B Complex;Dermatologic Agents;Calcium-Regulating Hormones and Agents,"Tyrosinemias;Neurodegenerative Diseases;Renal Insufficiency, Chronic;Anemia, Pernicious;Lung Neoplasms;Nutritional and Metabolic Diseases;Neoplasms;Anemia, Hemolytic;Diabetes Mellitus;Alcohol-Induced Disorders, Nervous System;Crohn Disease;Hypophosphatemia, Familial;Malnutrition;Anemia, Macrocytic;Kidney Failure, Chronic;Lacrimal Apparatus Diseases;Psoriasis;Vitamin A Deficiency;Beriberi;Autoimmune Diseases of the Nervous System;Alcoholic Neuropathy;Autoimmune Diseases;Wounds, Penetrating;Dermatitis;Respiratory Tract Infections;Hypophosphatemia;Polyneuropathies;Vitamin B 12 Deficiency;Leukoencephalopathies;Diabetic Neuropathies;Neurologic Manifestations;Virus Diseases;Osteoporosis;Drug-Related Side Effects and Adverse Reactions;Skin Neoplasms;Picornaviridae Infections;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Male Urogenital Diseases;Dementia;Cardiovascular Diseases;Common Cold;Immune System Diseases;Scurvy;Multiple Sclerosis;Rickets;Renal Tubular Transport, Inborn Errors;Pellagra;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Ascorbic Acid Deficiency;Female Urogenital Diseases;Calcium Metabolism Disorders;Vascular Diseases;Anemia, Megaloblastic;Hypertriglyceridemia;Hypercholesterolemia;Vitamin B 6 Deficiency;Skin Diseases;Tauopathies;Sensation Disorders;Skin Diseases, Papulosquamous;Diabetes Complications;Neurotoxicity Syndromes;Respiratory Tract Diseases;Anemia;Bone Diseases;Pathologic Processes;Disease;Hemorrhagic Disorders;Skin and Connective Tissue Diseases;Renal Insufficiency;Urologic Diseases;Endocrine System Diseases;Thoracic Neoplasms;Hyperlipidemias;Digestive System Diseases;Neoplasms by Site;Lung Diseases;Inflammatory Bowel Diseases;Photosensitivity Disorders;Hypoparathyroidism;Nutrition Disorders;Intestinal Diseases;Wernicke Encephalopathy;RNA Virus Infections;Bone Diseases, Metabolic;Mental Disorders;Alcohol-Induced Disorders;Metabolism, Inborn Errors;Riboflavin Deficiency;Dry Eye Syndromes;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Hemostatic Disorders;Kidney Diseases;Dyskinesias;Respiratory Tract Neoplasms;Peripheral Nervous System Diseases;Brain Diseases, Metabolic, Inborn;Vision Disorders;Hemic and Lymphatic Diseases;Gastroenteritis;Alzheimer Disease;Rickets, Hypophosphatemic;Poisoning;Xerophthalmia;Deficiency Diseases;Dyskinesia, Drug-Induced;Avitaminosis;Hematologic Diseases;Lipid Metabolism Disorders;Thiamine Deficiency;Vitamin D Deficiency;Night Blindness;Methemoglobinemia;Musculoskeletal Diseases;Alcohol-Related Disorders;Phosphorus Metabolism Disorders;Conjunctival Diseases;Vitamin E Deficiency;Wounds and Injuries;Urogenital Diseases;Glucose Metabolism Disorders;Brain Diseases, Metabolic;Gastrointestinal Diseases;Parathyroid Diseases;Amino Acid Metabolism, Inborn Errors;Dyslipidemias;Disease Attributes;Metal Metabolism, Inborn Errors;Chronic Disease;Infections;Eye Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Demyelinating Autoimmune Diseases, CNS;Demyelinating Diseases;Neuromuscular Diseases;Substance-Related Disorders;Familial Hypophosphatemic Rickets;Central Nervous System Diseases;Chemically-Induced Disorders;Genetic Diseases, Inborn;Neurocognitive Disorders;Movement Disorders;Peripheral Vascular Diseases;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Peptic Ulcer;Vascular Diseases;Cardiovascular Diseases;Gastrointestinal Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Stomach Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Hypotension;Digestive System Diseases;Intestinal Diseases;Hemorrhage;Pathological Conditions, Signs and Symptoms;Duodenal Diseases;Pathologic Processes;Disease","Deficiency Diseases;Dyskinesia, Drug-Induced;Avitaminosis;Dementia;Neurodegenerative Diseases;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Hematologic Diseases;Dental Caries;Infant, Newborn, Diseases;Anemia, Hemolytic;Myocardial Ischemia;Dental Plaque;Heart Diseases;Periodontal Diseases;Wounds and Injuries;Ventilator-Induced Lung Injury;Thoracic Injuries;Vitamin E Deficiency;Dental Deposits;Lung Diseases;Malnutrition;Nutrition Disorders;Mouth Diseases;Vitamin A Deficiency;Mental Disorders;Coronary Disease;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Tooth Diseases;Disease;Vascular Diseases;Riboflavin Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Arteriosclerosis;Vitamin B 6 Deficiency;Vitamin B 12 Deficiency;Tauopathies;Coronary Artery Disease;Neurologic Manifestations;Dyskinesias;Drug-Related Side Effects and Adverse Reactions;Stomatognathic Diseases;Tooth Demineralization;Neurotoxicity Syndromes;Central Nervous System Diseases;Tooth Loss;Signs and Symptoms;Chemically-Induced Disorders;Bronchopulmonary Dysplasia;Respiratory Tract Diseases;Lung Injury;Anemia;Neurocognitive Disorders;Arterial Occlusive Diseases;Movement Disorders;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Alzheimer Disease;Nervous System Diseases;Poisoning;Infant, Premature, Diseases;Brain Diseases","Hydrocarbons, Cyclic;Terpenes;Vitamin A;Secosteroids;Substances;Nicotinic Acids;Heterocyclic Compounds, 3-Ring;Pyrans;Anions;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Retinoids;Heterocyclic Compounds, 2-Ring;Membrane Lipids;Diterpenes;Pteridines;Picolines;Acids, Noncarboxylic;Steroids;Niacin;Vitamin B 6;Electrolytes;Thiamine;Sugar Acids;Azoles;Cyclohexanes;Sterols;Vitamin B 12;Acids, Heterocyclic;Acids, Acyclic;Cholestanes;Fused-Ring Compounds;Carotenoids;Polyenes;Inorganic Chemicals;Cariostatic Agents;Cholestenes;Carbohydrates;Carboxylic Acids;Flavins;Fluorides;Coenzymes;Pigments, Biological;Biomedical and Dental Materials;Sulfur Compounds;Thiazoles;Hydroxy Acids;Biological Factors;Cyclohexenes;Pyrroles;Fluorine Compounds;Heterocyclic Compounds;Hydrofluoric Acid;Sodium Compounds;Riboflavin;Polycyclic Compounds;Vitamin D;Vitamin E;Specialty Uses of Chemicals;Benzopyrans;Substances and Cells (CHEM);Pyridines;Tetrapyrroles;Chemical Actions and Uses;Hydrocarbons, Acyclic;Cholecalciferol;Acids;Enzymes and Coenzymes;Macrocyclic Compounds;Ascorbic Acid;Lipids;Ions;Hydrocarbons, Alicyclic;Protective Agents;Sodium Fluoride;Corrinoids;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Alkenes;Heterocyclic Compounds, 1-Ring;Cycloparaffins;Pyrimidines",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Unknown Cellular or Molecular Interaction;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Carbohydrate Metabolism Alteration;Organ System Specific Effects;Glucose Metabolism Alteration;Bone Formation Alteration;Cholesterol Synthesis Alteration;Decreased Vitamin Uptake and Modification;Bone Formation Stimulation;Lipid Metabolism Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Cholesterol Metabolism Alteration;Vitamin Uptake and Modification Alteration;Stimulation Small Intestine Fluid/Electrolyte Absorption;Small Intestine Fluid/Electrolyte Alteration;Digestive/GI System Activity Alteration;Decreased Renal Ca++ Excretion;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Absorption Alteration;Musculoskeletal Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Metabolic Activity Alteration;Sterol Metabolism Alteration;Decreased Cholesterol Synthesis;Bone Alteration,Established Pharmacologic Class (EPC);Vitamin B12;Hormone;Vitamin or Mineral;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin C;Vitamin A,,,"Diterpenes;Carboxylic Acids;Hydrocarbons, Cyclic;Steroids;Pigments, Biological;Terpenes;Substances and Cells (CHEM);Vitamin A;Pyridines;Sugar Acids;Azoles;Tetrapyrroles;Cyclohexanes;Vitamin D;Secosteroids;Substances;Nicotinic Acids;Hydrocarbons, Acyclic;Vitamin B 12;Acids, Heterocyclic;Macrocyclic Compounds;Ascorbic Acid;Acids, Acyclic;Hydroxy Acids;Hydrocarbons, Alicyclic;Biological Factors;Cyclohexenes;Pyrroles;Fused-Ring Compounds;Corrinoids;Carotenoids;Polyenes;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Alkenes;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Retinoids;Heterocyclic Compounds, 1-Ring;Cycloparaffins;Polycyclic Compounds;Carbohydrates",,,,"Diarrhea;Urologic Diseases;Signs and Symptoms;Flatulence;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperoxaluria;Flushing;Female Urogenital Diseases and Pregnancy Complications;Skin Manifestations;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,"Gastrointestinal Diseases;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malabsorption Syndromes;Intestinal Diseases;Metabolic Diseases;Digestive System Diseases;Disease",
77,18,Concomitant Medications,Generic Name,RxNorm,multivitamin,,,,,1234482.0,1234482,True,,,Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Alcohol-containing product;Azole-containing product;Vitamin D and/or vitamin D derivative-containing product;Metal and/or metallic compound-containing product;Retinoid-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Thiazole-containing product;Medicinal product categorized by structure;Vitamin A and/or vitamin A derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Steroid-containing product,Hormone-containing product;Medicinal product categorized by disposition;Calcium regulating hormone-containing product,"VITAMINS;LIPID MODIFYING AGENTS, PLAIN;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);Other nasal preparations;Vitamin A, plain;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Organic acids;Vitamin B1, plain;GENITO URINARY SYSTEM AND SEX HORMONES;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;LIPID MODIFYING AGENTS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;ANTIANEMIC PREPARATIONS;Vitamin D and analogues;OPHTHALMOLOGICALS;Other plain vitamin preparations;Ascorbic acid (vitamin C), plain;CARDIOVASCULAR SYSTEM;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;STOMATOLOGICAL PREPARATIONS;Caries prophylactic agents;Retinoids for topical use in acne;OTHER PLAIN VITAMIN PREPARATIONS;PERIPHERAL VASODILATORS;Nicotinic acid and derivatives;NASAL PREPARATIONS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;BLOOD AND BLOOD FORMING ORGANS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;DERMATOLOGICALS;Fluoride;MINERAL SUPPLEMENTS",Antimetabolites;Micronutrients;Radiation-Sensitizing Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Vasodilator Agents;Therapeutic Uses;Bone Density Conservation Agents;Lipid Regulating Agents;Vitamins;Protective Agents;Antioxidants;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Cariostatic Agents;Cardiovascular Agents;Photosensitizing Agents;Vitamin B Complex;Dermatologic Agents;Calcium-Regulating Hormones and Agents,"Tyrosinemias;Neurodegenerative Diseases;Renal Insufficiency, Chronic;Anemia, Pernicious;Lung Neoplasms;Nutritional and Metabolic Diseases;Neoplasms;Anemia, Hemolytic;Diabetes Mellitus;Alcohol-Induced Disorders, Nervous System;Crohn Disease;Hypophosphatemia, Familial;Malnutrition;Anemia, Macrocytic;Kidney Failure, Chronic;Lacrimal Apparatus Diseases;Psoriasis;Vitamin A Deficiency;Beriberi;Autoimmune Diseases of the Nervous System;Alcoholic Neuropathy;Autoimmune Diseases;Wounds, Penetrating;Dermatitis;Respiratory Tract Infections;Hypophosphatemia;Polyneuropathies;Vitamin B 12 Deficiency;Leukoencephalopathies;Diabetic Neuropathies;Neurologic Manifestations;Virus Diseases;Osteoporosis;Drug-Related Side Effects and Adverse Reactions;Skin Neoplasms;Picornaviridae Infections;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Male Urogenital Diseases;Dementia;Cardiovascular Diseases;Common Cold;Immune System Diseases;Scurvy;Multiple Sclerosis;Rickets;Renal Tubular Transport, Inborn Errors;Pellagra;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Ascorbic Acid Deficiency;Female Urogenital Diseases;Calcium Metabolism Disorders;Vascular Diseases;Anemia, Megaloblastic;Hypertriglyceridemia;Hypercholesterolemia;Vitamin B 6 Deficiency;Skin Diseases;Tauopathies;Sensation Disorders;Skin Diseases, Papulosquamous;Diabetes Complications;Neurotoxicity Syndromes;Respiratory Tract Diseases;Anemia;Bone Diseases;Pathologic Processes;Disease;Hemorrhagic Disorders;Skin and Connective Tissue Diseases;Renal Insufficiency;Urologic Diseases;Endocrine System Diseases;Thoracic Neoplasms;Hyperlipidemias;Digestive System Diseases;Neoplasms by Site;Lung Diseases;Inflammatory Bowel Diseases;Photosensitivity Disorders;Hypoparathyroidism;Nutrition Disorders;Intestinal Diseases;Wernicke Encephalopathy;RNA Virus Infections;Bone Diseases, Metabolic;Mental Disorders;Alcohol-Induced Disorders;Metabolism, Inborn Errors;Riboflavin Deficiency;Dry Eye Syndromes;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Hemostatic Disorders;Kidney Diseases;Dyskinesias;Respiratory Tract Neoplasms;Peripheral Nervous System Diseases;Brain Diseases, Metabolic, Inborn;Vision Disorders;Hemic and Lymphatic Diseases;Gastroenteritis;Alzheimer Disease;Rickets, Hypophosphatemic;Poisoning;Xerophthalmia;Deficiency Diseases;Dyskinesia, Drug-Induced;Avitaminosis;Hematologic Diseases;Lipid Metabolism Disorders;Thiamine Deficiency;Vitamin D Deficiency;Night Blindness;Methemoglobinemia;Musculoskeletal Diseases;Alcohol-Related Disorders;Phosphorus Metabolism Disorders;Conjunctival Diseases;Vitamin E Deficiency;Wounds and Injuries;Urogenital Diseases;Glucose Metabolism Disorders;Brain Diseases, Metabolic;Gastrointestinal Diseases;Parathyroid Diseases;Amino Acid Metabolism, Inborn Errors;Dyslipidemias;Disease Attributes;Metal Metabolism, Inborn Errors;Chronic Disease;Infections;Eye Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Demyelinating Autoimmune Diseases, CNS;Demyelinating Diseases;Neuromuscular Diseases;Substance-Related Disorders;Familial Hypophosphatemic Rickets;Central Nervous System Diseases;Chemically-Induced Disorders;Genetic Diseases, Inborn;Neurocognitive Disorders;Movement Disorders;Peripheral Vascular Diseases;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Peptic Ulcer;Vascular Diseases;Cardiovascular Diseases;Gastrointestinal Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Stomach Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Hypotension;Digestive System Diseases;Intestinal Diseases;Hemorrhage;Pathological Conditions, Signs and Symptoms;Duodenal Diseases;Pathologic Processes;Disease","Deficiency Diseases;Dyskinesia, Drug-Induced;Avitaminosis;Dementia;Neurodegenerative Diseases;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Hematologic Diseases;Dental Caries;Infant, Newborn, Diseases;Anemia, Hemolytic;Myocardial Ischemia;Dental Plaque;Heart Diseases;Periodontal Diseases;Wounds and Injuries;Ventilator-Induced Lung Injury;Thoracic Injuries;Vitamin E Deficiency;Dental Deposits;Lung Diseases;Malnutrition;Nutrition Disorders;Mouth Diseases;Vitamin A Deficiency;Mental Disorders;Coronary Disease;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Tooth Diseases;Disease;Vascular Diseases;Riboflavin Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Arteriosclerosis;Vitamin B 6 Deficiency;Vitamin B 12 Deficiency;Tauopathies;Coronary Artery Disease;Neurologic Manifestations;Dyskinesias;Drug-Related Side Effects and Adverse Reactions;Stomatognathic Diseases;Tooth Demineralization;Neurotoxicity Syndromes;Central Nervous System Diseases;Tooth Loss;Signs and Symptoms;Chemically-Induced Disorders;Bronchopulmonary Dysplasia;Respiratory Tract Diseases;Lung Injury;Anemia;Neurocognitive Disorders;Arterial Occlusive Diseases;Movement Disorders;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Alzheimer Disease;Nervous System Diseases;Poisoning;Infant, Premature, Diseases;Brain Diseases","Hydrocarbons, Cyclic;Terpenes;Vitamin A;Secosteroids;Substances;Nicotinic Acids;Heterocyclic Compounds, 3-Ring;Pyrans;Anions;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Retinoids;Heterocyclic Compounds, 2-Ring;Membrane Lipids;Diterpenes;Pteridines;Picolines;Acids, Noncarboxylic;Steroids;Niacin;Vitamin B 6;Electrolytes;Thiamine;Sugar Acids;Azoles;Cyclohexanes;Sterols;Vitamin B 12;Acids, Heterocyclic;Acids, Acyclic;Cholestanes;Fused-Ring Compounds;Carotenoids;Polyenes;Inorganic Chemicals;Cariostatic Agents;Cholestenes;Carbohydrates;Carboxylic Acids;Flavins;Fluorides;Coenzymes;Pigments, Biological;Biomedical and Dental Materials;Sulfur Compounds;Thiazoles;Hydroxy Acids;Biological Factors;Cyclohexenes;Pyrroles;Fluorine Compounds;Heterocyclic Compounds;Hydrofluoric Acid;Sodium Compounds;Riboflavin;Polycyclic Compounds;Vitamin D;Vitamin E;Specialty Uses of Chemicals;Benzopyrans;Substances and Cells (CHEM);Pyridines;Tetrapyrroles;Chemical Actions and Uses;Hydrocarbons, Acyclic;Cholecalciferol;Acids;Enzymes and Coenzymes;Macrocyclic Compounds;Ascorbic Acid;Lipids;Ions;Hydrocarbons, Alicyclic;Protective Agents;Sodium Fluoride;Corrinoids;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Alkenes;Heterocyclic Compounds, 1-Ring;Cycloparaffins;Pyrimidines",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Unknown Cellular or Molecular Interaction;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Carbohydrate Metabolism Alteration;Organ System Specific Effects;Glucose Metabolism Alteration;Bone Formation Alteration;Cholesterol Synthesis Alteration;Decreased Vitamin Uptake and Modification;Bone Formation Stimulation;Lipid Metabolism Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Cholesterol Metabolism Alteration;Vitamin Uptake and Modification Alteration;Stimulation Small Intestine Fluid/Electrolyte Absorption;Small Intestine Fluid/Electrolyte Alteration;Digestive/GI System Activity Alteration;Decreased Renal Ca++ Excretion;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Absorption Alteration;Musculoskeletal Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Metabolic Activity Alteration;Sterol Metabolism Alteration;Decreased Cholesterol Synthesis;Bone Alteration,Established Pharmacologic Class (EPC);Vitamin B12;Hormone;Vitamin or Mineral;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin C;Vitamin A,,,"Diterpenes;Carboxylic Acids;Hydrocarbons, Cyclic;Steroids;Pigments, Biological;Terpenes;Substances and Cells (CHEM);Vitamin A;Pyridines;Sugar Acids;Azoles;Tetrapyrroles;Cyclohexanes;Vitamin D;Secosteroids;Substances;Nicotinic Acids;Hydrocarbons, Acyclic;Vitamin B 12;Acids, Heterocyclic;Macrocyclic Compounds;Ascorbic Acid;Acids, Acyclic;Hydroxy Acids;Hydrocarbons, Alicyclic;Biological Factors;Cyclohexenes;Pyrroles;Fused-Ring Compounds;Corrinoids;Carotenoids;Polyenes;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Alkenes;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Retinoids;Heterocyclic Compounds, 1-Ring;Cycloparaffins;Polycyclic Compounds;Carbohydrates",,,,"Diarrhea;Urologic Diseases;Signs and Symptoms;Flatulence;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperoxaluria;Flushing;Female Urogenital Diseases and Pregnancy Complications;Skin Manifestations;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,"Gastrointestinal Diseases;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malabsorption Syndromes;Intestinal Diseases;Metabolic Diseases;Digestive System Diseases;Disease",
78,43,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,,,Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Alcohol-containing product;Azole-containing product;Vitamin D and/or vitamin D derivative-containing product;Metal and/or metallic compound-containing product;Retinoid-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Thiazole-containing product;Medicinal product categorized by structure;Vitamin A and/or vitamin A derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Steroid-containing product,Hormone-containing product;Medicinal product categorized by disposition;Calcium regulating hormone-containing product,"VITAMINS;LIPID MODIFYING AGENTS, PLAIN;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);Other nasal preparations;Vitamin A, plain;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Organic acids;Vitamin B1, plain;GENITO URINARY SYSTEM AND SEX HORMONES;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;LIPID MODIFYING AGENTS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;ANTIANEMIC PREPARATIONS;Vitamin D and analogues;OPHTHALMOLOGICALS;Other plain vitamin preparations;Ascorbic acid (vitamin C), plain;CARDIOVASCULAR SYSTEM;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;STOMATOLOGICAL PREPARATIONS;Caries prophylactic agents;Retinoids for topical use in acne;OTHER PLAIN VITAMIN PREPARATIONS;PERIPHERAL VASODILATORS;Nicotinic acid and derivatives;NASAL PREPARATIONS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;BLOOD AND BLOOD FORMING ORGANS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;DERMATOLOGICALS;Fluoride;MINERAL SUPPLEMENTS",Antimetabolites;Micronutrients;Radiation-Sensitizing Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Vasodilator Agents;Therapeutic Uses;Bone Density Conservation Agents;Lipid Regulating Agents;Vitamins;Protective Agents;Antioxidants;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Cariostatic Agents;Cardiovascular Agents;Photosensitizing Agents;Vitamin B Complex;Dermatologic Agents;Calcium-Regulating Hormones and Agents,"Tyrosinemias;Neurodegenerative Diseases;Renal Insufficiency, Chronic;Anemia, Pernicious;Lung Neoplasms;Nutritional and Metabolic Diseases;Neoplasms;Anemia, Hemolytic;Diabetes Mellitus;Alcohol-Induced Disorders, Nervous System;Crohn Disease;Hypophosphatemia, Familial;Malnutrition;Anemia, Macrocytic;Kidney Failure, Chronic;Lacrimal Apparatus Diseases;Psoriasis;Vitamin A Deficiency;Beriberi;Autoimmune Diseases of the Nervous System;Alcoholic Neuropathy;Autoimmune Diseases;Wounds, Penetrating;Dermatitis;Respiratory Tract Infections;Hypophosphatemia;Polyneuropathies;Vitamin B 12 Deficiency;Leukoencephalopathies;Diabetic Neuropathies;Neurologic Manifestations;Virus Diseases;Osteoporosis;Drug-Related Side Effects and Adverse Reactions;Skin Neoplasms;Picornaviridae Infections;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Male Urogenital Diseases;Dementia;Cardiovascular Diseases;Common Cold;Immune System Diseases;Scurvy;Multiple Sclerosis;Rickets;Renal Tubular Transport, Inborn Errors;Pellagra;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Ascorbic Acid Deficiency;Female Urogenital Diseases;Calcium Metabolism Disorders;Vascular Diseases;Anemia, Megaloblastic;Hypertriglyceridemia;Hypercholesterolemia;Vitamin B 6 Deficiency;Skin Diseases;Tauopathies;Sensation Disorders;Skin Diseases, Papulosquamous;Diabetes Complications;Neurotoxicity Syndromes;Respiratory Tract Diseases;Anemia;Bone Diseases;Pathologic Processes;Disease;Hemorrhagic Disorders;Skin and Connective Tissue Diseases;Renal Insufficiency;Urologic Diseases;Endocrine System Diseases;Thoracic Neoplasms;Hyperlipidemias;Digestive System Diseases;Neoplasms by Site;Lung Diseases;Inflammatory Bowel Diseases;Photosensitivity Disorders;Hypoparathyroidism;Nutrition Disorders;Intestinal Diseases;Wernicke Encephalopathy;RNA Virus Infections;Bone Diseases, Metabolic;Mental Disorders;Alcohol-Induced Disorders;Metabolism, Inborn Errors;Riboflavin Deficiency;Dry Eye Syndromes;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Hemostatic Disorders;Kidney Diseases;Dyskinesias;Respiratory Tract Neoplasms;Peripheral Nervous System Diseases;Brain Diseases, Metabolic, Inborn;Vision Disorders;Hemic and Lymphatic Diseases;Gastroenteritis;Alzheimer Disease;Rickets, Hypophosphatemic;Poisoning;Xerophthalmia;Deficiency Diseases;Dyskinesia, Drug-Induced;Avitaminosis;Hematologic Diseases;Lipid Metabolism Disorders;Thiamine Deficiency;Vitamin D Deficiency;Night Blindness;Methemoglobinemia;Musculoskeletal Diseases;Alcohol-Related Disorders;Phosphorus Metabolism Disorders;Conjunctival Diseases;Vitamin E Deficiency;Wounds and Injuries;Urogenital Diseases;Glucose Metabolism Disorders;Brain Diseases, Metabolic;Gastrointestinal Diseases;Parathyroid Diseases;Amino Acid Metabolism, Inborn Errors;Dyslipidemias;Disease Attributes;Metal Metabolism, Inborn Errors;Chronic Disease;Infections;Eye Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Demyelinating Autoimmune Diseases, CNS;Demyelinating Diseases;Neuromuscular Diseases;Substance-Related Disorders;Familial Hypophosphatemic Rickets;Central Nervous System Diseases;Chemically-Induced Disorders;Genetic Diseases, Inborn;Neurocognitive Disorders;Movement Disorders;Peripheral Vascular Diseases;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Peptic Ulcer;Vascular Diseases;Cardiovascular Diseases;Gastrointestinal Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Stomach Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Hypotension;Digestive System Diseases;Intestinal Diseases;Hemorrhage;Pathological Conditions, Signs and Symptoms;Duodenal Diseases;Pathologic Processes;Disease","Deficiency Diseases;Dyskinesia, Drug-Induced;Avitaminosis;Dementia;Neurodegenerative Diseases;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Hematologic Diseases;Dental Caries;Infant, Newborn, Diseases;Anemia, Hemolytic;Myocardial Ischemia;Dental Plaque;Heart Diseases;Periodontal Diseases;Wounds and Injuries;Ventilator-Induced Lung Injury;Thoracic Injuries;Vitamin E Deficiency;Dental Deposits;Lung Diseases;Malnutrition;Nutrition Disorders;Mouth Diseases;Vitamin A Deficiency;Mental Disorders;Coronary Disease;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Tooth Diseases;Disease;Vascular Diseases;Riboflavin Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Arteriosclerosis;Vitamin B 6 Deficiency;Vitamin B 12 Deficiency;Tauopathies;Coronary Artery Disease;Neurologic Manifestations;Dyskinesias;Drug-Related Side Effects and Adverse Reactions;Stomatognathic Diseases;Tooth Demineralization;Neurotoxicity Syndromes;Central Nervous System Diseases;Tooth Loss;Signs and Symptoms;Chemically-Induced Disorders;Bronchopulmonary Dysplasia;Respiratory Tract Diseases;Lung Injury;Anemia;Neurocognitive Disorders;Arterial Occlusive Diseases;Movement Disorders;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Alzheimer Disease;Nervous System Diseases;Poisoning;Infant, Premature, Diseases;Brain Diseases","Hydrocarbons, Cyclic;Terpenes;Vitamin A;Secosteroids;Substances;Nicotinic Acids;Heterocyclic Compounds, 3-Ring;Pyrans;Anions;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Retinoids;Heterocyclic Compounds, 2-Ring;Membrane Lipids;Diterpenes;Pteridines;Picolines;Acids, Noncarboxylic;Steroids;Niacin;Vitamin B 6;Electrolytes;Thiamine;Sugar Acids;Azoles;Cyclohexanes;Sterols;Vitamin B 12;Acids, Heterocyclic;Acids, Acyclic;Cholestanes;Fused-Ring Compounds;Carotenoids;Polyenes;Inorganic Chemicals;Cariostatic Agents;Cholestenes;Carbohydrates;Carboxylic Acids;Flavins;Fluorides;Coenzymes;Pigments, Biological;Biomedical and Dental Materials;Sulfur Compounds;Thiazoles;Hydroxy Acids;Biological Factors;Cyclohexenes;Pyrroles;Fluorine Compounds;Heterocyclic Compounds;Hydrofluoric Acid;Sodium Compounds;Riboflavin;Polycyclic Compounds;Vitamin D;Vitamin E;Specialty Uses of Chemicals;Benzopyrans;Substances and Cells (CHEM);Pyridines;Tetrapyrroles;Chemical Actions and Uses;Hydrocarbons, Acyclic;Cholecalciferol;Acids;Enzymes and Coenzymes;Macrocyclic Compounds;Ascorbic Acid;Lipids;Ions;Hydrocarbons, Alicyclic;Protective Agents;Sodium Fluoride;Corrinoids;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Alkenes;Heterocyclic Compounds, 1-Ring;Cycloparaffins;Pyrimidines",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Unknown Cellular or Molecular Interaction;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Carbohydrate Metabolism Alteration;Organ System Specific Effects;Glucose Metabolism Alteration;Bone Formation Alteration;Cholesterol Synthesis Alteration;Decreased Vitamin Uptake and Modification;Bone Formation Stimulation;Lipid Metabolism Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Cholesterol Metabolism Alteration;Vitamin Uptake and Modification Alteration;Stimulation Small Intestine Fluid/Electrolyte Absorption;Small Intestine Fluid/Electrolyte Alteration;Digestive/GI System Activity Alteration;Decreased Renal Ca++ Excretion;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Absorption Alteration;Musculoskeletal Activity Alteration;Decreased Renal Ion Excretion;Renal Ion Transport Alteration;Metabolic Activity Alteration;Sterol Metabolism Alteration;Decreased Cholesterol Synthesis;Bone Alteration,Established Pharmacologic Class (EPC);Vitamin B12;Hormone;Vitamin or Mineral;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin C;Vitamin A,,,"Diterpenes;Carboxylic Acids;Hydrocarbons, Cyclic;Steroids;Pigments, Biological;Terpenes;Substances and Cells (CHEM);Vitamin A;Pyridines;Sugar Acids;Azoles;Tetrapyrroles;Cyclohexanes;Vitamin D;Secosteroids;Substances;Nicotinic Acids;Hydrocarbons, Acyclic;Vitamin B 12;Acids, Heterocyclic;Macrocyclic Compounds;Ascorbic Acid;Acids, Acyclic;Hydroxy Acids;Hydrocarbons, Alicyclic;Biological Factors;Cyclohexenes;Pyrroles;Fused-Ring Compounds;Corrinoids;Carotenoids;Polyenes;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Alkenes;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Retinoids;Heterocyclic Compounds, 1-Ring;Cycloparaffins;Polycyclic Compounds;Carbohydrates",,,,"Diarrhea;Urologic Diseases;Signs and Symptoms;Flatulence;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperoxaluria;Flushing;Female Urogenital Diseases and Pregnancy Complications;Skin Manifestations;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,"Gastrointestinal Diseases;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malabsorption Syndromes;Intestinal Diseases;Metabolic Diseases;Digestive System Diseases;Disease",
79,17,Concomitant Medications,Generic Name,RxNorm,Aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;SKELETAL MUSCLE RELAXANTS;VA CLASSES;ANALGESICS;COLD REMEDIES,COMBINATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;SODIUM BICARBONATE CONTAINING ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;GASTROINTESTINAL MEDICATIONS;ANTACIDS;PLATELET AGGREGATION INHIBITORS;NON-OPIOID ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;SKELETAL MUSCLE RELAXANTS;VA CLASSES;ANALGESICS;COLD REMEDIES,COMBINATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;SODIUM BICARBONATE CONTAINING ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;GASTROINTESTINAL MEDICATIONS;ANTACIDS;PLATELET AGGREGATION INHIBITORS;NON-OPIOID ANALGESICS",Medicinal product categorized by structure;Salicylate-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,OTHER ANALGESICS AND ANTIPYRETICS;Salicylic acid and derivatives;BLOOD AND BLOOD FORMING ORGANS;OPIOIDS;ANTITHROMBOTIC AGENTS;ALIMENTARY TRACT AND METABOLISM;STOMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;Platelet aggregation inhibitors excl. heparin;NERVOUS SYSTEM;Opioids in combination with non-opioid analgesics;Other agents for local oral treatment,"Hypnotics and Sedatives;Analgesics;Antipyretics;Fibrinolytic Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Cyclooxygenase Inhibitors;Anti-Inflammatory Agents;Platelet Aggregation Inhibitors;Sensory System Agents;Physiological Effects of Drugs;Therapeutic Uses;Central Nervous System Depressants;Fibrin Modulating Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Hematologic Agents;Analgesics, Non-Narcotic;Cardiovascular Agents;Antirheumatic Agents","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Immune System Diseases;Pain;Arthritis;Crystal Arthropathies;Joint Diseases;Metabolic Diseases;Autoimmune Diseases;Streptococcal Infections;Infections;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Rheumatic Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Bacterial Infections;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Nervous System Diseases;Gout;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases","Hematologic Diseases;Drug Hypersensitivity;Adolescent;Lung Diseases, Obstructive;Immune System Diseases;Child, Preschool;Hemorrhage;Digestive System Diseases;Pregnancy Trimester, Third;Lung Diseases;Gastrointestinal Diseases;Polyps;Life Phases, Behavior Mechanisms and Physiologic States;Gastrointestinal Hemorrhage;Pregnancy Trimesters;Herpesviridae Infections;Infections;Asthma;DNA Virus Infections;Blood Coagulation Disorders;Respiratory Tract Infections;Blood Platelet Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Age Groups;Infant;Vomiting;Otorhinolaryngologic Diseases;Signs and Symptoms, Digestive;Hypersensitivity, Immediate;Melena;Virus Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hematemesis;Child;Respiratory Tract Diseases;Reproductive Physiological Phenomena;Signs and Symptoms;Nasal Polyps;Bronchial Diseases;Hypersensitivity;Chemically-Induced Disorders;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Nose Diseases;Varicella Zoster Virus Infection;Chickenpox;Pathologic Processes;Disease;Hemorrhagic Disorders;Rhinitis","Cardiovascular Diseases;Brain Ischemia;Stroke;Hypertension;Hypertension, Pregnancy-Induced;Myocardial Ischemia;Heart Diseases;Pain;Urogenital Diseases;Cerebral Infarction;Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Cerebrovascular Disorders;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pre-Eclampsia;Pathologic Processes;Ischemic Attack, Transient;Ischemia;Infarction;Neurologic Manifestations;Central Nervous System Diseases;Signs and Symptoms;Necrosis;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Brain Infarction;Brain Diseases","Hydrocarbons;Phenols;Hydroxybenzoates;Benzene Derivatives;Benzoates;Carboxylic Acids;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Acids, Carbocyclic;Organic Chemicals;Hydroxy Acids;Salicylates;Substances;Substances and Cells (CHEM);Aspirin",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Platelet Aggregation Alteration;Organ System Specific Effects;Coagulation Activity Alteration;Decreased Coagulation Activity;Physiologic Effect (PE);Generalized Systemic Effects;Hemostasis Alteration;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production;Decreased Platelet Aggregation;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Hematologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity,Established Pharmacologic Class (EPC);Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug,SCHEDULE III;CSA SCHEDULE;SCHEDULE IV;SCHEDULE II,,,,,,,,,
80,29,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;SKELETAL MUSCLE RELAXANTS;VA CLASSES;ANALGESICS;COLD REMEDIES,COMBINATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;SODIUM BICARBONATE CONTAINING ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;GASTROINTESTINAL MEDICATIONS;ANTACIDS;PLATELET AGGREGATION INHIBITORS;NON-OPIOID ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;SKELETAL MUSCLE RELAXANTS;VA CLASSES;ANALGESICS;COLD REMEDIES,COMBINATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;SODIUM BICARBONATE CONTAINING ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;GASTROINTESTINAL MEDICATIONS;ANTACIDS;PLATELET AGGREGATION INHIBITORS;NON-OPIOID ANALGESICS",Medicinal product categorized by structure;Salicylate-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,OTHER ANALGESICS AND ANTIPYRETICS;Salicylic acid and derivatives;BLOOD AND BLOOD FORMING ORGANS;OPIOIDS;ANTITHROMBOTIC AGENTS;ALIMENTARY TRACT AND METABOLISM;STOMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;Platelet aggregation inhibitors excl. heparin;NERVOUS SYSTEM;Opioids in combination with non-opioid analgesics;Other agents for local oral treatment,"Hypnotics and Sedatives;Analgesics;Antipyretics;Fibrinolytic Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Cyclooxygenase Inhibitors;Anti-Inflammatory Agents;Platelet Aggregation Inhibitors;Sensory System Agents;Physiological Effects of Drugs;Therapeutic Uses;Central Nervous System Depressants;Fibrin Modulating Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Hematologic Agents;Analgesics, Non-Narcotic;Cardiovascular Agents;Antirheumatic Agents","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Immune System Diseases;Pain;Arthritis;Crystal Arthropathies;Joint Diseases;Metabolic Diseases;Autoimmune Diseases;Streptococcal Infections;Infections;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Rheumatic Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Bacterial Infections;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Nervous System Diseases;Gout;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases","Hematologic Diseases;Drug Hypersensitivity;Adolescent;Lung Diseases, Obstructive;Immune System Diseases;Child, Preschool;Hemorrhage;Digestive System Diseases;Pregnancy Trimester, Third;Lung Diseases;Gastrointestinal Diseases;Polyps;Life Phases, Behavior Mechanisms and Physiologic States;Gastrointestinal Hemorrhage;Pregnancy Trimesters;Herpesviridae Infections;Infections;Asthma;DNA Virus Infections;Blood Coagulation Disorders;Respiratory Tract Infections;Blood Platelet Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Age Groups;Infant;Vomiting;Otorhinolaryngologic Diseases;Signs and Symptoms, Digestive;Hypersensitivity, Immediate;Melena;Virus Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hematemesis;Child;Respiratory Tract Diseases;Reproductive Physiological Phenomena;Signs and Symptoms;Nasal Polyps;Bronchial Diseases;Hypersensitivity;Chemically-Induced Disorders;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Nose Diseases;Varicella Zoster Virus Infection;Chickenpox;Pathologic Processes;Disease;Hemorrhagic Disorders;Rhinitis","Cardiovascular Diseases;Brain Ischemia;Stroke;Hypertension;Hypertension, Pregnancy-Induced;Myocardial Ischemia;Heart Diseases;Pain;Urogenital Diseases;Cerebral Infarction;Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Cerebrovascular Disorders;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pre-Eclampsia;Pathologic Processes;Ischemic Attack, Transient;Ischemia;Infarction;Neurologic Manifestations;Central Nervous System Diseases;Signs and Symptoms;Necrosis;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Brain Infarction;Brain Diseases","Hydrocarbons;Phenols;Hydroxybenzoates;Benzene Derivatives;Benzoates;Carboxylic Acids;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Acids, Carbocyclic;Organic Chemicals;Hydroxy Acids;Salicylates;Substances;Substances and Cells (CHEM);Aspirin",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Platelet Aggregation Alteration;Organ System Specific Effects;Coagulation Activity Alteration;Decreased Coagulation Activity;Physiologic Effect (PE);Generalized Systemic Effects;Hemostasis Alteration;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production;Decreased Platelet Aggregation;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Hematologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity,Established Pharmacologic Class (EPC);Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug,SCHEDULE III;CSA SCHEDULE;SCHEDULE IV;SCHEDULE II,,,,,,,,,
81,30,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;SKELETAL MUSCLE RELAXANTS;VA CLASSES;ANALGESICS;COLD REMEDIES,COMBINATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;SODIUM BICARBONATE CONTAINING ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;GASTROINTESTINAL MEDICATIONS;ANTACIDS;PLATELET AGGREGATION INHIBITORS;NON-OPIOID ANALGESICS","CENTRAL NERVOUS SYSTEM MEDICATIONS;SKELETAL MUSCLE RELAXANTS;VA CLASSES;ANALGESICS;COLD REMEDIES,COMBINATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;SODIUM BICARBONATE CONTAINING ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;RESPIRATORY TRACT MEDICATIONS;GASTROINTESTINAL MEDICATIONS;ANTACIDS;PLATELET AGGREGATION INHIBITORS;NON-OPIOID ANALGESICS",Medicinal product categorized by structure;Salicylate-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,OTHER ANALGESICS AND ANTIPYRETICS;Salicylic acid and derivatives;BLOOD AND BLOOD FORMING ORGANS;OPIOIDS;ANTITHROMBOTIC AGENTS;ALIMENTARY TRACT AND METABOLISM;STOMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;Platelet aggregation inhibitors excl. heparin;NERVOUS SYSTEM;Opioids in combination with non-opioid analgesics;Other agents for local oral treatment,"Hypnotics and Sedatives;Analgesics;Antipyretics;Fibrinolytic Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents, Non-Steroidal;Cyclooxygenase Inhibitors;Anti-Inflammatory Agents;Platelet Aggregation Inhibitors;Sensory System Agents;Physiological Effects of Drugs;Therapeutic Uses;Central Nervous System Depressants;Fibrin Modulating Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Hematologic Agents;Analgesics, Non-Narcotic;Cardiovascular Agents;Antirheumatic Agents","Purine-Pyrimidine Metabolism, Inborn Errors;Nutritional and Metabolic Diseases;Osteoarthritis;Musculoskeletal Diseases;Immune System Diseases;Pain;Arthritis;Crystal Arthropathies;Joint Diseases;Metabolic Diseases;Autoimmune Diseases;Streptococcal Infections;Infections;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Connective Tissue Diseases;Metabolism, Inborn Errors;Inflammation;Rheumatic Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Neurologic Manifestations;Arthritis, Rheumatoid;Bacterial Infections;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Genetic Diseases, Inborn;Rheumatic Diseases;Signs and Symptoms;Nervous System Diseases;Gout;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Skin and Connective Tissue Diseases","Hematologic Diseases;Drug Hypersensitivity;Adolescent;Lung Diseases, Obstructive;Immune System Diseases;Child, Preschool;Hemorrhage;Digestive System Diseases;Pregnancy Trimester, Third;Lung Diseases;Gastrointestinal Diseases;Polyps;Life Phases, Behavior Mechanisms and Physiologic States;Gastrointestinal Hemorrhage;Pregnancy Trimesters;Herpesviridae Infections;Infections;Asthma;DNA Virus Infections;Blood Coagulation Disorders;Respiratory Tract Infections;Blood Platelet Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Age Groups;Infant;Vomiting;Otorhinolaryngologic Diseases;Signs and Symptoms, Digestive;Hypersensitivity, Immediate;Melena;Virus Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hematemesis;Child;Respiratory Tract Diseases;Reproductive Physiological Phenomena;Signs and Symptoms;Nasal Polyps;Bronchial Diseases;Hypersensitivity;Chemically-Induced Disorders;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Hemic and Lymphatic Diseases;Nose Diseases;Varicella Zoster Virus Infection;Chickenpox;Pathologic Processes;Disease;Hemorrhagic Disorders;Rhinitis","Cardiovascular Diseases;Brain Ischemia;Stroke;Hypertension;Hypertension, Pregnancy-Induced;Myocardial Ischemia;Heart Diseases;Pain;Urogenital Diseases;Cerebral Infarction;Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases and Pregnancy Complications;Cerebrovascular Disorders;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pre-Eclampsia;Pathologic Processes;Ischemic Attack, Transient;Ischemia;Infarction;Neurologic Manifestations;Central Nervous System Diseases;Signs and Symptoms;Necrosis;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Brain Infarction;Brain Diseases","Hydrocarbons;Phenols;Hydroxybenzoates;Benzene Derivatives;Benzoates;Carboxylic Acids;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Acids, Carbocyclic;Organic Chemicals;Hydroxy Acids;Salicylates;Substances;Substances and Cells (CHEM);Aspirin",Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Platelet Aggregation Alteration;Organ System Specific Effects;Coagulation Activity Alteration;Decreased Coagulation Activity;Physiologic Effect (PE);Generalized Systemic Effects;Hemostasis Alteration;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Immunologically Active Molecule Production;Decreased Platelet Aggregation;Decreased Platelet Activating Factor Production;Decreased Thromboxane Production;Hematologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity,Established Pharmacologic Class (EPC);Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug,SCHEDULE III;CSA SCHEDULE;SCHEDULE IV;SCHEDULE II,,,,,,,,,
82,17,Concomitant Medications,Generic Name,RxNorm,Levothyroxin,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,THYROID MODIFIERS;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,THYROID MODIFIERS;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,,,"Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;THYROID THERAPY;Thyroid hormones;THYROID PREPARATIONS",,"Neoplasms;Skin and Connective Tissue Diseases;Endocrine System Diseases;Thyroiditis;Immune System Diseases;Head and Neck Neoplasms;Neoplasms by Site;Goiter;Endocrine Gland Neoplasms;Autoimmune Diseases;Mucinoses;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperthyroidism;Thyroiditis, Autoimmune;Thyroid Diseases;Thyrotoxicosis;Hypothyroidism;Myxedema;Disease;Thyroid Neoplasms","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Myocardial Ischemia;Heart Diseases;Adrenal Gland Diseases;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperthyroidism;Ischemia;Infarction;Drug-Related Side Effects and Adverse Reactions;Thyroid Diseases;Thyrotoxicosis;Chemically-Induced Disorders;Necrosis;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Myocardial Infarction;Adrenal Insufficiency","Thyroid Diseases;Hypothyroidism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease","Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic;Hormones;Thyroxine;Thyroid Hormones;Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",,Receptor Interactions;Thyroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Carbohydrate Metabolism Alteration;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Metabolic Rate Alteration;Glucose Metabolism Alteration;Increased Metabolic Rate;Increased Gluconeogenesis;Metabolic Activity Alteration,l-Thyroxine;Chemical Structure;Established Pharmacologic Class (EPC);Hormone,,,"Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic;Hormones;Thyroxine;Thyroid Hormones;Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",,,,,,"Thyroid Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease",
83,29,Concomitant Medications,Generic Name,RxNorm,levothyroxine,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,THYROID MODIFIERS;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,THYROID MODIFIERS;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,,,"Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;THYROID THERAPY;Thyroid hormones;THYROID PREPARATIONS",,"Neoplasms;Skin and Connective Tissue Diseases;Endocrine System Diseases;Thyroiditis;Immune System Diseases;Head and Neck Neoplasms;Neoplasms by Site;Goiter;Endocrine Gland Neoplasms;Autoimmune Diseases;Mucinoses;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperthyroidism;Thyroiditis, Autoimmune;Thyroid Diseases;Thyrotoxicosis;Hypothyroidism;Myxedema;Disease;Thyroid Neoplasms","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Myocardial Ischemia;Heart Diseases;Adrenal Gland Diseases;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperthyroidism;Ischemia;Infarction;Drug-Related Side Effects and Adverse Reactions;Thyroid Diseases;Thyrotoxicosis;Chemically-Induced Disorders;Necrosis;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Myocardial Infarction;Adrenal Insufficiency","Thyroid Diseases;Hypothyroidism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease","Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic;Hormones;Thyroxine;Thyroid Hormones;Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",,Receptor Interactions;Thyroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Carbohydrate Metabolism Alteration;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Metabolic Rate Alteration;Glucose Metabolism Alteration;Increased Metabolic Rate;Increased Gluconeogenesis;Metabolic Activity Alteration,l-Thyroxine;Chemical Structure;Established Pharmacologic Class (EPC);Hormone,,,"Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic;Hormones;Thyroxine;Thyroid Hormones;Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",,,,,,"Thyroid Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease",
84,44,Concomitant Medications,Generic Name,RxNorm,Levothyroxine,,,,10582.0,10582.0,10582,False,THYROID MODIFIERS;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,THYROID MODIFIERS;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,,,"Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;THYROID THERAPY;Thyroid hormones;THYROID PREPARATIONS",,"Neoplasms;Skin and Connective Tissue Diseases;Endocrine System Diseases;Thyroiditis;Immune System Diseases;Head and Neck Neoplasms;Neoplasms by Site;Goiter;Endocrine Gland Neoplasms;Autoimmune Diseases;Mucinoses;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperthyroidism;Thyroiditis, Autoimmune;Thyroid Diseases;Thyrotoxicosis;Hypothyroidism;Myxedema;Disease;Thyroid Neoplasms","Cardiovascular Diseases;Drug Hypersensitivity;Endocrine System Diseases;Myocardial Ischemia;Heart Diseases;Adrenal Gland Diseases;Vascular Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hyperthyroidism;Ischemia;Infarction;Drug-Related Side Effects and Adverse Reactions;Thyroid Diseases;Thyrotoxicosis;Chemically-Induced Disorders;Necrosis;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Myocardial Infarction;Adrenal Insufficiency","Thyroid Diseases;Hypothyroidism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease","Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic;Hormones;Thyroxine;Thyroid Hormones;Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",,Receptor Interactions;Thyroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Carbohydrate Metabolism Alteration;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Metabolic Rate Alteration;Glucose Metabolism Alteration;Increased Metabolic Rate;Increased Gluconeogenesis;Metabolic Activity Alteration,l-Thyroxine;Chemical Structure;Established Pharmacologic Class (EPC);Hormone,,,"Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic;Hormones;Thyroxine;Thyroid Hormones;Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",,,,,,"Thyroid Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease",
85,17,Concomitant Medications,Generic Name,RxNorm,Calcium,Calcium,1895.0,Calcium,1895.0,1895.0,1895,False,,,Medicinal product categorized by structure;Metal and/or metallic compound-containing product;Calcium and/or calcium compound-containing product;Mineral-containing product;Medicinal product categorized by chemical element,,,Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA);Calcium-Regulating Hormones and Agents,,,,"Amino Acids, Peptides, and Proteins;Calcium;Proteins;Metals, Alkaline Earth;Blood Proteins;Metals;Blood Coagulation Factors;Biological Factors;Elements;Substances and Cells (CHEM);Substances;Inorganic Chemicals",,Chelating Activity;Physiochemical Activity;Mechanism of Action (MoA);Binding Activity;Phosphate Chelating Activity,,Established Pharmacologic Class (EPC);Calcium;Vitamin or Mineral;Chemical Structure;Phosphate Binder;Physical or Chemical Agent,,,"Amino Acids, Peptides, and Proteins;Calcium;Proteins;Metals, Alkaline Earth;Blood Proteins;Metals;Blood Coagulation Factors;Biological Factors;Elements;Substances and Cells (CHEM);Substances;Inorganic Chemicals",,,,,,,
86,18,Concomitant Medications,Generic Name,RxNorm,tegretol,Tegretol Oral Product,1180855.0,Tegretol Oral Product,203029.0,203029.0,203029,False,,ANTICONVULSANTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,,,Anatomical Therapeutic Chemical (ATC1-4);ANTIEPILEPTICS;NERVOUS SYSTEM;Carboxamide derivatives,"Membrane Transport Modulators;Tranquilizing Agents;Analgesics;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Sodium Channel Blockers;Sensory System Agents;Physiological Effects of Drugs;Metabolic Side Effects of Drugs and Substances;Therapeutic Uses;Anticonvulsants;Central Nervous System Depressants;Psychotropic Drugs;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Cytochrome P-450 Enzyme Inducers;Analgesics, Non-Narcotic;Cardiovascular Agents;Cytochrome P-450 CYP3A Inducers;Antimanic Agents","Schizophrenia Spectrum and Other Psychotic Disorders;Trigeminal Nerve Diseases;Facial Neuralgia;Psychotic Disorders;Mouth Diseases;Bipolar and Related Disorders;Schizophrenia;Facial Nerve Diseases;Sleep Disorders, Intrinsic;Epilepsy, Complex Partial;Mental Disorders;Epilepsy, Tonic-Clonic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Substance-Related Disorders;Cranial Nerve Diseases;Stress Disorders, Post-Traumatic;Parasomnias;Stress Disorders, Traumatic;Restless Legs Syndrome;Neurologic Manifestations;Epilepsy;Stomatognathic Diseases;Epilepsy, Generalized;Central Nervous System Diseases;Trigeminal Neuralgia;Chemically-Induced Disorders;Signs and Symptoms;Bipolar Disorder;Substance Withdrawal Syndrome;Epilepsies, Partial;Trauma and Stressor Related Disorders;Dyssomnias;Pathological Conditions, Signs and Symptoms;Mood Disorders;Sleep Wake Disorders;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Hematologic Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Bone Marrow Diseases;Hemic and Lymphatic Diseases;Disease",,"Dibenzazepines;Carbamazepine;Heterocyclic Compounds, 3-Ring;Substances;Substances and Cells (CHEM);Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Cytochrome P450 1A Inducers;Cytochrome P450 1A2 Inducers;Enzyme Inducers;Receptor Interactions;Cytochrome P450 3A Inducers;Ion Channel Interactions;Cytochrome P450 2C19 Inducers;Cytochrome P450 2C9 Inducers;Transcription Factor Activity;Cytochrome P450 2B6 Inducers;Sodium Channel Interactions;Unknown Cellular or Molecular Interaction;Enzyme Interactions;Mechanism of Action (MoA);Cytochrome P450 3A4 Inducers;Membrane Transporter Interactions;Cytochrome P450 Inducers,Physiologic Effect (PE);Decreased Central Nervous System Disorganized Electrical Activity;Organ System Specific Effects;Decreased Organized Electrical Activity;Decreased Disorganized Electrical Activity;Disorganized Electrical Activity Alteration;Organized Electrical Activity Alteration;Electrical Activity Alteration;Nervous System Activity Alteration,Nervous System Agent;Established Pharmacologic Class (EPC);Mood Stabilizer,,"Azoles;Triazoles;Heterocyclic Compounds, 1-Ring;Piperazines;Substances;Substances and Cells (CHEM);Heterocyclic Compounds",,Medicinal product categorized by therapeutic role;Anticonvulsant agent,Antimanic Agent;Central Nervous System Agent;Antidepressive Agent;Therapeutic Categories,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
87,20,Concomitant Medications,Generic Name,RxNorm,albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,"VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Adrenergic beta-Agonists;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Reproductive Control Agents;Tocolytic Agents;Neurotransmitter Agents;Adrenergic Agonists;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Hypersensitivity, Immediate;Disease","Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Disease","Lung Diseases;Respiratory Hypersensitivity;Disease;Asthma, Exercise-Induced;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Exercise-Induced Allergies;Asthma",Phenethylamines;Amino Alcohols;Alcohols;Organic Chemicals;Ethanol;Albuterol;Substances;Ethylamines;Substances and Cells (CHEM);Amines;Ethanolamines,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Adrenergic beta-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic beta2-Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist,,,,,,,,,,
88,25,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol 0.09 MG/ACTUAT,329498.0,Albuterol 0.09 MG/ACTUAT,435.0,435.0,435,False,"VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Adrenergic beta-Agonists;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Reproductive Control Agents;Tocolytic Agents;Neurotransmitter Agents;Adrenergic Agonists;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Hypersensitivity, Immediate;Disease","Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Disease","Lung Diseases;Respiratory Hypersensitivity;Disease;Asthma, Exercise-Induced;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Exercise-Induced Allergies;Asthma",Phenethylamines;Amino Alcohols;Alcohols;Organic Chemicals;Ethanol;Albuterol;Substances;Ethylamines;Substances and Cells (CHEM);Amines;Ethanolamines,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Adrenergic beta-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic beta2-Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist,,,,,,,,,,
89,33,Concomitant Medications,Generic Name,RxNorm,albuteral,Albuterol Sulfate,142153.0,Albuterol Sulfate,,435.0,435,True,"VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Adrenergic beta-Agonists;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Reproductive Control Agents;Tocolytic Agents;Neurotransmitter Agents;Adrenergic Agonists;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Hypersensitivity, Immediate;Disease","Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Disease","Lung Diseases;Respiratory Hypersensitivity;Disease;Asthma, Exercise-Induced;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Exercise-Induced Allergies;Asthma",Phenethylamines;Amino Alcohols;Alcohols;Organic Chemicals;Ethanol;Albuterol;Substances;Ethylamines;Substances and Cells (CHEM);Amines;Ethanolamines,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Adrenergic beta-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic beta2-Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist,,,,,,,,,,
90,34,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,"VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Adrenergic beta-Agonists;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Reproductive Control Agents;Tocolytic Agents;Neurotransmitter Agents;Adrenergic Agonists;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Hypersensitivity, Immediate;Disease","Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Disease","Lung Diseases;Respiratory Hypersensitivity;Disease;Asthma, Exercise-Induced;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Exercise-Induced Allergies;Asthma",Phenethylamines;Amino Alcohols;Alcohols;Organic Chemicals;Ethanol;Albuterol;Substances;Ethylamines;Substances and Cells (CHEM);Amines;Ethanolamines,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Adrenergic beta-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic beta2-Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist,,,,,,,,,,
91,38,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,"VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Adrenergic beta-Agonists;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Reproductive Control Agents;Tocolytic Agents;Neurotransmitter Agents;Adrenergic Agonists;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Hypersensitivity, Immediate;Disease","Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Disease","Lung Diseases;Respiratory Hypersensitivity;Disease;Asthma, Exercise-Induced;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Exercise-Induced Allergies;Asthma",Phenethylamines;Amino Alcohols;Alcohols;Organic Chemicals;Ethanol;Albuterol;Substances;Ethylamines;Substances and Cells (CHEM);Amines;Ethanolamines,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Adrenergic beta-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic beta2-Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist,,,,,,,,,,
92,43,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,"VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product,Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,"Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;ADRENERGICS, INHALANTS;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Adrenergic beta-Agonists;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic beta-2 Receptor Agonists;Adrenergic Agents;Reproductive Control Agents;Tocolytic Agents;Neurotransmitter Agents;Adrenergic Agonists;Physiological Effects of Drugs;Bronchodilator Agents,"Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Hypersensitivity, Immediate;Disease","Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Disease","Lung Diseases;Respiratory Hypersensitivity;Disease;Asthma, Exercise-Induced;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Exercise-Induced Allergies;Asthma",Phenethylamines;Amino Alcohols;Alcohols;Organic Chemicals;Ethanol;Albuterol;Substances;Ethylamines;Substances and Cells (CHEM);Amines;Ethanolamines,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Adrenergic beta-Agonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic beta2-Agonists,Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Organ System Specific Effects;Bronchial Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Smooth Muscle Tone Alteration;Bronchodilation;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Agonist;beta-Adrenergic Agonist;Receptor Interaction;Nervous System Agent;Sympathomimetic Agent;beta2-Adrenergic Agonist,,,,,,,,,,
93,21,Concomitant Medications,Generic Name,RxNorm,Vitamin C,Vitamin C TR,220879.0,Vitamin C TR,1151.0,1151.0,1151,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;HYPEROSMOTIC LAXATIVES;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS","VITAMINS;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;IRON;HYPEROSMOTIC LAXATIVES;ELECTROLYTES/MINERALS;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS",Carbohydrate-containing product;Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product,,"GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Anatomical Therapeutic Chemical (ATC1-4);ALIMENTARY TRACT AND METABOLISM;OPHTHALMOLOGICALS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Ascorbic acid (vitamin C), plain;Organic acids",Micronutrients;Antioxidants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Vitamins;Protective Agents;Physiological Effects of Drugs,"Deficiency Diseases;Tyrosinemias;Avitaminosis;Cardiovascular Diseases;Hematologic Diseases;Nutritional and Metabolic Diseases;Methemoglobinemia;Common Cold;Scurvy;Wounds and Injuries;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Amino Acid Metabolism, Inborn Errors;Metabolic Diseases;Ascorbic Acid Deficiency;RNA Virus Infections;Infections;Wounds, Penetrating;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Vascular Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemostatic Disorders;Virus Diseases;Respiratory Tract Diseases;Central Nervous System Diseases;Picornaviridae Infections;Genetic Diseases, Inborn;Brain Diseases, Metabolic, Inborn;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Hemorrhagic Disorders;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,,,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,,,"Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,,
94,24,Concomitant Medications,Generic Name,RxNorm,vitamin c,,,,1151.0,1151.0,1151,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;HYPEROSMOTIC LAXATIVES;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS","VITAMINS;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;IRON;HYPEROSMOTIC LAXATIVES;ELECTROLYTES/MINERALS;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS",Carbohydrate-containing product;Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product,,"GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Anatomical Therapeutic Chemical (ATC1-4);ALIMENTARY TRACT AND METABOLISM;OPHTHALMOLOGICALS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Ascorbic acid (vitamin C), plain;Organic acids",Micronutrients;Antioxidants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Vitamins;Protective Agents;Physiological Effects of Drugs,"Deficiency Diseases;Tyrosinemias;Avitaminosis;Cardiovascular Diseases;Hematologic Diseases;Nutritional and Metabolic Diseases;Methemoglobinemia;Common Cold;Scurvy;Wounds and Injuries;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Amino Acid Metabolism, Inborn Errors;Metabolic Diseases;Ascorbic Acid Deficiency;RNA Virus Infections;Infections;Wounds, Penetrating;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Vascular Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemostatic Disorders;Virus Diseases;Respiratory Tract Diseases;Central Nervous System Diseases;Picornaviridae Infections;Genetic Diseases, Inborn;Brain Diseases, Metabolic, Inborn;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Hemorrhagic Disorders;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,,,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,,,"Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,,
95,25,Concomitant Medications,Generic Name,RxNorm,Vitamin C,Vitamin C TR,220879.0,Vitamin C TR,1151.0,1151.0,1151,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;HYPEROSMOTIC LAXATIVES;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS","VITAMINS;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;IRON;HYPEROSMOTIC LAXATIVES;ELECTROLYTES/MINERALS;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS",Carbohydrate-containing product;Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product,,"GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Anatomical Therapeutic Chemical (ATC1-4);ALIMENTARY TRACT AND METABOLISM;OPHTHALMOLOGICALS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Ascorbic acid (vitamin C), plain;Organic acids",Micronutrients;Antioxidants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Vitamins;Protective Agents;Physiological Effects of Drugs,"Deficiency Diseases;Tyrosinemias;Avitaminosis;Cardiovascular Diseases;Hematologic Diseases;Nutritional and Metabolic Diseases;Methemoglobinemia;Common Cold;Scurvy;Wounds and Injuries;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Amino Acid Metabolism, Inborn Errors;Metabolic Diseases;Ascorbic Acid Deficiency;RNA Virus Infections;Infections;Wounds, Penetrating;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Vascular Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemostatic Disorders;Virus Diseases;Respiratory Tract Diseases;Central Nervous System Diseases;Picornaviridae Infections;Genetic Diseases, Inborn;Brain Diseases, Metabolic, Inborn;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Hemorrhagic Disorders;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,,,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,,,"Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,,
96,30,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;HYPEROSMOTIC LAXATIVES;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS","VITAMINS;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;IRON;HYPEROSMOTIC LAXATIVES;ELECTROLYTES/MINERALS;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS",Carbohydrate-containing product;Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product,,"GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Anatomical Therapeutic Chemical (ATC1-4);ALIMENTARY TRACT AND METABOLISM;OPHTHALMOLOGICALS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Ascorbic acid (vitamin C), plain;Organic acids",Micronutrients;Antioxidants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Vitamins;Protective Agents;Physiological Effects of Drugs,"Deficiency Diseases;Tyrosinemias;Avitaminosis;Cardiovascular Diseases;Hematologic Diseases;Nutritional and Metabolic Diseases;Methemoglobinemia;Common Cold;Scurvy;Wounds and Injuries;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Amino Acid Metabolism, Inborn Errors;Metabolic Diseases;Ascorbic Acid Deficiency;RNA Virus Infections;Infections;Wounds, Penetrating;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Vascular Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemostatic Disorders;Virus Diseases;Respiratory Tract Diseases;Central Nervous System Diseases;Picornaviridae Infections;Genetic Diseases, Inborn;Brain Diseases, Metabolic, Inborn;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Hemorrhagic Disorders;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,,,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,,,"Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,,
97,37,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;HYPEROSMOTIC LAXATIVES;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS","VITAMINS;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;IRON;HYPEROSMOTIC LAXATIVES;ELECTROLYTES/MINERALS;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS",Carbohydrate-containing product;Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product,,"GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Anatomical Therapeutic Chemical (ATC1-4);ALIMENTARY TRACT AND METABOLISM;OPHTHALMOLOGICALS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Ascorbic acid (vitamin C), plain;Organic acids",Micronutrients;Antioxidants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Vitamins;Protective Agents;Physiological Effects of Drugs,"Deficiency Diseases;Tyrosinemias;Avitaminosis;Cardiovascular Diseases;Hematologic Diseases;Nutritional and Metabolic Diseases;Methemoglobinemia;Common Cold;Scurvy;Wounds and Injuries;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Amino Acid Metabolism, Inborn Errors;Metabolic Diseases;Ascorbic Acid Deficiency;RNA Virus Infections;Infections;Wounds, Penetrating;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Vascular Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemostatic Disorders;Virus Diseases;Respiratory Tract Diseases;Central Nervous System Diseases;Picornaviridae Infections;Genetic Diseases, Inborn;Brain Diseases, Metabolic, Inborn;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Hemorrhagic Disorders;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,,,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,,,"Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,,
98,45,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;HYPEROSMOTIC LAXATIVES;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS","VITAMINS;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMIN COMBINATIONS,OTHER;LAXATIVES;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN C;MULTIVITAMINS WITH MINERALS;IRON;HYPEROSMOTIC LAXATIVES;ELECTROLYTES/MINERALS;MULTIVITAMINS;GASTROINTESTINAL MEDICATIONS",Carbohydrate-containing product;Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product,,"GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Anatomical Therapeutic Chemical (ATC1-4);ALIMENTARY TRACT AND METABOLISM;OPHTHALMOLOGICALS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;Ascorbic acid (vitamin C), plain;Organic acids",Micronutrients;Antioxidants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Vitamins;Protective Agents;Physiological Effects of Drugs,"Deficiency Diseases;Tyrosinemias;Avitaminosis;Cardiovascular Diseases;Hematologic Diseases;Nutritional and Metabolic Diseases;Methemoglobinemia;Common Cold;Scurvy;Wounds and Injuries;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Amino Acid Metabolism, Inborn Errors;Metabolic Diseases;Ascorbic Acid Deficiency;RNA Virus Infections;Infections;Wounds, Penetrating;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Vascular Diseases;Respiratory Tract Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemostatic Disorders;Virus Diseases;Respiratory Tract Diseases;Central Nervous System Diseases;Picornaviridae Infections;Genetic Diseases, Inborn;Brain Diseases, Metabolic, Inborn;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Hemorrhagic Disorders;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,Oxidation-Reduction Activity;Reduction Activity;Physiochemical Activity;Free Radical Scavenging Activity;Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,,,"Ascorbic Acid;Acids, Acyclic;Sugar Acids;Carboxylic Acids;Organic Chemicals;Hydroxy Acids;Substances;Substances and Cells (CHEM);Carbohydrates",,,,"Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Female Urogenital Diseases",,,
99,22,Concomitant Medications,Generic Name,RxNorm,citalopram,Citalopram,2556.0,Citalopram,2556.0,2556.0,2556,False,"ANTIDEPRESSANTS,OTHER;VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS","ANTIDEPRESSANTS,OTHER;VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Propylamine-containing product,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,ANTIDEPRESSANTS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;PSYCHOANALEPTICS;Selective serotonin reuptake inhibitors,"Physiological Effects of Drugs;Central Nervous System Agents;Therapeutic Uses;Molecular Mechanisms of Pharmacological Action;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Selective Serotonin Reuptake Inhibitors;Psychotropic Drugs;Serotonin Agents;Neurotransmitter Agents;Antidepressive Agents, Second-Generation;Antidepressive Agents","Dementia;Alcoholism;Nutritional and Metabolic Diseases;Endocrine System Diseases;Diabetes Mellitus;Alcohol-Related Disorders;Depressive Disorder;Glucose Metabolism Disorders;Obsessive-Compulsive Disorder;Metabolic Diseases;Anxiety Disorders;Mental Disorders;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Substance-Related Disorders;Diabetic Neuropathies;Diabetes Complications;Central Nervous System Diseases;Chemically-Induced Disorders;Neurocognitive Disorders;Peripheral Nervous System Diseases;Tobacco Use Disorder;Mood Disorders;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Organic Chemicals;Propylamines;Citalopram;Heterocyclic Compounds, 2-Ring;Benzofurans;Substances;Substances and Cells (CHEM);Nitriles;Amines;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Receptor Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Neurotransmitter Transporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions,Increased Immunologically Active Molecule Activity;Generalized Systemic Effects;Physiologic Effect (PE);Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Increased Immunologic Activity;Increased Serotonin Activity;Serotonin Activity Alteration;Immunologic Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Increased Central Nervous System Serotonin Activity;Nervous System Activity Alteration,Nervous System Agent;Serotonin Reuptake Inhibitor;Established Pharmacologic Class (EPC),,"Oxazolidinones;Carboxylic Acids;Substances and Cells (CHEM);Phenothiazines;Azoles;Acetamides;Sulfur Compounds;Amides;Substances;Fatty Acids, Volatile;Fatty Acids;Acids, Acyclic;Lipids;Heterocyclic Compounds, 3-Ring;Linezolid;Inorganic Chemicals;Benzimidazoles;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Methylene Blue;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Acetates;Oxazoles;Heterocyclic Compounds, 2-Ring;Pimozide",,Medicinal product categorized by therapeutic role;Antidepressant agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
100,23,Concomitant Medications,Generic Name,RxNorm,chlorthaladone,,,,,2409.0,2409,True,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;DIURETICS;CARDIOVASCULAR MEDICATIONS;THIAZIDES/RELATED DIURETICS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;DIURETICS;CARDIOVASCULAR MEDICATIONS;THIAZIDES/RELATED DIURETICS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Sulfonamide diuretic agent,,"CARDIOVASCULAR SYSTEM;Sulfonamides, plain;Anatomical Therapeutic Chemical (ATC1-4);DIURETICS;LOW-CEILING DIURETICS, EXCL. THIAZIDES",Physiological Effects of Drugs;Sodium Chloride Symporter Inhibitors;Therapeutic Uses;Molecular Mechanisms of Pharmacological Action;Membrane Transport Modulators;MeSH Pharmacologic Actions (MESHPA);Cardiovascular Agents;Diuretics;Natriuretic Agents;Antihypertensive Agents,"Cardiovascular Diseases;Urologic Diseases;Liver Diseases;Hypertension;Heart Diseases;Fibrosis;Urogenital Diseases;Digestive System Diseases;Glomerulonephritis;Female Urogenital Diseases and Pregnancy Complications;Nephrosis;Female Urogenital Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Cirrhosis;Nephrotic Syndrome;Kidney Diseases;Edema;Nephritis;Signs and Symptoms;Heart Failure;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Male Urogenital Diseases;Renal Insufficiency","Drug-Related Side Effects and Adverse Reactions;Anuria;Urination Disorders;Pregnancy;Urologic Diseases;Reproductive Physiological Phenomena;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Renal Insufficiency",,"Carboxylic Acids;Hydrocarbons, Cyclic;Phthalimides;Substances and Cells (CHEM);Hydrocarbons, Aromatic;Amides;Ketones;Sulfur Compounds;Substances;Isoindoles;Benzene Derivatives;Phthalic Acids;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Chlorthalidone;Sulfonamides;Organic Chemicals;Benzophenones;Acids, Carbocyclic;Sulfones;Imides;Heterocyclic Compounds, 2-Ring",,Sodium Chloride Symporter Inhibitors;Receptor Interactions;Sodium Chloride Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions,Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Renal H+ Excretion;Increased Renal Ion Excretion;Decreased Intravascular Volume;Physiologic Effect (PE);Increased Distal Tubule Cl- Excretion;Decreased Blood Pressure;Increased Distal Tubule H+ Excretion;Increased Diuresis;Increased Distal Tubule K+ Excretion;Increased Renal K+ Excretion;Renal/Urological Activity Alteration;Blood Pressure Alteration;Increased Renal Na+ Excretion;Hematologic Activity Alteration;Renal Ion Transport Alteration;Increased Distal Tubule Na+ Excretion;Increased Renal Cl- Excretion;Intravascular Volume Alteration;Blood & Lymphatic Fluid Function Alteration;Diuresis Alteration;Hemic/Lymphatic Activity Alteration,Diuretic;Thiazide-like Diuretic;Established Pharmacologic Class (EPC),,Sulfonamides;Organic Chemicals;Sulfones;Amides;Sulfur Compounds;Substances;Substances and Cells (CHEM);Inorganic Chemicals,,Medicinal product categorized by therapeutic role;Diuretic agent;Sulfonamide diuretic agent,,,,,,
101,23,Concomitant Medications,Generic Name,RxNorm,propanolol,,,,8787.0,8787.0,8787,False,CARDIOVASCULAR MEDICATIONS;VA CLASSES;BETA BLOCKERS/RELATED,CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;BETA BLOCKERS/RELATED;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product,Beta adrenergic receptor antagonist-containing product;Medicinal product categorized by disposition;Adrenergic receptor antagonist-containing product,"Anatomical Therapeutic Chemical (ATC1-4);BETA BLOCKING AGENTS;Beta blocking agents, non-selective;CARDIOVASCULAR SYSTEM",Physiological Effects of Drugs;Therapeutic Uses;Molecular Mechanisms of Pharmacological Action;Anti-Arrhythmia Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agents;Cardiovascular Agents;Adrenergic Antagonists;Neurotransmitter Agents;Antihypertensive Agents;Adrenergic beta-Antagonists;Vasodilator Agents,"Arrhythmias, Cardiac;Cardiovascular Diseases;Tachycardia;Neoplasms;Liver Diseases;Hypertension;Neuroectodermal Tumors;Tachycardia, Supraventricular;Hypertension, Portal;Myocardial Ischemia;Heart Diseases;Chest Pain;Pain;Digestive System Diseases;Paraganglioma;Myocardial Infarction;Essential Tremor;Gastrointestinal Diseases;Esophageal and Gastric Varices;Neoplasms by Histologic Type;Tachycardia, Ventricular;Anxiety Disorders;Mental Disorders;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Panic Disorder;Neoplasms, Germ Cell and Embryonal;Ischemia;Infarction;Neurologic Manifestations;Central Nervous System Diseases;Cardiac Conduction System Disease;Signs and Symptoms;Nervous System Diseases;Heart Failure;Neuroendocrine Tumors;Necrosis;Movement Disorders;Esophageal Diseases;Pathological Conditions, Signs and Symptoms;Neoplasms, Nerve Tissue;Pathologic Processes;Disease;Pheochromocytoma;Ventricular Fibrillation;Angina Pectoris","Arrhythmias, Cardiac;Cardiovascular Diseases;Drug Hypersensitivity;Lung Diseases, Obstructive;Bradycardia;Myocardial Ischemia;Heart Diseases;Thrombosis;Immune System Diseases;Shock, Cardiogenic;Shock;Pulmonary Edema;Myocardial Infarction;Lung Diseases;Heart Block;Raynaud Disease;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Peripheral Vascular Diseases;Arrhythmia, Sinus;Asthma;Bronchial Hyperreactivity;Vascular Diseases;Atrioventricular Block;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypotension;Livedoid Vasculopathy;Skin Diseases, Vascular;Hypersensitivity, Immediate;Skin Diseases;Ischemia;Infarction;Sick Sinus Syndrome;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Pregnancy;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Cardiac Conduction System Disease;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Heart Failure;Necrosis;Pathological Conditions, Signs and Symptoms;Embolism and Thrombosis;Pathologic Processes;Disease;Skin and Connective Tissue Diseases","Migraine Disorders;Central Nervous System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Headache Disorders;Headache Disorders, Primary;Nervous System Diseases;Disease;Brain Diseases","Hydrocarbons;Substances and Cells (CHEM);Amino Alcohols;Alcohols;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Polycyclic Compounds;Naphthalenes;Propranolol;Propanolamines;Polycyclic Aromatic Hydrocarbons;Phenoxypropanolamines;Substances;Propanols;Amines",,Adrenergic beta1-Antagonists;Receptor Interactions;Adrenergic Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Adrenergic Antagonists;Adrenergic beta-Antagonists;Adrenergic beta2-Antagonists,Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Cardiovascular Activity Alteration;Smooth Muscle Tone Alteration;Respiratory/Pulmonary Activity Alteration;Arterial Vasodilation;Bronchoconstriction;Physiologic Effect (PE);Decreased Blood Pressure;Vascular Alterations;Vasodilation;Negative Inotropy;Blood Pressure Alteration;Negative Chronotropy;Musculoskeletal Activity Alteration;Cardiac Contractility Alteration;Vascular Tone Alteration;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Autonomic Nervous System Activity Alteration;Cardiac Rate Alteration;Cardiac Rhythm Alteration;Nervous System Activity Alteration,Cardiovascular Agent;Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Nervous System Agent;beta-Adrenergic Blocker,,,,,,,,Physiologic Effect (PE);Organ System Specific Effects;Negative Chronotropy;Cardiovascular Activity Alteration;Cardiac Rate Alteration,,
102,23,Concomitant Medications,Generic Name,RxNorm,loratadine,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,1112258.0,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,28889.0,28889.0,28889,False,"ANTIHISTAMINE/DECONGESTANT;VA CLASSES;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINES;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES,OTHER","ANTIHISTAMINE/DECONGESTANT;VA CLASSES;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINES;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES,OTHER",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Piperidine derivative-containing product,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Other antihistamines for systemic use;ANTIHISTAMINES FOR SYSTEMIC USE,"Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Anti-Allergic Agents;Histamine H1 Antagonists;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Histamine Agents;Dermatologic Agents;Neurotransmitter Agents;Physiological Effects of Drugs;Antipruritics","Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Rhinitis, Allergic;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases, Vascular;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Nose Diseases;Skin Diseases;Infections;Disease;Skin and Connective Tissue Diseases;Rhinitis;Urticaria","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Hydrocarbons;Cyproheptadine;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Piperidines;Loratadine;Benzocycloheptenes;Dibenzocycloheptenes;Heterocyclic Compounds, 1-Ring;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Polycyclic Compounds;Heterocyclic Compounds",,Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,,,,,,,,,,,
103,23,Concomitant Medications,Generic Name,RxNorm,xyzol,,,,,398335.0,398335,True,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Piperazine derivatives;ANTIHISTAMINES FOR SYSTEMIC USE,"Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Histamine Agents;Neurotransmitter Agents;Physiological Effects of Drugs","Immune System Diseases;Rhinitis, Allergic;Urticaria;Infections;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases, Vascular;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Skin Diseases;Rhinitis, Allergic, Seasonal;Respiratory Hypersensitivity;Respiratory Tract Diseases;Hypersensitivity;Nose Diseases;Disease;Skin and Connective Tissue Diseases;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Urologic Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Kidney Diseases;Urogenital Diseases;Disease;Male Urogenital Diseases;Renal Insufficiency",,"Heterocyclic Compounds, 1-Ring;Cetirizine;Piperazines;Substances;Hydroxyzine;Substances and Cells (CHEM);Heterocyclic Compounds",,Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Immunologic Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Histamine-1 Receptor Antagonist;Receptor Interaction;Established Pharmacologic Class (EPC);Receptor Antagonist,,,,,,,,,,
104,23,Concomitant Medications,Generic Name,RxNorm,finesteride,,,,,25025.0,25025,True,"HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Steroid-containing product,5-alpha reductase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,GENITO URINARY SYSTEM AND SEX HORMONES;DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY;Testosterone-5-alpha reductase inhibitors;Anatomical Therapeutic Chemical (ATC1-4);DERMATOLOGICALS;Other dermatologicals;OTHER DERMATOLOGICAL PREPARATIONS;UROLOGICALS,"Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Genitourinary Agents;MeSH Pharmacologic Actions (MESHPA);Hormone Antagonists;Steroid Synthesis Inhibitors;Urological Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs;5-alpha Reductase Inhibitors","Alopecia;Genital Diseases, Male;Skin and Connective Tissue Diseases;Neoplasms;Urogenital Diseases;Virilism;Neoplasms by Site;Prostatic Neoplasms;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Genital Neoplasms, Male;Female Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Skin Diseases;Urogenital Neoplasms;Hirsutism;Signs and Symptoms;Pathological Conditions, Anatomical;Hypotrichosis;Pathological Conditions, Signs and Symptoms;Hair Diseases;Disease;Male Urogenital Diseases;Prostatic Hyperplasia","Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Child;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Age Groups;Disease",,"Substances and Cells (CHEM);Steroids, Heterocyclic;Steroids;Androstenes;Androstanes;Substances;Fused-Ring Compounds;Azasteroids;Polycyclic Compounds;Finasteride",,Androgen Synthesis Inhibitors;Enzyme Inhibitors;Steroid Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Sex Hormone Synthesis Inhibitors;5-alpha Reductase Inhibitors,Physiologic Effect (PE);Endocrine Activity Alteration;Organ System Specific Effects;Testicular Endocrine Activity Alteration;Decreased Dihydrotestosterone Secretion,Enzyme Interaction;Established Pharmacologic Class (EPC);5-alpha Reductase Inhibitor;Enzyme Inhibitor,,,,,,,,,,
105,24,Concomitant Medications,Generic Name,RxNorm,pioglitazone,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,1368403.0,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,33738.0,33738.0,33738,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Thiazole-containing product;Thiazolidinedione-containing product;Sulfur and/or sulfur compound-containing product,Peroxisome proliferator-activated receptor agonist-containing product;Peroxisome proliferator-activated gamma receptor agonist-containing product;Thiazolidinedione-containing product;Medicinal product categorized by disposition,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Combinations of oral blood glucose lowering drugs;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Thiazolidinediones",Physiological Effects of Drugs;Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA),"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Drug-Related Side Effects and Adverse Reactions;Cardiovascular Diseases;Drug Hypersensitivity;Liver Diseases;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Heart Failure;Heart Diseases;Digestive System Diseases;Disease",,"Thiazoles;Azoles;Organic Chemicals;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;Substances;Pioglitazone;Substances and Cells (CHEM);Inorganic Chemicals;Heterocyclic Compounds;Thiazolidinediones",,Insulin Receptor Agonists;Receptor Interactions;Transcription Factor Activity;Peroxisome Proliferator-activated Receptor Activity;Mechanism of Action (MoA);Receptor Protein Kinase Interactions;Insulin Receptor Interactions;Peroxisome Proliferator-activated Receptor alpha Agonists,Physiologic Effect (PE);Generalized Systemic Effects;Increased Glycolysis;Carbohydrate Metabolism Alteration;Cell Glucose Transport Alteration;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Metabolic Activity Alteration,Blood Glucose Regulator;Established Pharmacologic Class (EPC);Peroxisome Proliferator Receptor alpha Agonist;Receptor Agonist;Thiazolidinedione;Receptor Interaction;Chemical Structure;Peroxisome Proliferator Receptor gamma Agonist,,,"Peroxisome Proliferator-Activated Receptors;Thiazoles;Amino Acids, Peptides, and Proteins;Organic Chemicals;Azoles;Receptors, Cytoplasmic and Nuclear;Sulfur Compounds;Proteins;Heterocyclic Compounds, 1-Ring;PPAR gamma;PPAR alpha;Substances;Substances and Cells (CHEM);Inorganic Chemicals;Heterocyclic Compounds;Thiazolidinediones;Transcription Factors",,,,,,,
106,24,Concomitant Medications,Generic Name,RxNorm,vitamin d,,,,11253.0,11253.0,11253,False,,,,,,Micronutrients;Bone Density Conservation Agents;MeSH Pharmacologic Actions (MESHPA);Vitamins;Physiological Effects of Drugs,,,,Steroids;Secosteroids;Substances;Fused-Ring Compounds;Substances and Cells (CHEM);Polycyclic Compounds;Vitamin D,,,,,,,,,,,,,,
107,34,Concomitant Medications,Generic Name,RxNorm,Vitamin D,,,,11253.0,11253.0,11253,False,,,,,,Micronutrients;Bone Density Conservation Agents;MeSH Pharmacologic Actions (MESHPA);Vitamins;Physiological Effects of Drugs,,,,Steroids;Secosteroids;Substances;Fused-Ring Compounds;Substances and Cells (CHEM);Polycyclic Compounds;Vitamin D,,,,,,,,,,,,,,
108,45,Concomitant Medications,Generic Name,RxNorm,Vitamin D,Vitamin D,11253.0,Vitamin D,11253.0,11253.0,11253,False,,,,,,Micronutrients;Bone Density Conservation Agents;MeSH Pharmacologic Actions (MESHPA);Vitamins;Physiological Effects of Drugs,,,,Steroids;Secosteroids;Substances;Fused-Ring Compounds;Substances and Cells (CHEM);Polycyclic Compounds;Vitamin D,,,,,,,,,,,,,,
109,25,Concomitant Medications,Generic Name,RxNorm,Codeine cough syrup,,,,,756905.0,756905,True,,,Medicinal product categorized by structure;Morphinan-containing product;Naturally occurring alkaloid-containing product;Isoquinoline-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Ether structure-containing product,Opioid receptor agonist-containing product;Medicinal product categorized by disposition;Morphinan opioid-containing product,"COUGH AND COLD PREPARATIONS;OPIOIDS;Natural opium alkaloids;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;RESPIRATORY SYSTEM;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants","Respiratory System Agents;Central Nervous System Agents;Analgesics, Opioid;Therapeutic Uses;Peripheral Nervous System Agents;Narcotics;MeSH Pharmacologic Actions (MESHPA);Central Nervous System Depressants;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Expectorants","Signs and Symptoms, Respiratory;Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Pain;Rhinitis, Allergic;Respiration Disorders;Lung Diseases;Postoperative Complications;RNA Virus Infections;Infections;Pain, Postoperative;Pharyngeal Diseases;Bordetella Infections;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Whooping Cough;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Gram-Negative Bacterial Infections;Virus Diseases;Neurologic Manifestations;Bacterial Infections;Stomatognathic Diseases;Pharyngitis;Respiratory Hypersensitivity;Bacterial Infections and Mycoses;Respiratory Tract Diseases;Laryngeal Diseases;Picornaviridae Infections;Signs and Symptoms;Bronchial Diseases;Hypersensitivity;Bronchitis;Laryngitis;Nose Diseases;Pathological Conditions, Signs and Symptoms;Cough;Nervous System Diseases;Disease;Rhinitis","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Respiration Disorders;Lung Diseases;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Intracranial Hypertension;Respiratory Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Pregnancy;Reproductive Physiological Phenomena;Respiratory Tract Diseases;Central Nervous System Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Nervous System Diseases;Disease;Brain Diseases",,"Phenols;Hydrocarbons, Cyclic;Alkaloids;Substances and Cells (CHEM);Opiate Alkaloids;Morphinans;Morphine Derivatives;Heterocyclic Compounds, Bridged-Ring;Phenyl Ethers;Ethers;Guaifenesin;Hydrocarbons, Aromatic;Substances;Benzene Derivatives;Catechols;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Guaiacol;Hydrocarbons;Methyl Ethers;Organic Chemicals;Hydromorphone;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds",,Receptor Interactions;Full Opioid Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Opioid Receptor Interactions;Opioid Agonists;Opioid mu-Receptor Agonists,Physiologic Effect (PE);Respiratory Secretion Alteration;Central Nervous System Depression;Organ System Specific Effects;Sensory System Activity Alteration;Decreased Organized Electrical Activity;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Decreased Respiratory Secretion Viscosity;Respiratory/Pulmonary Activity Alteration;Increased Respiratory Secretions;Organized Electrical Activity Alteration;Respiratory Secretion Viscosity Alteration;Electrical Activity Alteration;Analgesia;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Expectorant;Receptor Agonist;Receptor Interaction;Respiratory Agent;Nervous System Agent;Opioid Agonist,,,,Medicinal product categorized by therapeutic role;Expectorant agent,,,,Physiologic Effect (PE);Decreased Organized Electrical Activity;Organ System Specific Effects;Decreased Central Nervous System Organized Electrical Activity;Organized Electrical Activity Alteration;Electrical Activity Alteration;Nervous System Activity Alteration,,
110,25,Concomitant Medications,Generic Name,RxNorm,azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,"VA CLASSES;ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;ANTI-INFECTIVE,TOPICAL OPHTHALMIC;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC","VA CLASSES;ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;ANTI-INFECTIVE,TOPICAL OPHTHALMIC;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC",Medicinal product categorized by structure;Macrolide antibacterial agent;Macrolide-containing product,,"ANTIINFECTIVES FOR SYSTEMIC USE;Macrolides;SENSORY ORGANS;ANTIINFECTIVES;Anatomical Therapeutic Chemical (ATC1-4);Antibiotics;OPHTHALMOLOGICALS;MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE",Anti-Infective Agents;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"Pasteurellaceae Infections;Sexually Transmitted Diseases, Bacterial;Urologic Diseases;Skin and Connective Tissue Diseases;Sexually Transmitted Diseases;Neisseriaceae Infections;Pneumonia, Bacterial;Tonsillitis;Urethritis;Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Pneumonia;Lung Diseases;Actinomycetales Infections;Haemophilus Infections;Mycoplasma Infections;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Disease Attributes;Streptococcal Infections;Pneumonia, Mycoplasma;Otitis Media;Infections;Female Urogenital Diseases;Chlamydiaceae Infections;Urethral Diseases;Pharyngeal Diseases;Mycoplasmatales Infections;Respiratory Tract Infections;Otitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycobacterium Infections;Gram-Negative Bacterial Infections;Otorhinolaryngologic Diseases;Staphylococcal Infections;Skin Diseases;Bacterial Infections;Stomatognathic Diseases;Ear Diseases;Bacterial Infections and Mycoses;Pharyngitis;Respiratory Tract Diseases;Gram-Positive Bacterial Infections;Chlamydia Infections;Skin Diseases, Infectious;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Male Urogenital Diseases;Communicable Diseases","Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Immune System Diseases;Digestive System Diseases;Disease","Bacterial Infections;Bacterial Infections and Mycoses;Actinomycetales Infections;Gram-Positive Bacterial Infections;Disease;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocarditis, Bacterial;Mycobacterium Infections;Heart Diseases;Endocarditis;Cardiovascular Infections;Infections;Mycobacterium Infections, Nontuberculous",Macrocyclic Compounds;Macrolides;Erythromycin;Azithromycin;Organic Chemicals;Polycyclic Compounds;Polyketides;Substances;Substances and Cells (CHEM);Lactones,Pharmacokinetics (PK);Route of Excretion;Hepatic Excretion;Elimination,Enzyme Interactions;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cellular Synthetic Activity Alteration;Organ System Specific Effects;Musculoskeletal Activity Alteration;Cellular Cycle Alteration;Translation Alteration;Striated Muscle Anabolism Alteration;Striated Muscle Metabolic Alteration;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Macrolide;Chemical Structure;Antimicrobial;Anti-infective;Macrolide Antimicrobial,,"Pimozide;Substances;Benzimidazoles;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Macrocyclic Compounds;Macrolides;Organic Chemicals;Polycyclic Compounds;Polyketides;Substances;Substances and Cells (CHEM);Lactones,Medicinal product categorized by therapeutic role;Antibacterial agent;Macrolide antibacterial agent;Antiinfective agent,Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,,,,,
111,34,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,"VA CLASSES;ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;ANTI-INFECTIVE,TOPICAL OPHTHALMIC;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC","VA CLASSES;ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;ANTI-INFECTIVE,TOPICAL OPHTHALMIC;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC",Medicinal product categorized by structure;Macrolide antibacterial agent;Macrolide-containing product,,"ANTIINFECTIVES FOR SYSTEMIC USE;Macrolides;SENSORY ORGANS;ANTIINFECTIVES;Anatomical Therapeutic Chemical (ATC1-4);Antibiotics;OPHTHALMOLOGICALS;MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE",Anti-Infective Agents;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"Pasteurellaceae Infections;Sexually Transmitted Diseases, Bacterial;Urologic Diseases;Skin and Connective Tissue Diseases;Sexually Transmitted Diseases;Neisseriaceae Infections;Pneumonia, Bacterial;Tonsillitis;Urethritis;Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Pneumonia;Lung Diseases;Actinomycetales Infections;Haemophilus Infections;Mycoplasma Infections;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Disease Attributes;Streptococcal Infections;Pneumonia, Mycoplasma;Otitis Media;Infections;Female Urogenital Diseases;Chlamydiaceae Infections;Urethral Diseases;Pharyngeal Diseases;Mycoplasmatales Infections;Respiratory Tract Infections;Otitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycobacterium Infections;Gram-Negative Bacterial Infections;Otorhinolaryngologic Diseases;Staphylococcal Infections;Skin Diseases;Bacterial Infections;Stomatognathic Diseases;Ear Diseases;Bacterial Infections and Mycoses;Pharyngitis;Respiratory Tract Diseases;Gram-Positive Bacterial Infections;Chlamydia Infections;Skin Diseases, Infectious;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Male Urogenital Diseases;Communicable Diseases","Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Immune System Diseases;Digestive System Diseases;Disease","Bacterial Infections;Bacterial Infections and Mycoses;Actinomycetales Infections;Gram-Positive Bacterial Infections;Disease;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocarditis, Bacterial;Mycobacterium Infections;Heart Diseases;Endocarditis;Cardiovascular Infections;Infections;Mycobacterium Infections, Nontuberculous",Macrocyclic Compounds;Macrolides;Erythromycin;Azithromycin;Organic Chemicals;Polycyclic Compounds;Polyketides;Substances;Substances and Cells (CHEM);Lactones,Pharmacokinetics (PK);Route of Excretion;Hepatic Excretion;Elimination,Enzyme Interactions;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cellular Synthetic Activity Alteration;Organ System Specific Effects;Musculoskeletal Activity Alteration;Cellular Cycle Alteration;Translation Alteration;Striated Muscle Anabolism Alteration;Striated Muscle Metabolic Alteration;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Macrolide;Chemical Structure;Antimicrobial;Anti-infective;Macrolide Antimicrobial,,"Pimozide;Substances;Benzimidazoles;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Macrocyclic Compounds;Macrolides;Organic Chemicals;Polycyclic Compounds;Polyketides;Substances;Substances and Cells (CHEM);Lactones,Medicinal product categorized by therapeutic role;Antibacterial agent;Macrolide antibacterial agent;Antiinfective agent,Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,,,,,
112,43,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,"VA CLASSES;ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;ANTI-INFECTIVE,TOPICAL OPHTHALMIC;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC","VA CLASSES;ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;ANTI-INFECTIVE,TOPICAL OPHTHALMIC;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC",Medicinal product categorized by structure;Macrolide antibacterial agent;Macrolide-containing product,,"ANTIINFECTIVES FOR SYSTEMIC USE;Macrolides;SENSORY ORGANS;ANTIINFECTIVES;Anatomical Therapeutic Chemical (ATC1-4);Antibiotics;OPHTHALMOLOGICALS;MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE",Anti-Infective Agents;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"Pasteurellaceae Infections;Sexually Transmitted Diseases, Bacterial;Urologic Diseases;Skin and Connective Tissue Diseases;Sexually Transmitted Diseases;Neisseriaceae Infections;Pneumonia, Bacterial;Tonsillitis;Urethritis;Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Pneumonia;Lung Diseases;Actinomycetales Infections;Haemophilus Infections;Mycoplasma Infections;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Disease Attributes;Streptococcal Infections;Pneumonia, Mycoplasma;Otitis Media;Infections;Female Urogenital Diseases;Chlamydiaceae Infections;Urethral Diseases;Pharyngeal Diseases;Mycoplasmatales Infections;Respiratory Tract Infections;Otitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycobacterium Infections;Gram-Negative Bacterial Infections;Otorhinolaryngologic Diseases;Staphylococcal Infections;Skin Diseases;Bacterial Infections;Stomatognathic Diseases;Ear Diseases;Bacterial Infections and Mycoses;Pharyngitis;Respiratory Tract Diseases;Gram-Positive Bacterial Infections;Chlamydia Infections;Skin Diseases, Infectious;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Male Urogenital Diseases;Communicable Diseases","Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Immune System Diseases;Digestive System Diseases;Disease","Bacterial Infections;Bacterial Infections and Mycoses;Actinomycetales Infections;Gram-Positive Bacterial Infections;Disease;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocarditis, Bacterial;Mycobacterium Infections;Heart Diseases;Endocarditis;Cardiovascular Infections;Infections;Mycobacterium Infections, Nontuberculous",Macrocyclic Compounds;Macrolides;Erythromycin;Azithromycin;Organic Chemicals;Polycyclic Compounds;Polyketides;Substances;Substances and Cells (CHEM);Lactones,Pharmacokinetics (PK);Route of Excretion;Hepatic Excretion;Elimination,Enzyme Interactions;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cellular Synthetic Activity Alteration;Organ System Specific Effects;Musculoskeletal Activity Alteration;Cellular Cycle Alteration;Translation Alteration;Striated Muscle Anabolism Alteration;Striated Muscle Metabolic Alteration;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Macrolide;Chemical Structure;Antimicrobial;Anti-infective;Macrolide Antimicrobial,,"Pimozide;Substances;Benzimidazoles;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Macrocyclic Compounds;Macrolides;Organic Chemicals;Polycyclic Compounds;Polyketides;Substances;Substances and Cells (CHEM);Lactones,Medicinal product categorized by therapeutic role;Antibacterial agent;Macrolide antibacterial agent;Antiinfective agent,Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,,,,,
113,25,Concomitant Medications,Generic Name,RxNorm,Qvar,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],966537.0,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],226084.0,226084.0,226084,False,"ANTIASTHMA/BRONCHODILATORS;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;RESPIRATORY TRACT MEDICATIONS","ANTIASTHMA/BRONCHODILATORS;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product;Steroid-containing product;Glucocorticoid-containing product,,"NASAL PREPARATIONS;Glucocorticoids;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;RESPIRATORY SYSTEM;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);DERMATOLOGICALS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;CORTICOSTEROIDS, PLAIN;Corticosteroids;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES","Glucocorticoids;Respiratory System Agents;Therapeutic Uses;Anti-Asthmatic Agents;Hormones;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Inflammation;Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Infections;Nose Diseases;Pathologic Processes;Disease;Rhinitis;Rhinitis, Allergic","Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Respiratory Hypersensitivity;Disease;Respiratory Tract Diseases;Drug Hypersensitivity;Bronchial Diseases;Status Asthmaticus;Hypersensitivity;Lung Diseases, Obstructive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Chemically-Induced Disorders;Immune System Diseases;Hypersensitivity, Immediate;Asthma","Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Polyps;Nasal Polyps;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Bronchial Diseases;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Nose Diseases;Pathological Conditions, Signs and Symptoms;Disease","Substances and Cells (CHEM);Steroids, Chlorinated;Pregnadienes;Pregnanes;Steroids;Substances;Pregnadienetriols;Fused-Ring Compounds;Polycyclic Compounds;Beclomethasone",Fecal Excretion;Pharmacokinetics (PK);Elimination;Renal Excretion;Route of Excretion,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Cellular Synthetic Activity Alteration;Organ System Specific Effects;Translation Alteration;Cellular Cycle Alteration;Cardiovascular Activity Alteration;Cellular Motion Alteration;Vasoconstriction;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Vascular Alterations;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Vascular Tone Alteration;Decreased Cellular Migration;Adrenal Cortical Activity Alteration;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
114,25,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,Cholecalciferol 50000 UNT Oral Tablet [Dialyvite Vitamin D3 Max],1303916.0,Cholecalciferol 50000 UNT Oral Tablet [Dialyvite Vitamin D3 Max],1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
115,26,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
116,29,Concomitant Medications,Generic Name,RxNorm,vitamin d3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
117,30,Concomitant Medications,Generic Name,RxNorm,vitamin d3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
118,32,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
119,25,Concomitant Medications,Generic Name,RxNorm,Acetaminophen,Acetaminophen,161.0,Acetaminophen,161.0,161.0,161,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID ANALGESICS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC","ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;OPIOID ANALGESICS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NON-OPIOID ANALGESICS;VA CLASSES;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANTIHISTAMINE/ANTITUSSIVE;MUSCULOSKELETAL MEDICATIONS;CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;CNS MEDICATIONS,OTHER;DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANALGESICS;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NONSALICYLATE NSAIs,ANTIRHEUMATIC;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC",Medicinal product categorized by structure;Morphinan-containing product;Naturally occurring alkaloid-containing product;Isoquinoline-containing product;Nitrogen and/or nitrogen compound-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Phenol structure-containing product,Opioid receptor agonist-containing product;Medicinal product categorized by disposition;Morphinan opioid-containing product,OTHER ANALGESICS AND ANTIPYRETICS;OPIOIDS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Opioids in combination with non-opioid analgesics;Anilides,"Central Nervous System Agents;Analgesics, Opioid;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Narcotics;Central Nervous System Depressants;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,SCHEDULE III;SCHEDULE V;SCHEDULE IV;CSA SCHEDULE;SCHEDULE II,,,,,,,,,
120,39,Concomitant Medications,Generic Name,RxNorm,acetaminophen,Acetaminophen,161.0,Acetaminophen,161.0,161.0,161,False,"CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;VA CLASSES;ANALGESICS;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;CNS MEDICATIONS,OTHER;COLD REMEDIES,COMBINATIONS;DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;OPIOID ANALGESICS;ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID ANALGESICS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC","ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;OPIOID ANALGESICS;RESPIRATORY TRACT MEDICATIONS;ANTIRHEUMATICS;NON-OPIOID ANALGESICS;VA CLASSES;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANTIHISTAMINE/ANTITUSSIVE;MUSCULOSKELETAL MEDICATIONS;CENTRAL NERVOUS SYSTEM MEDICATIONS;COLD REMEDIES,OTHER;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;CNS MEDICATIONS,OTHER;DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANALGESICS;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NONSALICYLATE NSAIs,ANTIRHEUMATIC;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC",Medicinal product categorized by structure;Morphinan-containing product;Naturally occurring alkaloid-containing product;Isoquinoline-containing product;Nitrogen and/or nitrogen compound-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Phenol structure-containing product,Opioid receptor agonist-containing product;Medicinal product categorized by disposition;Morphinan opioid-containing product,OTHER ANALGESICS AND ANTIPYRETICS;OPIOIDS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM;Opioids in combination with non-opioid analgesics;Anilides,"Central Nervous System Agents;Analgesics, Opioid;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Narcotics;Central Nervous System Depressants;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Antirheumatic Agents;Anti-Inflammatory Agents;Sensory System Agents;Analgesics;Physiological Effects of Drugs;Antipyretics","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations","Hematologic Diseases;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Liver Diseases;Digestive System Diseases;Carbohydrate Metabolism, Inborn Errors;Glucosephosphate Dehydrogenase Deficiency;Metabolic Diseases;Anemia, Hemolytic, Congenital;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Anemia;Genetic Diseases, Inborn;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Fever;Body Temperature Changes;Pathological Conditions, Signs and Symptoms;Pain;Nervous System Diseases;Disease;Neurologic Manifestations",Substances and Cells (CHEM);Aniline Compounds;Organic Chemicals;Amides;Acetaminophen;Substances;Acetanilides;Amines;Anilides,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Route of Excretion;Renal Excretion;Metabolism;Site of Metabolism,Prostaglandin Receptor Interactions;Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Endocrine Activity Alteration;Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Immunologically Active Molecule Production;Decreased Prostaglandin Production;Hypothalamic Endocrine Activity Alteration;Nervous System Activity Alteration,,SCHEDULE III;SCHEDULE V;SCHEDULE IV;CSA SCHEDULE;SCHEDULE II,,,,,,,,,
121,26,Concomitant Medications,Generic Name,RxNorm,Hydrocortisone 2%,,,,,197784.0,197784,True,"ANTI-INFLAMMATORY,TOPICAL;DERMATOLOGICAL AGENTS;VA CLASSES","ANTI-INFLAMMATORY,TOPICAL;DERMATOLOGICAL AGENTS;VA CLASSES",Medicinal product categorized by structure;Glucocorticoid-containing product;Steroid-containing product;Corticosteroid and/or corticosteroid derivative-containing product,Adrenal hormone-containing product;Hormone-containing product;Adrenal cortex hormone-containing product;Medicinal product categorized by disposition,"ANTIINFLAMMATORY AGENTS;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Corticosteroids, weak (group I);Corticosteroids for local oral treatment;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);VASOPROTECTIVES;Corticosteroids, weak, other combinations;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;CORTICOSTEROIDS FOR SYSTEMIC USE;CORTICOSTEROIDS, PLAIN;Corticosteroids/antiinfectives/mydriatics in combination;OPHTHALMOLOGICALS;CARDIOVASCULAR SYSTEM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;INTESTINAL ANTIINFLAMMATORY AGENTS;STOMATOLOGICAL PREPARATIONS;CORTICOSTEROIDS, OTHER COMBINATIONS;Glucocorticoids;CORTICOSTEROIDS;SENSORY ORGANS;Corticosteroids acting locally;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;Corticosteroids, plain;DERMATOLOGICALS;Corticosteroids;OTOLOGICALS",MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents,"Foot Diseases;Disorders of Sex Development;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Adrenogenital Syndrome;Lung Diseases, Obstructive;Endocrine System Diseases;Musculoskeletal Diseases;Immune System Diseases;Gonadal Disorders;Rectal Diseases;Shock;Urogenital Diseases;Digestive System Diseases;Adrenal Gland Diseases;Lung Diseases;Inflammatory Bowel Diseases;Colitis;Gastrointestinal Diseases;Scalp Dermatoses;Leg Dermatoses;Intestinal Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Foot Dermatoses;Anus Diseases;Asthma;Female Urogenital Diseases;Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Inflammation;Dermatitis;Vascular Diseases;Colitis, Ulcerative;Congenital Abnormalities;Adrenal Insufficiency;Status Asthmaticus;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Dermatitis, Contact;Hypersensitivity, Immediate;Skin Manifestations;Pruritus Ani;Skin Diseases;Adrenal Hyperplasia, Congenital;Pruritus;Colonic Diseases;Hand Dermatoses;Respiratory Hypersensitivity;Steroid Metabolism, Inborn Errors;Hemorrhoids;Respiratory Tract Diseases;Skin Diseases, Eczematous;Bronchial Diseases;Signs and Symptoms;Hypersensitivity;Rheumatic Diseases;Genetic Diseases, Inborn;Pathological Conditions, Signs and Symptoms;Gastroenteritis;Male Urogenital Diseases;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Facial Dermatoses;Urogenital Abnormalities","Drug Hypersensitivity;Actinomycetales Infections;Tuberculosis, Cutaneous;Dermatomycoses;Skin Diseases, Viral;Skin Diseases, Parasitic;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycobacterium Infections;Tuberculosis;Mycoses;Skin Diseases;Virus Diseases;Bacterial Infections;Drug-Related Side Effects and Adverse Reactions;Skin Diseases, Infectious;Bacterial Infections and Mycoses;Parasitic Diseases;Gram-Positive Bacterial Infections;Chemically-Induced Disorders;Tuberculosis, Extrapulmonary;Skin Diseases, Bacterial;Disease;Skin and Connective Tissue Diseases",,"Substances and Cells (CHEM);Adrenal Cortex Hormones;Hormones;Pregnanes;Steroids;17-Hydroxycorticosteroids;11-Hydroxycorticosteroids;Pregnenes;Hydrocortisone;Fused-Ring Compounds;Pregnenediones;Hormones, Hormone Substitutes, and Hormone Antagonists;Polycyclic Compounds;Substances;Hydroxycorticosteroids",,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Enzyme Inhibitors;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Lipoxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Carbohydrate Metabolism Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Cellular Synthetic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Activity;Cardiovascular Activity Alteration;Cellular Cycle Alteration;Translation Alteration;Cellular Motion Alteration;Lipid Metabolism Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Leukotriene Activity;Decreased Thromboxane Activity;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Decreased Eicosanoid Activity;Vascular Permeability Alteration;Vascular Alterations;Decreased Polymorphonuclear Leukocyte Migration;Immunologically Active Molecule Activity Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Decreased Cellular Migration;Metabolic Activity Alteration;Decreased Prostaglandin Activity;Decreased Vascular Permeability;Adrenal Cortical Activity Alteration;Decreased Fibroblast Migration;Immunologic Activity Alteration;Decreased Immunologic Activity;Decreased Capillary Permeability;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
122,27,Concomitant Medications,Generic Name,RxNorm,Decadron,Decadron Pill,1170298.0,Decadron Pill,227682.0,227682.0,227682,False,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Pregnane-containing product;Steroid-containing product;Glucocorticoid-containing product,Medicinal product categorized by disposition;Immunomodulator-containing product,"Corticosteroids, moderately potent, other combinations;ANTIINFLAMMATORY AGENTS;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;ANTI-ACNE PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Corticosteroids for local oral treatment;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;Corticosteroids, combinations for treatment of acne;ALIMENTARY TRACT AND METABOLISM;Corticosteroids, moderately potent (group II);Anatomical Therapeutic Chemical (ATC1-4);VASOPROTECTIVES;RESPIRATORY SYSTEM;Corticosteroids/antiinfectives/mydriatics in combination;CORTICOSTEROIDS FOR SYSTEMIC USE;CORTICOSTEROIDS, PLAIN;OPHTHALMOLOGICALS;CARDIOVASCULAR SYSTEM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;STOMATOLOGICAL PREPARATIONS;CORTICOSTEROIDS, OTHER COMBINATIONS;NASAL PREPARATIONS;Glucocorticoids;CORTICOSTEROIDS;SENSORY ORGANS;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, plain;DERMATOLOGICALS;Corticosteroids;OTOLOGICALS","Glucocorticoids;Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Antineoplastic Agents;Antineoplastic Agents, Hormonal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Hormones;Antiemetics;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs;Gastrointestinal Agents","Purpura;Nutritional and Metabolic Diseases;Lymphoma;Neoplasms;Addison Disease;Mycosis Fungoides;Collagen Diseases;Hypersensitivity, Delayed;Rhinitis, Allergic;Systemic Inflammatory Response Syndrome;Spondylarthritis;Iritis;Neoplasms by Histologic Type;Autoimmune Diseases;Thrombocytopenia;Dermatitis;Colitis, Ulcerative;Respiratory Tract Infections;Spinal Diseases;Skin Diseases, Vesiculobullous;Skin Manifestations;Hypersensitivity, Immediate;Signs and Symptoms, Digestive;Otorhinolaryngologic Diseases;Signs and Symptoms;Sepsis;Pathological Conditions, Signs and Symptoms;Nervous System Diseases;Thyroiditis;Immune System Diseases;Hemorrhage;Shock;Arthritis;Actinomycetales Infections;Joint Diseases;Nausea;Metabolic Diseases;Calcium Metabolism Disorders;Blood Coagulation Disorders;Water-Electrolyte Imbalance;Brain Diseases;Mycobacterium Infections;Pemphigus;Vomiting;Skin Diseases;Bursitis;Lymphoproliferative Disorders;Dermatitis Herpetiformis;Bacterial Infections and Mycoses;Lymphatic Diseases;Respiratory Tract Diseases;Gram-Positive Bacterial Infections;Uveal Diseases;Rheumatic Diseases;Hypersensitivity;Corneal Diseases;Bone Diseases;Pathologic Processes;Disease;Hemorrhagic Disorders;Skin and Connective Tissue Diseases;Uveitis;Lymphoma, T-Cell;Endocrine System Diseases;Purpura, Thrombocytopenic, Idiopathic;Digestive System Diseases;Lung Diseases;Inflammatory Bowel Diseases;Leukemia;Purpura, Thrombocytopenic;Intestinal Diseases;Ankylosis;Connective Tissue Diseases;Uveitis, Anterior;Axial Spondyloarthritis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Spondylarthropathies;Bacterial Infections;Respiratory Hypersensitivity;Shock, Septic;Thrombotic Microangiopathies;Keratitis;Hemic and Lymphatic Diseases;Gastroenteritis;Sarcoidosis;Hematologic Diseases;Lupus Erythematosus, Systemic;Musculoskeletal Diseases;Lymphoma, Non-Hodgkin;Panuveitis;Bone Diseases, Infectious;Adrenal Gland Diseases;Colitis;Gastrointestinal Diseases;Brain Edema;Lymphoma, T-Cell, Cutaneous;Tuberculosis, Pulmonary;Immunoproliferative Disorders;Infections;Eye Diseases;Inflammation;Spondylitis, Ankylosing;Rhinitis, Allergic, Perennial;Blood Platelet Disorders;Tuberculosis;Colonic Diseases;Hypercalcemia;Thyroid Diseases;Central Nervous System Diseases;Spondylitis;Nose Diseases;Iris Diseases;Adrenal Insufficiency;Rhinitis","Bacterial Infections;Drug-Related Side Effects and Adverse Reactions;Bacterial Infections and Mycoses;Tuberculosis, Ocular;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Eye Infections, Bacterial;Eye Infections;Eye Infections, Viral;Mycoses;Eye Infections, Fungal;Infections;Disease;Virus Diseases;Eye Diseases","Lung Diseases, Obstructive;Immune System Diseases;Lung Diseases;Polyps;Nausea;Asthma;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vomiting;Otorhinolaryngologic Diseases;Signs and Symptoms, Digestive;Hypersensitivity, Immediate;Respiratory Hypersensitivity;Respiratory Tract Diseases;Signs and Symptoms;Nasal Polyps;Bronchial Diseases;Hypersensitivity;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Nose Diseases;Disease","Substances and Cells (CHEM);Steroids, Fluorinated;Pregnadienes;Pregnanes;Steroids;Substances;Pregnadienetriols;Dexamethasone;Fused-Ring Compounds;Polycyclic Compounds",,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Enzyme Inhibitors;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Lipoxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Hematological Cell Quantity Alteration;Carbohydrate Metabolism Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Cellular Synthetic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Activity;Cardiovascular Activity Alteration;Cellular Cycle Alteration;Translation Alteration;Cellular Motion Alteration;Decreased Histamine Activity;Lipid Metabolism Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Decreased Intravascular Volume;Decreased Leukotriene Activity;Decreased Hematopoiesis;Decreased Complement Production;Decreased Thromboxane Activity;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Decreased Protein Synthesis;Striated Muscle Metabolic Alteration;Decreased Eicosanoid Activity;Vascular Permeability Alteration;Vascular Alterations;Decreased Immunologically Active Molecule Production;Decreased Polymorphonuclear Leukocyte Migration;Immunologically Active Molecule Activity Alteration;Hematopoiesis Alteration;Decreased Kinin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Hematologic Activity Alteration;Decreased Lysosomal Function;Immunologically Active Molecule Production Alteration;Intravascular Volume Alteration;Decreased Cellular Migration;Decreased Prostaglandin Activity;Metabolic Activity Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Vascular Permeability;Adrenal Cortical Activity Alteration;Decreased Adhesion Factor Activity;Decreased Fibroblast Migration;Immunologic Activity Alteration;Hemic/Lymphatic Activity Alteration;Decreased Immunologic Activity;Decreased Myeloid Cell Production;Decreased Immunologically Active Biogenic Amine Activity;Decreased Capillary Permeability;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,"Adrenal Gland Diseases;Disease;Cushing Syndrome;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Depressive Disorder;Mood Disorders;Adrenocortical Hyperfunction;Mental Disorders",
123,27,Concomitant Medications,Generic Name,RxNorm,Tamoxifen,Tamoxifen,10324.0,Tamoxifen,10324.0,10324.0,10324,False,ANTINEOPLASTIC HORMONES;ANTINEOPLASTICS;VA CLASSES,ANTINEOPLASTIC HORMONES;ANTINEOPLASTICS;VA CLASSES,,Hormone receptor antagonist-containing product;Estrogen receptor antagonist-containing product;Medicinal product categorized by disposition,ENDOCRINE THERAPY;Anatomical Therapeutic Chemical (ATC1-4);Anti-estrogens;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;HORMONE ANTAGONISTS AND RELATED AGENTS,"Estrogen Antagonists;Antineoplastic Agents;Therapeutic Uses;Antineoplastic Agents, Hormonal;Bone Density Conservation Agents;Selective Estrogen Receptor Modulators;MeSH Pharmacologic Actions (MESHPA);Estrogen Receptor Modulators;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Digestive System Neoplasms;Pancreatic Neoplasms;Neoplasms;Neoplasms by Site;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Digestive System Diseases;Gonadal Disorders;Breast Neoplasms;Endocrine Gland Neoplasms;Pancreatic Diseases;Skin Diseases;Gynecomastia;Breast Diseases;Disease;Skin and Connective Tissue Diseases;Puberty, Precocious","Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Pulmonary Embolism;Vascular Diseases;Cardiovascular Diseases;Respiratory Tract Diseases;Venous Thrombosis;Pregnancy;Reproductive Physiological Phenomena;Embolism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Thrombosis;Chemically-Induced Disorders;Embolism and Thrombosis;Disease","Carcinoma, Ductal;Adenocarcinoma;Disease;Neoplasms;Skin and Connective Tissue Diseases;Carcinoma;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Breast Neoplasms;Carcinoma, Ductal, Breast;Neoplasms by Histologic Type;Skin Diseases;Breast Diseases;Neoplasms, Glandular and Epithelial;Neoplasms by Site;Neoplasms, Ductal, Lobular, and Medullary","Hydrocarbons;Benzene Derivatives;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Stilbenes;Tamoxifen;Substances;Substances and Cells (CHEM);Benzylidene Compounds",,Receptor Interactions;Selective Estrogen Receptor Modulators;Transcription Factor Activity;Hormone Receptor Modulators;Mechanism of Action (MoA);Hormone Receptor Interactions;Steroid Receptor Modulators,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects;Ovulation Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Cellular Synthetic Activity Alteration;Nucleic Acid Replication Alteration;Cellular Cycle Alteration;Stimulate Ovulation;Decreased DNA Replication;Reproductive System Activity Alteration;DNA Replication Alteration;Female Reproductive System Activity Alteration;Ovarian Endocrine Activity Alteration;Decreased Ovarian Estrogen Secretion;Ovarian Function Alteration,Established Pharmacologic Class (EPC);Receptor Agonist;Estrogen Agonist/Antagonist;Receptor Antagonist;Receptor Interaction,,"Substances and Cells (CHEM);Benzopyrans;Heterocyclic Compounds, 1-Ring;Substances;4-Hydroxycoumarins;Warfarin;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Coumarins;Pyrans",,,,,,,,
124,28,Concomitant Medications,Generic Name,RxNorm,Januvia,Januvia Pill,1167815.0,Januvia Pill,638596.0,638596.0,638596,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product,Hydrolase inhibitor-containing product;Proteinase inhibitor-containing product;Medicinal product categorized by disposition;Dipeptidyl peptidase IV inhibitor-containing product;Serine proteinase inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Dipeptidyl peptidase 4 (DPP-4) inhibitors;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS","Incretins;Protease Inhibitors;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Dipeptidyl-Peptidase IV Inhibitors;MeSH Pharmacologic Actions (MESHPA);Hormones;Hypoglycemic Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Nutritional and Metabolic Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Acid-Base Imbalance;Acidosis;Diabetes Mellitus;Immune System Diseases;Metabolic Diseases;Ketosis;Autoimmune Diseases;Diabetes Mellitus, Type 1;Glucose Metabolism Disorders;Disease",,"Pyrazines;Azoles;Triazoles;Heterocyclic Compounds, 1-Ring;Substances;Substances and Cells (CHEM);Sitagliptin Phosphate;Heterocyclic Compounds",,Protease Inhibitors;Dipeptidyl Peptidase 4 Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Endocrine Activity Alteration;Pancreatic Islet Activity Alteration;Organ System Specific Effects;Decreased Glucagon Secretion;Increased Insulin Secretion,Established Pharmacologic Class (EPC);Blood Glucose Regulator;Enzyme Inhibitor;Dipeptidyl Peptidase 4 Inhibitor;Enzyme Interaction;Protease Inhibitor;Antimicrobial;Anti-infective,,,,,,,,,,
125,28,Concomitant Medications,Generic Name,RxNorm,robitussin dm,Robitussin DM,827249.0,Robitussin DM,,1790650.0,1790650,True,,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Ether structure-containing product,Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Medicinal product categorized by disposition,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Antagonists;Antitussive Agents;Neurotransmitter Agents;Physiological Effects of Drugs;Expectorants,"Signs and Symptoms, Respiratory;Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Respiration Disorders;Lung Diseases;RNA Virus Infections;Infections;Pharyngeal Diseases;Bordetella Infections;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Whooping Cough;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Gram-Negative Bacterial Infections;Virus Diseases;Bacterial Infections;Stomatognathic Diseases;Pharyngitis;Respiratory Hypersensitivity;Bacterial Infections and Mycoses;Respiratory Tract Diseases;Laryngeal Diseases;Picornaviridae Infections;Signs and Symptoms;Bronchial Diseases;Hypersensitivity;Bronchitis;Laryngitis;Nose Diseases;Pathological Conditions, Signs and Symptoms;Cough;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Phenols;Hydrocarbons, Cyclic;Alkaloids;Substances and Cells (CHEM);Opiate Alkaloids;Morphinans;Heterocyclic Compounds, Bridged-Ring;Phenyl Ethers;Ethers;Guaifenesin;Hydrocarbons, Aromatic;Substances;Benzene Derivatives;Catechols;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Guaiacol;Hydrocarbons;Methyl Ethers;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Dextromethorphan",,Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Sigma-1 Receptor Interactions;Serotonin Transporter Interactions;Sigma Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ligand-Gated Ion Channel Interactions;Membrane Transporter Interactions;Symporter Interactions;NMDA Receptor Antagonists,Physiologic Effect (PE);Respiratory Secretion Alteration;Organ System Specific Effects;Decreased Respiratory Secretion Viscosity;Respiratory/Pulmonary Activity Alteration;Increased Respiratory Secretions;Medullary Respiratory Center Activity Alteration;Respiratory Secretion Viscosity Alteration;Decreased Medullary Respiratory Drive,Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Expectorant;Receptor Antagonist;Sigma-1 Agonist;Receptor Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Respiratory Agent;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Expectorant agent;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
126,28,Concomitant Medications,Generic Name,RxNorm,tessalon,Tessalon Perles,220224.0,Tessalon Perles,227783.0,227783.0,227783,False,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Other cough suppressants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Butylamines;Alkanes;Organic Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Acyclic;Amines;Butanes",,Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions;Antiporter Interactions,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Tracheobronchial Stretch Receptor Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Non-narcotic Antitussive,,,,Medicinal product categorized by therapeutic role;Antitussive agent,Respiratory System Agent;Therapeutic Categories;Antitussive Agent,,,,,
127,33,Concomitant Medications,Generic Name,RxNorm,tessalon,Tessalon Perles,220224.0,Tessalon Perles,227783.0,227783.0,227783,False,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Organic acid and/or organic acid derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Other cough suppressants",Respiratory System Agents;Central Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents,"Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Hydrocarbons;Butylamines;Alkanes;Organic Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Acyclic;Amines;Butanes",,Receptor Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions;Antiporter Interactions,Physiologic Effect (PE);Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Tracheobronchial Stretch Receptor Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Non-narcotic Antitussive,,,,Medicinal product categorized by therapeutic role;Antitussive agent,Respiratory System Agent;Therapeutic Categories;Antitussive Agent,,,,,
128,29,Concomitant Medications,Generic Name,RxNorm,clonazepam,clonazePAM,2598.0,clonazePAM,2598.0,2598.0,2598,False,BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;SEDATIVES/HYPONTICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;SEDATIVES/HYPONTICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Benzazepine-containing product;Benzodiazepine-containing product,,Anatomical Therapeutic Chemical (ATC1-4);ANTIEPILEPTICS;NERVOUS SYSTEM;Benzodiazepine derivatives,Central Nervous System Agents;GABA Modulators;Therapeutic Uses;Anticonvulsants;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Agents;Physiological Effects of Drugs;GABA Agents,"Schizophrenia Spectrum and Other Psychotic Disorders;Dysarthria;Behavior and Behavior Mechanisms;Neuralgia;Pain;Speech Disorders;Tic Disorders;Epilepsy, Absence;Seizures;Epilepsies, Myoclonic;Lennox Gastaut Syndrome;Life Phases, Behavior Mechanisms and Physiologic States;Bipolar and Related Disorders;Schizophrenia;Sleep Disorders, Intrinsic;Anxiety Disorders;Mental Disorders;Neurodevelopmental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Panic Disorder;Epileptic Syndromes;Communication Disorders;Parasomnias;Language Disorders;Restless Legs Syndrome;Neurologic Manifestations;Epilepsy;Articulation Disorders;Epilepsy, Generalized;Central Nervous System Diseases;Bipolar Disorder;Signs and Symptoms;Neurobehavioral Manifestations;Genetic Diseases, Inborn;Peripheral Nervous System Diseases;Movement Disorders;Dyssomnias;Pathological Conditions, Signs and Symptoms;Mood Disorders;Sleep Wake Disorders;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Glaucoma;Drug Hypersensitivity;Liver Diseases;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Glaucoma, Angle-Closure;Ocular Hypertension;Digestive System Diseases;Disease;Eye Diseases",,"Benzazepines;Clonazepam;Benzodiazepinones;Substances;Benzodiazepines;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Chloride Channel Interactions;Receptor Interactions;GABA A Receptor Interactions;Ion Channel Interactions;Mechanism of Action (MoA);Ligand-Gated Ion Channel Interactions;Membrane Transporter Interactions;GABA A Modulators,Physiologic Effect (PE);Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Increased GABA Activity;Gamma Amino Butyric Acid (GABA) Activity Alteration;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Chemical Structure;Benzodiazepine;Nervous System Agent,CSA SCHEDULE;SCHEDULE IV,"Benzazepines;Substances;Benzodiazepines;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring","Benzazepines;Substances;Benzodiazepines;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Medicinal product categorized by therapeutic role;Anticonvulsant agent,,,,,,
129,29,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMINS,COMBINATIONS;VA CLASSES;MULTIVITAMINS WITH MINERALS;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER;CYANOCOBALAMIN","VITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMINS,COMBINATIONS;VA CLASSES;MULTIVITAMINS WITH MINERALS;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER;CYANOCOBALAMIN",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product,,BLOOD AND BLOOD FORMING ORGANS;Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);ANTIANEMIC PREPARATIONS,Micronutrients;MeSH Pharmacologic Actions (MESHPA);Vitamins;Vitamin B Complex;Physiological Effects of Drugs,"Deficiency Diseases;Avitaminosis;Anemia, Pernicious;Nutritional and Metabolic Diseases;Hematologic Diseases;Endocrine System Diseases;Diabetes Mellitus;Alcohol-Induced Disorders, Nervous System;Immune System Diseases;Alcohol-Related Disorders;Glucose Metabolism Disorders;Multiple Sclerosis;Malnutrition;Anemia, Macrocytic;Nutrition Disorders;Metabolic Diseases;Autoimmune Diseases of the Nervous System;Autoimmune Diseases;Alcoholic Neuropathy;Mental Disorders;Alcohol-Induced Disorders;Demyelinating Autoimmune Diseases, CNS;Anemia, Megaloblastic;Neuromuscular Diseases;Demyelinating Diseases;Poisoning;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Substance-Related Disorders;Polyneuropathies;Vitamin B Deficiency;Vitamin B 12 Deficiency;Leukoencephalopathies;Diabetic Neuropathies;Diabetes Complications;Neurotoxicity Syndromes;Central Nervous System Diseases;Anemia;Chemically-Induced Disorders;Peripheral Nervous System Diseases;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Deficiency Diseases;Avitaminosis;Nutritional and Metabolic Diseases;Malnutrition;Nutrition Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Vitamin B 12 Deficiency;Disease","Macrocyclic Compounds;Azoles;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Corrinoids;Polycyclic Compounds;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Vitamin B 12",,Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin B12,,,"Macrocyclic Compounds;Azoles;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Corrinoids;Polycyclic Compounds;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Vitamin B 12",,,,,,,
130,32,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,"VITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMINS,COMBINATIONS;VA CLASSES;MULTIVITAMINS WITH MINERALS;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER;CYANOCOBALAMIN","VITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMINS,COMBINATIONS;VA CLASSES;MULTIVITAMINS WITH MINERALS;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER;CYANOCOBALAMIN",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product,,BLOOD AND BLOOD FORMING ORGANS;Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);ANTIANEMIC PREPARATIONS,Micronutrients;MeSH Pharmacologic Actions (MESHPA);Vitamins;Vitamin B Complex;Physiological Effects of Drugs,"Deficiency Diseases;Avitaminosis;Anemia, Pernicious;Nutritional and Metabolic Diseases;Hematologic Diseases;Endocrine System Diseases;Diabetes Mellitus;Alcohol-Induced Disorders, Nervous System;Immune System Diseases;Alcohol-Related Disorders;Glucose Metabolism Disorders;Multiple Sclerosis;Malnutrition;Anemia, Macrocytic;Nutrition Disorders;Metabolic Diseases;Autoimmune Diseases of the Nervous System;Autoimmune Diseases;Alcoholic Neuropathy;Mental Disorders;Alcohol-Induced Disorders;Demyelinating Autoimmune Diseases, CNS;Anemia, Megaloblastic;Neuromuscular Diseases;Demyelinating Diseases;Poisoning;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Substance-Related Disorders;Polyneuropathies;Vitamin B Deficiency;Vitamin B 12 Deficiency;Leukoencephalopathies;Diabetic Neuropathies;Diabetes Complications;Neurotoxicity Syndromes;Central Nervous System Diseases;Anemia;Chemically-Induced Disorders;Peripheral Nervous System Diseases;Hemic and Lymphatic Diseases;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Deficiency Diseases;Avitaminosis;Nutritional and Metabolic Diseases;Malnutrition;Nutrition Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Vitamin B 12 Deficiency;Disease","Macrocyclic Compounds;Azoles;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Corrinoids;Polycyclic Compounds;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Vitamin B 12",,Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin B12,,,"Macrocyclic Compounds;Azoles;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Heterocyclic Compounds, 1-Ring;Substances;Pyrroles;Substances and Cells (CHEM);Corrinoids;Polycyclic Compounds;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Vitamin B 12",,,,,,,
131,30,Concomitant Medications,Generic Name,RxNorm,Sumatriptan,SUMAtriptan,37418.0,SUMAtriptan,37418.0,37418.0,37418,False,ANALGESICS;ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANALGESICS;ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Sulfonamide-containing product;Sulfur and/or sulfur compound-containing product,Serotonin 5-HT1 receptor agonist-containing product;Medicinal product categorized by disposition;Serotonin receptor agonist-containing product,Selective serotonin (5HT1) agonists;ANTIMIGRAINE PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS;NERVOUS SYSTEM,Therapeutic Uses;Vasoconstrictor Agents;Serotonin Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Serotonin 5-HT1 Receptor Agonists;MeSH Pharmacologic Actions (MESHPA);Cardiovascular Agents;Serotonin Agents;Neurotransmitter Agents;Physiological Effects of Drugs,"Trigeminal Autonomic Cephalalgias;Migraine Disorders;Central Nervous System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Headache Disorders;Headache Disorders, Primary;Nervous System Diseases;Disease;Cluster Headache;Brain Diseases","Arrhythmias, Cardiac;Cardiovascular Diseases;Drug Hypersensitivity;Brain Ischemia;Hypertension;Stroke;Liver Diseases;Angina Pectoris, Variant;Myocardial Ischemia;Heart Diseases;Chest Pain;Headache Disorders, Primary;Pain;Digestive System Diseases;Myocardial Infarction;Peripheral Vascular Diseases;Cerebrovascular Disorders;Coronary Disease;Vascular Diseases;Migraine Disorders;Migraine with Aura;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Headache Disorders;Arteriosclerosis;Ischemic Attack, Transient;Ischemia;Infarction;Coronary Artery Disease;Neurologic Manifestations;Angina, Unstable;Drug-Related Side Effects and Adverse Reactions;Hypertension, Malignant;Central Nervous System Diseases;Arterial Occlusive Diseases;Signs and Symptoms;Chemically-Induced Disorders;Nervous System Diseases;Necrosis;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Brain Diseases;Angina Pectoris",,"Substances and Cells (CHEM);Sulfonamides;Organic Chemicals;Sulfones;Amides;Indoles;Sulfur Compounds;Heterocyclic Compounds, 2-Ring;Biogenic Monoamines;Sumatriptan;Substances;Tryptamines;Biogenic Amines;Amines;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Serotonin 1b Receptor Agonists;Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Serotonin Agonists;Serotonin Receptor Interactions;Serotonin 1d Receptor Agonists,Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Serotonin Activity;Serotonin Activity Alteration;Vasoconstriction;Physiologic Effect (PE);Generalized Systemic Effects;Increased Immunologic Activity;Arterial Vasoconstriction;Vascular Alterations;Increased Central Nervous System Serotonin Activity;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Vascular Tone Alteration;Cerebral Arterial Vasoconstriction;Increased Immunologically Active Molecule Activity;Immunologic Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Serotonin-1b and Serotonin-1d Receptor Agonist;Receptor Agonist;Receptor Interaction;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antimigraine agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
132,30,Concomitant Medications,Generic Name,RxNorm,B complex,,,,,801177.0,801177,True,,"VITAMINS;VITAMINS,COMBINATIONS;MULTIVITAMINS;VA CLASSES",Medicinal product categorized by structure;Vitamin B2 and/or vitamin B2 derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Sulfur and/or sulfur compound-containing product;Thiazole-containing product,,"VITAMINS;SENSORY ORGANS;Other ophthalmologicals;ALIMENTARY TRACT AND METABOLISM;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS;Other cicatrizants;CICATRIZANTS;DERMATOLOGICALS;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Other plain vitamin preparations;Vitamin B1, plain",Micronutrients;Therapeutic Uses;Radiation-Sensitizing Agents;MeSH Pharmacologic Actions (MESHPA);Vitamins;Photosensitizing Agents;Vitamin B Complex;Dermatologic Agents;Physiological Effects of Drugs,"Deficiency Diseases;Avitaminosis;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Lipid Metabolism Disorders;Thiamine Deficiency;Alcohol-Induced Disorders, Nervous System;Alcohol-Related Disorders;Hyperlipidemias;Brain Diseases, Metabolic;Malnutrition;Nutrition Disorders;Peripheral Vascular Diseases;Dyslipidemias;Pellagra;Beriberi;Alcoholic Neuropathy;Metabolic Diseases;Wernicke Encephalopathy;Mental Disorders;Alcohol-Induced Disorders;Vascular Diseases;Riboflavin Deficiency;Neuromuscular Diseases;Poisoning;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Hypercholesterolemia;Substance-Related Disorders;Polyneuropathies;Vitamin B Deficiency;Vitamin B 6 Deficiency;Neurotoxicity Syndromes;Central Nervous System Diseases;Chemically-Induced Disorders;Peripheral Nervous System Diseases;Nervous System Diseases;Disease;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Peptic Ulcer;Vascular Diseases;Cardiovascular Diseases;Gastrointestinal Diseases;Drug Hypersensitivity;Chemically-Induced Disorders;Stomach Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Hypotension;Digestive System Diseases;Intestinal Diseases;Hemorrhage;Pathological Conditions, Signs and Symptoms;Duodenal Diseases;Pathologic Processes;Disease","Deficiency Diseases;Avitaminosis;Cardiovascular Diseases;Nutritional and Metabolic Diseases;Myocardial Ischemia;Heart Diseases;Malnutrition;Nutrition Disorders;Pellagra;Coronary Disease;Vascular Diseases;Riboflavin Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vitamin B Deficiency;Arteriosclerosis;Vitamin B 6 Deficiency;Skin Diseases;Coronary Artery Disease;Arterial Occlusive Diseases;Disease;Skin and Connective Tissue Diseases","Pteridines;Picolines;Flavins;Pigments, Biological;Amino Acids;Coenzymes;Substances and Cells (CHEM);Pyrimidines;Vitamin B 6;Thiamine;Pyridines;Azoles;Sulfur Compounds;Alanine;beta-Alanine;Substances;Nicotinic Acids;Enzymes and Coenzymes;Acids, Heterocyclic;Thiazoles;Heterocyclic Compounds, 3-Ring;Niacinamide;Pantothenic Acid;Biological Factors;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Amino Acids, Peptides, and Proteins;Organic Chemicals;Riboflavin;Heterocyclic Compounds, 1-Ring;Imides;Heterocyclic Compounds, 2-Ring",,Enzyme Interactions;Mechanism of Action (MoA);Enzyme Activators,Physiologic Effect (PE);Generalized Systemic Effects;Cellular Activity Alteration;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Polysaccharide Metabolism Alteration;Cholesterol Metabolism Alteration;Triglyceride Metabolism Alteration;Decreased Cholesterol Synthesis;Sterol Metabolism Alteration;Increased Glycogenolysis;Metabolic Rate Alteration;Glucose Metabolism Alteration;Lipid Metabolism Alteration;Decreased Lipogenesis;Cholesterol Synthesis Alteration;Increased Metabolic Rate;Metabolic Activity Alteration,,,,,,,,"Diarrhea;Signs and Symptoms;Flatulence;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Flushing;Skin Manifestations;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Disease",,,
133,30,Concomitant Medications,Generic Name,RxNorm,"zinc, chelated",,,,253210.0,253210.0,253210,False,,,,,,,,,,,,,,,,,,,,,,,,
134,33,Concomitant Medications,Generic Name,RxNorm,budesonide,Budesonide 0.5 MG/ML Inhalant Solution,252559.0,Budesonide 0.5 MG/ML Inhalant Solution,19831.0,19831.0,19831,False,"GLUCOCORTICOIDS;ADRENAL CORTICOSTERIODS;VA CLASSES;ANTIASTHMA,OTHER;HORMONES/SYNTHETICS/MODIFIERS;NASAL AND THROAT AGENTS,TOPICAL;ANTI-INFLAMMATORIES,NASAL;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION","GLUCOCORTICOIDS;ADRENAL CORTICOSTERIODS;VA CLASSES;ANTIASTHMA,OTHER;HORMONES/SYNTHETICS/MODIFIERS;NASAL AND THROAT AGENTS,TOPICAL;ANTI-INFLAMMATORIES,NASAL;RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION",Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product;Steroid-containing product;Glucocorticoid-containing product,,"NASAL PREPARATIONS;Glucocorticoids;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;RESPIRATORY SYSTEM;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);DERMATOLOGICALS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;ADRENERGICS, INHALANTS;Corticosteroids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES","Glucocorticoids;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Peripheral Nervous System Agents;Hormones;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs;Bronchodilator Agents","Immune System Diseases;Digestive System Diseases;Rhinitis, Allergic;Inflammatory Bowel Diseases;Gastrointestinal Diseases;Intestinal Diseases;Infections;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Hypersensitivity;Nose Diseases;Gastroenteritis;Disease;Rhinitis","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Lung Diseases;Disease Attributes;Acute Disease;Asthma;Status Asthmaticus;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Respiratory Tract Diseases;Bronchial Diseases;Bronchial Spasm;Hypersensitivity;Chemically-Induced Disorders;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease","Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Polyps;Nasal Polyps;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Bronchial Diseases;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Nose Diseases;Pathological Conditions, Signs and Symptoms;Disease",Substances and Cells (CHEM);Budesonide;Pregnanes;Steroids;Pregnenes;Substances;Fused-Ring Compounds;Pregnenediones;Polycyclic Compounds,,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Cellular Synthetic Activity Alteration;Organ System Specific Effects;Translation Alteration;Cellular Cycle Alteration;Cellular Motion Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Decreased Cellular Migration;Adrenal Cortical Activity Alteration;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
135,33,Concomitant Medications,Generic Name,RxNorm,Prilosec,PriLOSEC,203345.0,PriLOSEC,203345.0,203345.0,203345,False,"VA CLASSES;ANTIULCER AGENTS;H. PYLORI AGENTS;GASTROINTESTINAL MEDICATIONS;GASTRIC MEDICATIONS,OTHER","GASTROINTESTINAL MEDICATIONS;GASTRIC MEDICATIONS,OTHER;VA CLASSES",Medicinal product categorized by structure;Benzimidazole-containing product,Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Proton pump inhibitor-containing product;Cytochrome P450 inhibitor-containing product;Enzyme inhibitor-containing product,DRUGS FOR ACID RELATED DISORDERS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Proton pump inhibitors;DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Proton Pump Inhibitors;Anti-Ulcer Agents;Gastrointestinal Agents,"Digestive System Neoplasms;Helicobacter Infections;Deglutition Disorders;Neoplasms;Esophageal Motility Disorders;Endocrine System Diseases;Digestive System Diseases;Neoplasms by Site;Gastrointestinal Diseases;Intestinal Diseases;Endocrine Gland Neoplasms;Duodenal Diseases;Infections;Pharyngeal Diseases;Peptic Ulcer;Heartburn;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Paraneoplastic Syndromes;Zollinger-Ellison Syndrome;Gram-Negative Bacterial Infections;Signs and Symptoms, Digestive;Otorhinolaryngologic Diseases;Bacterial Infections;Gastrointestinal Neoplasms;Paraneoplastic Endocrine Syndromes;Stomatognathic Diseases;Duodenal Ulcer;Bacterial Infections and Mycoses;Gastroesophageal Reflux;Stomach Diseases;Signs and Symptoms;Stomach Ulcer;Esophageal Diseases;Pathological Conditions, Signs and Symptoms;Gastroenteritis;Disease;Esophagitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Substances and Cells (CHEM);Sulfoxides;Pyridines;Organic Chemicals;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;Omeprazole;Substances;Benzimidazoles;2-Pyridinylmethylsulfinylbenzimidazoles;Heterocyclic Compounds, 2-Ring;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Cytochrome P450 2C19 Inhibitors;Cytochrome P450 Inhibitors;Receptor Interactions;Cation Transporter Interactions;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Proton Pump Inhibitors;Ion Transporter Interactions;Membrane Transporter Interactions;Proton Pump Interactions,Physiologic Effect (PE);Digestive/GI System Activity Alteration;Organ System Specific Effects;Gastric Acid Alteration;Inhibition Gastric Acid Secretion,Proton Pump Inhibitor;Gastrointestinal Agent;Established Pharmacologic Class (EPC);Ion Channel or Pump Agent,,,,,,,,,,Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Metabolism;Site of Metabolism
136,34,Concomitant Medications,Generic Name,RxNorm,Rybelsus,,,,2200645.0,2200645.0,2200645,False,"HYPOGLYCEMIC AGENTS,OTHER;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","HYPOGLYCEMIC AGENTS,OTHER;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Peptide-containing product,Glucagon-like peptide 1 receptor agonist-containing product;Medicinal product categorized by disposition,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Glucagon-like peptide-1 (GLP-1) analogues;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",,,"Neoplasms;Drug Hypersensitivity;Neuroectodermal Tumors;Endocrine System Diseases;Neoplastic Syndromes, Hereditary;Multiple Endocrine Neoplasia;Head and Neck Neoplasms;Neoplasms by Site;Adenocarcinoma;Endocrine Gland Neoplasms;Neoplasms by Histologic Type;Neoplasms, Glandular and Epithelial;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Carcinoma;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neoplasms, Germ Cell and Embryonal;Carcinoma, Neuroendocrine;Neoplasms, Multiple Primary;Drug-Related Side Effects and Adverse Reactions;Thyroid Diseases;Genetic Diseases, Inborn;Chemically-Induced Disorders;Neuroendocrine Tumors;Multiple Endocrine Neoplasia Type 2a;Neoplasms, Nerve Tissue;Multiple Endocrine Neoplasia Type 2b;Disease;Thyroid Neoplasms",,"Proglucagon;Substances and Cells (CHEM);Protein Precursors;Glucagon-Like Peptides;Amino Acids, Peptides, and Proteins;Pancreatic Hormones;Peptides;Hormones;Proteins;Substances;Peptide Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gastrointestinal Hormones",,Glucagon Receptor Interactions;Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Glucagon-like Peptide-1 (GLP-1) Agonists;Glucagon-like Peptide-1 (GLP-1) Receptor Interactions,Physiologic Effect (PE);Digestive/GI System Activity Alteration;Endocrine Activity Alteration;Pancreatic Islet Activity Alteration;Organ System Specific Effects;Decreased Glucagon Secretion;Decreased GI Motility;Increased Insulin Secretion;GI Motility Alteration;Decreased Gastric Motility,Blood Glucose Regulator;Established Pharmacologic Class (EPC);Receptor Agonist;Receptor Interaction;GLP-1 Receptor Agonist,,,"Proglucagon;Substances and Cells (CHEM);Protein Precursors;Glucagon-Like Peptides;Amino Acids, Peptides, and Proteins;Pancreatic Hormones;Glucagon-Like Peptide 1;Peptides;Hormones;Proteins;Substances;Peptide Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gastrointestinal Hormones",,,,,,,
137,34,Concomitant Medications,Generic Name,RxNorm,Synjardy,,,,1664316.0,1664316.0,1664316,False,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Biguanide-containing product,Medicinal product categorized by disposition;Sodium glucose cotransporter subtype 2 inhibitor-containing product,"ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Sodium-glucose co-transporter 2 (SGLT2) inhibitors;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Sodium-Glucose Transporter 2 Inhibitors;Hypoglycemic Agents;Physiological Effects of Drugs,"Diabetes Mellitus, Type 2;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Diabetes Mellitus;Metabolic Diseases;Glucose Metabolism Disorders;Disease","Nutritional and Metabolic Diseases;Urologic Diseases;Drug Hypersensitivity;Liver Diseases;Endocrine System Diseases;Acidosis;Acid-Base Imbalance;Diabetes Mellitus;Urogenital Diseases;Glucose Metabolism Disorders;Digestive System Diseases;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Female Urogenital Diseases;Diabetic Ketoacidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ketosis;Kidney Diseases;Drug-Related Side Effects and Adverse Reactions;Diabetes Complications;Chemically-Induced Disorders;Disease;Male Urogenital Diseases;Renal Insufficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Cardiovascular Diseases","Hydrocarbons;Amidines;Benzene Derivatives;Guanidines;Organic Chemicals;Glycosides;Benzhydryl Compounds;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Biguanides;Substances;Substances and Cells (CHEM);Glucosides;Metformin;Carbohydrates",Pharmacokinetics (PK);Route of Excretion;Renal Excretion;Elimination,Monosaccharide Transporter Interactions;Insulin Receptor Agonists;Receptor Interactions;Sodium-Glucose Transporter Inhibitors;Sodium-Glucose Transporter 2 Inhibitors;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Protein Kinase Interactions;Insulin Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Sodium-Glucose Transporter Interactions,Physiologic Effect (PE);Generalized Systemic Effects;Renal/Urological Activity Alteration;Carbohydrate Metabolism Alteration;Glycogen Metabolism Alteration;Organ System Specific Effects;Polysaccharide Metabolism Alteration;Cell Glucose Transport Alteration;Renal Organic Ion Transport Alteration;Decreased Gluconeogenesis;Glucose Metabolism Alteration;Increased Glucose Transport into Cells;Renal Ion Transport Alteration;Metabolic Activity Alteration;Increased Renal Organic Ion Excretion;Decreased Glycogenesis,Established Pharmacologic Class (EPC);Blood Glucose Regulator;Chemical Structure;Biguanide;Sodium-Glucose Cotransporter 2 Inhibitor,,,Amidines;Guanidines;Organic Chemicals;Biguanides;Substances;Substances and Cells (CHEM),,,,,,,
138,34,Concomitant Medications,Generic Name,RxNorm,Omega 3,,,,4301.0,4301.0,4301,False,,,,,,,"Nutritional and Metabolic Diseases;Lipid Metabolism Disorders;Hypertriglyceridemia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Dyslipidemias;Metabolic Diseases;Hyperlipidemias;Disease",,"Arrhythmias, Cardiac;Vascular Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Myocardial Ischemia;Heart Diseases;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Disease;Coronary Disease","Fatty Acids;Fish Oils;Dietary Fats, Unsaturated;Fats;Lipids;Fatty Acids, Unsaturated;Oils;Dietary Fats;Substances;Substances and Cells (CHEM);Fatty Acids, Omega-3",,Oxidation-Reduction Activity;Physiochemical Activity;Oxidation Activity;Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA),Physiologic Effect (PE);Generalized Systemic Effects;Increased Lipolysis;Cellular Activity Alteration;Cell Membrane Alteration;Triglyceride Metabolism Alteration;Cellular Structure Alteration;Cellular Communication Alteration;Decreased Lipogenesis;Metabolic Activity Alteration;Lipid Metabolism Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Omega-3 Fatty Acid,,,"Fatty Acids;Fish Oils;Dietary Fats, Unsaturated;Fats;Lipids;Fatty Acids, Unsaturated;Oils;Dietary Fats;Substances;Substances and Cells (CHEM);Fatty Acids, Omega-3",,,,,,,
139,34,Concomitant Medications,Generic Name,RxNorm,Cefpodoxime,cefpodoxime 200 MG Oral Tablet,309078.0,cefpodoxime 200 MG Oral Tablet,20489.0,20489.0,20489,False,CEPHALOSPORIN 3RD GENERATION;ANTIMICROBIALS;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES,CEPHALOSPORIN 3RD GENERATION;ANTIMICROBIALS;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES,Medicinal product categorized by structure;Third generation cephalosporin antibacterial agent;Beta-lactam antibacterial agent;Nitrogen and/or nitrogen compound-containing product;Cephalosporin antibacterial agent;Beta-lactam-containing product,Third generation cephalosporin antibacterial agent;Medicinal product categorized by disposition;Cephalosporin antibacterial agent,ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);OTHER BETA-LACTAM ANTIBACTERIALS;ANTIBACTERIALS FOR SYSTEMIC USE;Third-generation cephalosporins,Anti-Infective Agents;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"Moraxellaceae Infections;Pasteurellaceae Infections;Sexually Transmitted Diseases, Bacterial;Urologic Diseases;Gonorrhea;Skin and Connective Tissue Diseases;Sexually Transmitted Diseases;Lung Diseases, Obstructive;Neisseriaceae Infections;Pneumonia, Bacterial;Tonsillitis;Paranasal Sinus Diseases;Klebsiella Infections;Urogenital Diseases;Pneumonia;Lung Diseases;Proteus Infections;Maxillary Sinusitis;Haemophilus Infections;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Disease Attributes;Streptococcal Infections;Otitis Media;Staphylococcal Skin Infections;Infections;Cystitis;Female Urogenital Diseases;Pharyngeal Diseases;Respiratory Tract Infections;Soft Tissue Infections;Otitis;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Escherichia coli Infections;Urinary Bladder Diseases;Urinary Tract Infections;Otorhinolaryngologic Diseases;Staphylococcal Infections;Gram-Negative Bacterial Infections;Skin Diseases;Bacterial Infections;Stomatognathic Diseases;Pharyngitis;Bacterial Infections and Mycoses;Skin Diseases, Infectious;Respiratory Tract Diseases;Gram-Positive Bacterial Infections;Enterobacteriaceae Infections;Bronchial Diseases;Bronchitis;Ear Diseases;Skin Diseases, Bacterial;Nose Diseases;Pathological Conditions, Signs and Symptoms;Community-Acquired Infections;Pathologic Processes;Disease;Male Urogenital Diseases;Communicable Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Bacterial Infections;Bacterial Infections and Mycoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Infections;Disease","Ceftizoxime;Lactams;Organic Chemicals;Thiazines;Cefotaxime;beta-Lactams;Amides;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;Cephacetrile;Substances;Cephalosporins;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Enzyme Interactions;Mechanism of Action (MoA);Transpeptidase Inhibitors;Enzyme Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Decreased Cell Wall Synthesis & Repair;Cellular Structure Alteration;Cell Wall Alteration,Established Pharmacologic Class (EPC);Cephalosporin Antibacterial;Chemical Structure;Antimicrobial;Anti-infective;Antibacterial,,,"Lactams;Organic Chemicals;Thiazines;beta-Lactams;Amides;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;Substances;Cephalosporins;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Antiinfective agent;Third generation cephalosporin antibacterial agent;Beta-lactam antibacterial agent;Antibacterial agent;Cephalosporin antibacterial agent;Medicinal product categorized by therapeutic role,,,,,,
140,35,Concomitant Medications,Generic Name,RxNorm,methemazole,,,,,6835.0,6835,True,THYROID MODIFIERS;ANTITHYROID AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,THYROID MODIFIERS;ANTITHYROID AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Thiourea-containing product;Sulfur and/or sulfur compound-containing product,,"Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;THYROID THERAPY;Sulfur-containing imidazole derivatives;ANTITHYROID PREPARATIONS","Antithyroid Agents;MeSH Pharmacologic Actions (MESHPA);Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Goiter;Thyroid Diseases;Thyrotoxicosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Hyperthyroidism;Thyroid Crisis;Disease","Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Postpartum Period;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Lactation;Disease",,"Sulfhydryl Compounds;Methimazole;Azoles;Organic Chemicals;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds;Substances;Substances and Cells (CHEM);Inorganic Chemicals;Imidazoles",,Organic Anion Transporter Interactions;Receptor Interactions;Enzyme Inhibitors;Uncouplers;Thyroid Hormone Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Ion Transporter Interactions;Membrane Transporter Interactions;Anion Transporter Interactions,Cellular Activity Alteration;Endocrine Activity Alteration;Cellular Synthetic Activity Alteration;Organ System Specific Effects;Translation Alteration;Cellular Cycle Alteration;Decreased Iodine Organification;Decreased Protein Modification;Physiologic Effect (PE);Generalized Systemic Effects;Iodine Organification Alteration;Striated Muscle Metabolic Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Thyroid Hormone Iodination;Thyroid Gland Activity Alteration;Post Translation Protein Modification Alteration;Thyroid Hormone Iodination Alteration;Decreased Protein Synthesis,Enzyme Interaction;Thyroid Hormone Synthesis Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor,,,,Medicinal product categorized by therapeutic role;Antithyroid agent,,,,,,
141,36,Concomitant Medications,Generic Name,RxNorm,mirapex,Mirapex Pill,1180461.0,Mirapex Pill,218402.0,218402.0,218402,False,ANTIPARKINSON AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANTIPARKINSON AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,,Dopamine receptor agonist-containing product;Medicinal product categorized by disposition,DOPAMINERGIC AGENTS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;ANTI-PARKINSON DRUGS;Dopamine agonists,Central Nervous System Agents;Therapeutic Uses;Antioxidants;Molecular Mechanisms of Pharmacological Action;Dopamine Agonists;MeSH Pharmacologic Actions (MESHPA);Dopamine Agents;Antiparkinson Agents;Protective Agents;Neurotransmitter Agents;Physiological Effects of Drugs;Anti-Dyskinesia Agents,"Neurodegenerative Diseases;Parkinsonian Disorders;Proteostasis Deficiencies;Nutritional and Metabolic Diseases;Central Nervous System Diseases;Synucleinopathies;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mental Disorders;Movement Disorders;Metabolic Diseases;Parkinson Disease;Depressive Disorder;Mood Disorders;Nervous System Diseases;Disease;Basal Ganglia Diseases;Brain Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Thiazoles;Pramipexole;Benzothiazoles;Azoles;Organic Chemicals;Sulfur Compounds;Heterocyclic Compounds, 1-Ring;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Inorganic Chemicals;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Receptor Interactions;Dopamine Agonists;Dopamine Receptor Interactions;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions,Physiologic Effect (PE);Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Organ System Specific Effects;Increased Central Nervous System Dopamine Activity;Dopamine Activity Alteration;Increased Dopamine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Nonergot Dopamine Agonist;Receptor Agonist;Receptor Interaction;Nervous System Agent,,,,Medicinal product categorized by therapeutic role;Antiparkinson agent,,,,,,
142,36,Concomitant Medications,Generic Name,RxNorm,dupixent,,,,1876402.0,1876402.0,1876402,False,"DERMATOLOGICALS,SYSTEMIC,OTHER;DERMATOLOGICAL AGENTS;VA CLASSES","DERMATOLOGICALS,SYSTEMIC,OTHER;DERMATOLOGICAL AGENTS;VA CLASSES",Medicinal product categorized by structure;Monoclonal antibody-containing product;Nitrogen and/or nitrogen compound-containing product;Protein-containing product;Polypeptide-containing product;Antibody-containing product,Interleukin receptor antagonist-containing product;Medicinal product categorized by disposition;Interleukin-4 receptor alpha antagonist-containing product;Immunomodulator-containing product,"Anatomical Therapeutic Chemical (ATC1-4);OTHER DERMATOLOGICAL PREPARATIONS;DERMATOLOGICALS;Agents for dermatitis, excluding corticosteroids",,"Dermatitis;Dermatitis, Atopic;Skin Diseases, Eczematous;Genetic Diseases, Inborn;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Skin Diseases;Skin Diseases, Genetic;Disease;Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Antibodies;Amino Acids, Peptides, and Proteins;Antibodies, Monoclonal, Humanized;Immunoglobulins;Proteins;Blood Proteins;Globulins;Serum Globulins;Substances;Substances and Cells (CHEM);Antibodies, Monoclonal;Immunoproteins",,Interleukin 4 Receptor alpha Antagonists;Receptor Interactions;Interleukin 4 Receptor Interactions;Mechanism of Action (MoA);Cytokine Receptor Superfamily Interactions,Immunologic Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Decreased Immunologic Activity,Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Immunologic Agent;Interleukin Agent;Interleukin-4 Receptor alpha Antagonist,,,"Antibodies;Amino Acids, Peptides, and Proteins;Immunoglobulins;Proteins;Blood Proteins;Globulins;Serum Globulins;Substances;Substances and Cells (CHEM);Antibodies, Monoclonal;Immunoproteins",,,,,,,
143,37,Concomitant Medications,Generic Name,RxNorm,Chinese Medicine,,,,,1368530.0,1368530,True,,,,,,,,,,,,,,,,,,,,,,,,
144,37,Concomitant Medications,Generic Name,RxNorm,Vitamin B,,,,11251.0,11251.0,11251,False,,,,,,,,,,,,,,,,,,,,,,,,
145,38,Concomitant Medications,Generic Name,RxNorm,Fluticasone,,,,41126.0,41126.0,41126,False,"VA CLASSES;ANTIASTHMA,OTHER;ANTI-INFLAMMATORY,TOPICAL;DERMATOLOGICAL AGENTS;NASAL AND THROAT AGENTS,TOPICAL;ANTI-INFLAMMATORIES,NASAL;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION","VA CLASSES;ANTIASTHMA,OTHER;ANTI-INFLAMMATORY,TOPICAL;DERMATOLOGICAL AGENTS;NASAL AND THROAT AGENTS,TOPICAL;ANTI-INFLAMMATORIES,NASAL;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION",Medicinal product categorized by structure;Androstane-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product;Glucocorticoid-containing product,,"NASAL PREPARATIONS;Glucocorticoids;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;RESPIRATORY SYSTEM;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);DERMATOLOGICALS;CORTICOSTEROIDS, PLAIN;Corticosteroids;ADRENERGICS, INHALANTS;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES","Glucocorticoids;Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Anti-Allergic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Dermatologic Agents;Sympathomimetics;Anti-Inflammatory Agents;Physiological Effects of Drugs;Bronchodilator Agents","Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Nose Diseases;Infections;Disease;Rhinitis;Rhinitis, Allergic","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Lung Diseases;Infections;Asthma;Status Asthmaticus;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Skin Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Skin Diseases, Infectious;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Skin and Connective Tissue Diseases","Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Polyps;Nasal Polyps;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Bronchial Diseases;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Nose Diseases;Pathological Conditions, Signs and Symptoms;Disease",Substances and Cells (CHEM);Steroids;Androstenes;Androstanes;Substances;Fused-Ring Compounds;Fluticasone;Polycyclic Compounds;Androstadienes,,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Cellular Synthetic Activity Alteration;Translation Alteration;Cardiovascular Activity Alteration;Cellular Cycle Alteration;Cellular Motion Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Vascular Permeability Alteration;Vascular Alterations;Decreased Polymorphonuclear Leukocyte Migration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Decreased Cellular Migration;Decreased Vascular Permeability;Adrenal Cortical Activity Alteration;Decreased Fibroblast Migration;Decreased Capillary Permeability;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
146,40,Concomitant Medications,Generic Name,RxNorm,norgestimate/ethinyl estradiol,,,,214559.0,214559.0,214559,False,,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",Medicinal product categorized by structure;Steroid-containing product,Estrogen receptor agonist-containing product;Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,"GENITO URINARY SYSTEM AND SEX HORMONES;ENDOCRINE THERAPY;Estrogens;Natural and semisynthetic estrogens, plain;Anatomical Therapeutic Chemical (ATC1-4);SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;HORMONES AND RELATED AGENTS;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;Progestogens and estrogens, sequential preparations;ESTROGENS;Progestogens and estrogens, fixed combinations","Estrogens;Reproductive Control Agents;Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptives, Oral, Combined;Contraceptives, Oral, Hormonal;MeSH Pharmacologic Actions (MESHPA);Hormones;Contraceptive Agents;Contraceptive Agents, Female;Contraceptives, Oral;Contraceptive Agents, Hormonal;Hormones, Hormone Substitutes, and Hormone Antagonists;Physiological Effects of Drugs","Infertility, Female;Hot Flashes;Neoplasms;Genital Diseases, Male;Skin and Connective Tissue Diseases;Endocrine System Diseases;Gonadal Disorders;Hemorrhage;Menorrhagia;Urogenital Diseases;Neoplasms by Site;Menopause;Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Neoplasms;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Breast Diseases;Female Urogenital Diseases;Genital Neoplasms, Male;Climacteric;Menopause, Premature;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypogonadism;Ovarian Diseases;Amenorrhea;Breast Neoplasms;Prostatic Diseases;Sexual Development;Skin Diseases;Urogenital Neoplasms;Infertility;Uterine Hemorrhage;Adnexal Diseases;Reproductive Physiological Phenomena;Genital Diseases, Female;Uterine Diseases;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Primary Ovarian Insufficiency;Pathologic Processes;Disease;Male Urogenital Diseases;Menstruation Disturbances","Tobacco Use;Nutritional and Metabolic Diseases;Neoplasms;Drug Hypersensitivity;Diabetes Mellitus;Vasculitis;Intracranial Arterial Diseases;Embolism;Arteriosclerosis;Endometrial Neoplasms;Urogenital Neoplasms;Drug-Related Side Effects and Adverse Reactions;Arterial Occlusive Diseases;Heart Valve Diseases;Tobacco Use Disorder;Pathological Conditions, Signs and Symptoms;Embolism and Thrombosis;Thrombophlebitis;Nervous System Diseases;Male Urogenital Diseases;Cardiovascular Diseases;Behavior and Behavior Mechanisms;Heart Diseases;Thrombosis;Hemorrhage;Female Urogenital Diseases and Pregnancy Complications;Metabolic Diseases;Phlebitis;Female Urogenital Diseases;Coronary Disease;Vascular Diseases;Uterine Neoplasms;Breast Neoplasms;Skin Diseases;Pregnancy;Reproductive Physiological Phenomena;Uterine Diseases;Uterine Hemorrhage;Respiratory Tract Diseases;Genital Neoplasms, Female;Thromboembolism;Pathologic Processes;Disease;Skin and Connective Tissue Diseases;Hypertension;Endocrine System Diseases;Digestive System Diseases;Cerebral Arterial Diseases;Neoplasms by Site;Lung Diseases;Reproduction;Cerebrovascular Disorders;Liver Neoplasms;Breast Diseases;Mental Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemic and Lymphatic Diseases;Digestive System Neoplasms;Hematologic Diseases;Liver Diseases;Myocardial Ischemia;Thrombophilia;Neoplasms, Hormone-Dependent;Urogenital Diseases;Glucose Metabolism Disorders;Venous Thrombosis;Life Phases, Behavior Mechanisms and Physiologic States;Genital Diseases;Behavior;Headache Disorders;Substance-Related Disorders;Coronary Artery Disease;Pulmonary Embolism;Genital Diseases, Female;Central Nervous System Diseases;Chemically-Induced Disorders;Peripheral Vascular Diseases;Brain Diseases","Osteoporosis;Disease;Pregnancy;Nutritional and Metabolic Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Life Phases, Behavior Mechanisms and Physiologic States;Musculoskeletal Diseases;Metabolic Diseases;Osteoporosis, Postmenopausal;Bone Diseases;Bone Diseases, Metabolic","Substances and Cells (CHEM);Gonadal Steroid Hormones;Gonadal Hormones;Estrogenic Steroids, Alkylated;Hormones;Steroids;Norsteroids;Norgestrel;Estradiol Congeners;Ethinyl Estradiol;Norpregnanes;Substances;Norpregnenes;Fused-Ring Compounds;Hormones, Hormone Substitutes, and Hormone Antagonists;Polycyclic Compounds;Norpregnatrienes",Fecal Excretion;Aromatic hydroxylation;Hepatic Metabolism;Pharmacokinetics (PK);Elimination;Enzymatic Pathway of Metabolism;Site of Metabolism;Renal Excretion;Metabolism;Route of Excretion,Sex Hormone Receptor Agonists;Receptor Interactions;Progestational Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Estrogen Receptor Agonists;Hormone Receptor Interactions;Hormone Receptor Agonists,Organ System Specific Effects;Peripheral Nervous System Activity Alteration;Inhibit Ovulation;Embryonic Implantation Alteration;Smooth Muscle Tone Alteration;Bone Formation Alteration;Bone Formation Stimulation;Physiologic Effect (PE);Decreased Embryonic Implantation;Ovarian Follicular Phase Alteration;Female Reproductive System Activity Alteration;Ovarian Function Alteration;Ovulation Alteration;Musculoskeletal Activity Alteration;Decreased Uterine Smooth Muscle Contraction or Tone;Uterine Function Alteration;Embryonic & Fetal Alteration;Uterine Smooth Muscle Contraction or Tone;Inhibit Ovarian Follicular Phase;Reproductive System Activity Alteration;Autonomic Nervous System Activity Alteration;Vaginal Function Alteration;Bone Alteration;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Estrogen;Progestin,,,"Gonadal Steroid Hormones;Gonadal Hormones;Progesterone Congeners;Hormones;Substances;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists",Medicinal product categorized by therapeutic role;Contraceptive agent,,,,Physiologic Effect (PE);Blood Pressure Alteration;Hemostasis Alteration;Organ System Specific Effects;Coagulation Activity Alteration;Cardiovascular Activity Alteration;Hematologic Activity Alteration;Hemic/Lymphatic Activity Alteration;Increased Blood Pressure;Increased Coagulation Activity,,
147,42,Concomitant Medications,Generic Name,RxNorm,"""Viro-grip"" cold medicine",Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,1052645.0,Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,,1117392.0,1117392,True,,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE;VA CLASSES;RESPIRATORY TRACT MEDICATIONS",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Propylamine derivative histamine receptor antagonist product;Propylamine-containing product;Ether structure-containing product;Alcohol-containing product,Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Alpha adrenergic receptor agonist-containing product;Sigma-1 receptor agonist-containing product;Propylamine derivative histamine receptor antagonist product;Adrenergic receptor agonist-containing product;Histamine receptor antagonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;NMDA receptor antagonist-containing product,"NASAL PREPARATIONS;COUGH AND COLD PREPARATIONS;Substituted alkylamines;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics;ANTIHISTAMINES FOR SYSTEMIC USE",Autonomic Agents;Histamine Agents;Bronchodilator Agents;Central Nervous System Agents;Anti-Asthmatic Agents;Anti-Allergic Agents;Excitatory Amino Acid Agents;MeSH Pharmacologic Actions (MESHPA);Nasal Decongestants;Physiological Effects of Drugs;Therapeutic Uses;Histamine H1 Antagonists;Excitatory Amino Acid Antagonists;Respiratory System Agents;Histamine Antagonists;Vasoconstrictor Agents;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Cardiovascular Agents;Antitussive Agents;Dermatologic Agents;Neurotransmitter Agents;Antipruritics,"Signs and Symptoms, Respiratory;Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Urticaria;Respiration Disorders;Lung Diseases;RNA Virus Infections;Infections;Asthma;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases, Vascular;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Skin Diseases;Virus Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Picornaviridae Infections;Bronchial Diseases;Signs and Symptoms;Hypersensitivity;Nose Diseases;Pathological Conditions, Signs and Symptoms;Cough;Disease;Skin and Connective Tissue Diseases;Rhinitis","Urologic Diseases;Drug Hypersensitivity;Genital Diseases, Male;Lung Diseases, Obstructive;Immune System Diseases;Glaucoma, Angle-Closure;Urethral Obstruction;Urogenital Diseases;Digestive System Diseases;Duodenal Obstruction;Infant, Premature;Lung Diseases;Gastrointestinal Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Intestinal Diseases;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Duodenal Diseases;Asthma;Female Urogenital Diseases;Eye Diseases;Urethral Diseases;Peptic Ulcer;Glaucoma;Status Asthmaticus;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Urinary Bladder Diseases;Infant;Age Groups;Infant, Newborn;Hypersensitivity, Immediate;Ocular Hypertension;Prostatic Diseases;Urinary Bladder Neck Obstruction;Intestinal Obstruction;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Respiratory Tract Diseases;Stomach Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Male Urogenital Diseases;Prostatic Hyperplasia","Signs and Symptoms, Respiratory;Respiratory Tract Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Cough;Disease;Respiration Disorders","Phenethylamines;Pseudoephedrine;Alkaloids;Hydrocarbons, Cyclic;Chlorpheniramine;Pheniramine;Substances and Cells (CHEM);Opiate Alkaloids;Amines;Morphinans;Heterocyclic Compounds, Bridged-Ring;Pyridines;Alcohols;Amino Alcohols;Hydrocarbons, Aromatic;Propanolamines;Substances;Propanols;Ethylamines;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Hydrocarbons;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Heterocyclic Compounds, 1-Ring;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Dextromethorphan",,Receptor Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Interactions;Symporter Interactions;Adrenergic beta-Agonists;Ion Channel Interactions;Sigma Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists;Sigma-1 Receptor Agonists;Ionotropic Glutamate Receptor Antagonists;Neurotransmitter Transporter Interactions;Histamine Receptor Antagonists;Ion Transporter Interactions;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Interactions;Uncompetitive NMDA Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions;Adrenergic Agonists,Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Peripheral Nervous System Activity Alteration;Cardiovascular Activity Alteration;Smooth Muscle Tone Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Vasoconstriction;Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Vascular Alterations;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Musculoskeletal Activity Alteration;Vascular Tone Alteration;Decreased Medullary Respiratory Drive;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Bronchodilation;Immunologic Activity Alteration;Decreased Immunologic Activity;Autonomic Nervous System Activity Alteration;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Adrenergic Receptor Agonist;Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Receptor Antagonist;Receptor Agonist;Sigma-1 Agonist;Histamine-1 Receptor Antagonist;Receptor Interaction;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Sympathomimetic Agent;Nervous System Agent;alpha-Adrenergic Agonist,,,,Medicinal product categorized by therapeutic role;Antitussive agent,,Enzyme Interactions;Mechanism of Action (MoA);Monoamine Oxidase Inhibitors;Enzyme Inhibitors,,,,
148,42,Concomitant Medications,Generic Name,RxNorm,biotin,Biotin Pill,1154424.0,Biotin Pill,1588.0,1588.0,1588,False,"VITAMINS;VITAMINS,COMBINATIONS;VA CLASSES;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER","VITAMINS;HERBS/ALTERNATIVE THERAPIES;VA CLASSES;VITAMINS,COMBINATIONS;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER",Medicinal product categorized by structure;Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Imidazole-containing product,,VITAMINS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER PLAIN VITAMIN PREPARATIONS;Other plain vitamin preparations,Micronutrients;MeSH Pharmacologic Actions (MESHPA);Vitamins;Vitamin B Complex;Physiological Effects of Drugs,"Deficiency Diseases;Metabolism, Inborn Errors;Avitaminosis;Nutritional and Metabolic Diseases;Malnutrition;Genetic Diseases, Inborn;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nutrition Disorders;Vitamin B Deficiency;Metabolic Diseases;Disease;Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Enzymes and Coenzymes;Azoles;Coenzymes;Heterocyclic Compounds, 1-Ring;Substances;Substances and Cells (CHEM);Imidazoles;Heterocyclic Compounds;Biotin",,Enzyme Interactions;Mechanism of Action (MoA),Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE),,,,,,,,,,,
149,43,Concomitant Medications,Generic Name,RxNorm,Antivert,Meclizine Oral Tablet [Antivert],368885.0,Meclizine Oral Tablet [Antivert],91818.0,91818.0,91818,False,VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIVERTIGO AGENTS,VA CLASSES;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIVERTIGO AGENTS,Medicinal product categorized by structure;Piperazine and/or piperazine derivative-containing product;Piperazine derivative-containing product;Piperazine derivative histamine receptor antagonist product,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition;Piperazine derivative histamine receptor antagonist product,Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;Piperazine derivatives;ANTIHISTAMINES FOR SYSTEMIC USE,Cholinergic Agents;Cholinergic Antagonists;Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Histamine Antagonists;Anti-Allergic Agents;Molecular Mechanisms of Pharmacological Action;Histamine H1 Antagonists;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Histamine Agents;Antiemetics;Neurotransmitter Agents;Physiological Effects of Drugs;Gastrointestinal Agents,"Ear Diseases;Vertigo;Labyrinth Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Vestibular Diseases;Motion Sickness;Nervous System Diseases;Disease;Neurologic Manifestations","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathological Conditions, Signs and Symptoms;Motion Sickness;Disease","Hydrocarbons;Benzene Derivatives;Benzhydryl Compounds;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Piperazines;Substances;Substances and Cells (CHEM);Heterocyclic Compounds;Meclizine",,Cholinergic Antagonists;Receptor Interactions;Cholinergic Muscarinic Antagonists;Cholinergic Muscarinic Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Interactions;Cholinergic Interactions,Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Decreased Histamine Activity;GI Motility Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Histamine Activity Alteration;Digestive/GI System Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Central Nervous System Depression;Decreased GI Motility;Decreased Acetylcholine Activity;Emesis Suppression;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Acetylcholine Activity Alteration;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Gastrointestinal Agent;Established Pharmacologic Class (EPC);Antiemetic,,,,,Gastrointestinal Agent;Central Nervous System Agent;Anti-emetic Agent;Therapeutic Categories,,,,,
150,43,Concomitant Medications,Generic Name,RxNorm,Guaifenesin,Guaifenesin Pill,1159705.0,Guaifenesin Pill,5032.0,5032.0,5032,False,"DECONGESTANT/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;COLD REMEDIES,OTHER;VA CLASSES;COLD REMEDIES,COMBINATIONS;ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC","DECONGESTANT/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;COLD REMEDIES,OTHER;VA CLASSES;COLD REMEDIES,COMBINATIONS;ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC",Medicinal product categorized by structure;Ether structure-containing product,,"COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);RESPIRATORY SYSTEM;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants",Respiratory System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Expectorants,"Signs and Symptoms, Respiratory;Lung Diseases, Obstructive;Common Cold;Immune System Diseases;Paranasal Sinus Diseases;Rhinitis, Allergic;Respiration Disorders;Lung Diseases;RNA Virus Infections;Infections;Pharyngeal Diseases;Bordetella Infections;Respiratory Tract Infections;Rhinitis, Allergic, Perennial;Sinusitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Whooping Cough;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Gram-Negative Bacterial Infections;Virus Diseases;Bacterial Infections;Stomatognathic Diseases;Pharyngitis;Respiratory Hypersensitivity;Bacterial Infections and Mycoses;Respiratory Tract Diseases;Laryngeal Diseases;Picornaviridae Infections;Signs and Symptoms;Bronchial Diseases;Hypersensitivity;Bronchitis;Laryngitis;Nose Diseases;Pathological Conditions, Signs and Symptoms;Cough;Disease;Rhinitis","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Hydrocarbons;Methyl Ethers;Phenols;Phenyl Ethers;Benzene Derivatives;Ethers;Guaifenesin;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Organic Chemicals;Catechols;Substances;Substances and Cells (CHEM);Guaiacol",,,Physiologic Effect (PE);Respiratory Secretion Alteration;Organ System Specific Effects;Decreased Respiratory Secretion Viscosity;Respiratory/Pulmonary Activity Alteration;Increased Respiratory Secretions;Respiratory Secretion Viscosity Alteration,Established Pharmacologic Class (EPC);Respiratory Agent;Expectorant,SCHEDULE III;SCHEDULE V;CSA SCHEDULE;SCHEDULE II,,,Medicinal product categorized by therapeutic role;Expectorant agent,,,,,,
151,43,Concomitant Medications,Generic Name,RxNorm,Flonase,Flonase Nasal Product,1801248.0,Flonase Nasal Product,83373.0,83373.0,83373,False,"ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES","ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES",Medicinal product categorized by structure;Androstane-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product;Glucocorticoid-containing product,,"NASAL PREPARATIONS;Glucocorticoids;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;RESPIRATORY SYSTEM;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);DERMATOLOGICALS;CORTICOSTEROIDS, PLAIN;Corticosteroids;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES",Respiratory System Agents;Autonomic Agents;Therapeutic Uses;Anti-Asthmatic Agents;Anti-Allergic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents;Dermatologic Agents;Physiological Effects of Drugs;Bronchodilator Agents,"Respiratory Hypersensitivity;Respiratory Tract Infections;Respiratory Tract Diseases;Rhinitis, Allergic, Perennial;Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity, Immediate;Otorhinolaryngologic Diseases;Nose Diseases;Infections;Disease;Rhinitis;Rhinitis, Allergic","Drug Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Lung Diseases;Infections;Asthma;Status Asthmaticus;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Skin Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Skin Diseases, Infectious;Respiratory Tract Diseases;Bronchial Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Skin and Connective Tissue Diseases","Lung Diseases;Respiratory Hypersensitivity;Respiratory Tract Diseases;Polyps;Nasal Polyps;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Asthma;Bronchial Diseases;Hypersensitivity;Lung Diseases, Obstructive;Immune System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Hypersensitivity, Immediate;Nose Diseases;Pathological Conditions, Signs and Symptoms;Disease",Substances and Cells (CHEM);Steroids;Androstenes;Androstanes;Substances;Fused-Ring Compounds;Fluticasone;Polycyclic Compounds;Androstadienes,,Corticosteroid Hormone Receptor Agonists;Glucocorticoid Receptor Agonists;Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Mechanism of Action (MoA);Hormone Receptor Interactions;Hormone Receptor Agonists,Cellular Activity Alteration;Lysosomal Function Alteration;Endocrine Activity Alteration;Organ System Specific Effects;Cellular Synthetic Activity Alteration;Translation Alteration;Cardiovascular Activity Alteration;Cellular Cycle Alteration;Cellular Motion Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Glucocorticoid Secretion;Cellular Degradation/Digestion Alteration;Striated Muscle Metabolic Alteration;Vascular Permeability Alteration;Vascular Alterations;Decreased Polymorphonuclear Leukocyte Migration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration;Decreased Lysosomal Function;Decreased Cellular Migration;Decreased Vascular Permeability;Adrenal Cortical Activity Alteration;Decreased Fibroblast Migration;Decreased Capillary Permeability;Decreased Protein Synthesis,Established Pharmacologic Class (EPC);Hormone;Receptor Agonist;Receptor Interaction;Chemical Structure;Corticosteroid,,,,,,,,,,
152,43,Concomitant Medications,Generic Name,RxNorm,Ondansetron,Ondansetron,26225.0,Ondansetron,26225.0,26225.0,26225,False,GASTROINTESTINAL MEDICATIONS;ANTIEMETICS;VA CLASSES,GASTROINTESTINAL MEDICATIONS;ANTIEMETICS;VA CLASSES,,5-HT3 receptor antagonist-containing product;Medicinal product categorized by disposition,Anatomical Therapeutic Chemical (ATC1-4);Serotonin (5HT3) antagonists;ANTIEMETICS AND ANTINAUSEANTS;ALIMENTARY TRACT AND METABOLISM,Central Nervous System Agents;Autonomic Agents;Therapeutic Uses;Serotonin 5-HT3 Receptor Antagonists;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Serotonin Agents;Antiemetics;Dermatologic Agents;Neurotransmitter Agents;Physiological Effects of Drugs;Gastrointestinal Agents;Antipruritics;Serotonin Antagonists,"Alcoholism;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Substance-Related Disorders;Alcohol-Related Disorders;Disease;Mental Disorders","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Postoperative Complications;Signs and Symptoms;Nausea;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vomiting;Signs and Symptoms, Digestive;Pathological Conditions, Signs and Symptoms;Postoperative Nausea and Vomiting;Pathologic Processes;Disease","Substances and Cells (CHEM);Azoles;Heterocyclic Compounds, 3-Ring;Indoles;Heterocyclic Compounds, 1-Ring;Substances;Carbazoles;Ondansetron;Heterocyclic Compounds, 2-Ring;Imidazoles;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,Receptor Interactions;Ion Channel Interactions;Serotonin 5HT-3 Receptor Interactions;Serotonin 3 Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions;Serotonin 5HT-3 Antagonists;Membrane Transporter Interactions;Serotonin Receptor Interactions;Serotonin Antagonists,Organ System Specific Effects;Decreased Immunologically Active Molecule Activity;Serotonin Activity Alteration;GI Motility Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased Central Nervous System Serotonin Activity;Digestive/GI System Activity Alteration;Immunologically Active Molecule Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Central Nervous System Depression;Decreased GI Motility;Emesis Suppression;Decreased Serotonin Activity;Central Nervous System Activity Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Decreased Peripheral Nervous System Serotonin Activity;Decreased Immunologically Active Biogenic Amine Activity;Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Receptor Antagonist;Serotonin-3 Receptor Antagonist;Receptor Interaction;Nervous System Agent,,"Isoquinolines;Alkaloids;Aporphines;Heterocyclic Compounds, 4 or More Rings;Benzylisoquinolines;Heterocyclic Compounds, Fused-Ring;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds;Apomorphine",,Antiemetic agent;Medicinal product categorized by therapeutic role,,,,,,
153,43,Concomitant Medications,Generic Name,RxNorm,ofloxacin otic,Ofloxacin Otic Solution,377450.0,Ofloxacin Otic Solution,1160453.0,1160453.0,1160453,False,"OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES;ANTIBACTERIALS,TOPICAL OTIC","OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES;ANTIBACTERIALS,TOPICAL OTIC",Medicinal product categorized by structure;Quinoline-containing product;Nitrogen and/or nitrogen compound-containing product;Quinolone antibacterial agent;Fluoroquinolone antibacterial agent,Fluoroquinolone antibacterial agent;Medicinal product categorized by disposition,Fluoroquinolones;OTOLOGICALS;ANTIINFECTIVES FOR SYSTEMIC USE;SENSORY ORGANS;ANTIINFECTIVES;Antiinfectives;Anatomical Therapeutic Chemical (ATC1-4);OPHTHALMOLOGICALS;ANTIBACTERIALS FOR SYSTEMIC USE;QUINOLONE ANTIBACTERIALS,"Metabolic Side Effects of Drugs and Substances;Cytochrome P-450 Enzyme Inhibitors;Antineoplastic Agents;Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents, Urinary;Cytochrome P-450 CYP1A2 Inhibitors;Topoisomerase Inhibitors;Anti-Infective Agents;Anti-Bacterial Agents;Topoisomerase II Inhibitors","Conjunctivitis, Bacterial;Prostatitis;Helicobacter Infections;Corneal Ulcer;Pasteurellaceae Infections;Sexually Transmitted Diseases, Bacterial;Urologic Diseases;Gonorrhea;Genital Diseases, Male;Sexually Transmitted Diseases;Lung Diseases, Obstructive;Skin and Connective Tissue Diseases;Otitis Externa;Neisseriaceae Infections;Conjunctival Diseases;Klebsiella Infections;Urogenital Diseases;Lung Diseases;Actinomycetales Infections;Proteus Infections;Haemophilus Infections;Eye Infections;Female Urogenital Diseases and Pregnancy Complications;Genital Diseases;Disease Attributes;Tuberculosis, Pulmonary;Otitis Media;Infections;Cystitis;Eye Diseases;Female Urogenital Diseases;Chlamydiaceae Infections;Inflammation;Soft Tissue Infections;Respiratory Tract Infections;Otitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Escherichia coli Infections;Urinary Bladder Diseases;Mycobacterium Infections;Tuberculosis;Prostatic Diseases;Staphylococcal Infections;Gram-Negative Bacterial Infections;Otorhinolaryngologic Diseases;Suppuration;Skin Diseases;Urinary Tract Infections;Salmonella Infections;Bacterial Infections;Ear Diseases;Conjunctivitis;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Enterobacteriaceae Infections;Chlamydia Infections;Bronchial Diseases;Bronchitis;Respiratory Tract Diseases;Skin Diseases, Infectious;Keratitis;Eye Infections, Bacterial;Epididymitis;Corneal Diseases;Skin Diseases, Bacterial;Pathological Conditions, Signs and Symptoms;Otitis Media, Suppurative;Pathologic Processes;Disease;Male Urogenital Diseases;Communicable Diseases","Drug-Related Side Effects and Adverse Reactions;Drug Hypersensitivity;Chemically-Induced Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,"Fluoroquinolones;Quinolones;Ofloxacin;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Quinolines;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",,DNA Gyrase Inhibitors;Enzyme Inhibitors;Nucleic Acid Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Topoisomerase Inhibitors;Topoisomerase 4 Inhibitors;Topoisomerase 2 Inhibitors,Cellular Activity Alteration;Generalized Systemic Effects;Decreased Transcription to RNA;Physiologic Effect (PE);DNA Integrity Alteration;Cellular Synthetic Activity Alteration;Nucleic Acid Replication Alteration;Cellular Cycle Alteration;Decreased DNA Replication;Transcription to RNA Alteration;DNA Replication Alteration;Nucleic Acid Transcription Alteration;Decreased DNA Integrity,Established Pharmacologic Class (EPC);Chemical Structure;Antimicrobial;Anti-infective;Quinolone Antimicrobial,,,"Quinolones;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 2-Ring;Quinolines;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring",Antiinfective agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Quinolone antibacterial agent;Fluoroquinolone antibacterial agent,Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,,,,,
154,45,Concomitant Medications,Generic Name,RxNorm,Zinc,Zinc,11416.0,Zinc,11416.0,11416.0,11416,False,,,Medicinal product categorized by structure;Metal and/or metallic compound-containing product;Mineral-containing product;Zinc and/or zinc compound-containing product,,,Physiological Effects of Drugs;Trace Elements;MeSH Pharmacologic Actions (MESHPA);Micronutrients,,,,"Substances and Cells (CHEM);Zinc;Amino Acids, Peptides, and Proteins;Amino Acids, Essential;Organic Chemicals;Transition Elements;Organometallic Compounds;Amino Acids, Sulfur;Amino Acids;Methionine;Sulfur Compounds;Metals, Heavy;Metals;Substances;Elements;Amino Acids, Neutral;Inorganic Chemicals",,,,,,,,,,,,,,
